moretaxeslessbreadblog.blogspot

Breast Cancer Chlorella Fluoride Heart Disease HFCS Superfoods Spirulina

2012-01-10T11:08:00.000-08:00

Breast Cancer Chlorella Fluoride Heart Disease HFCS Superfoods Spirulina

Marijuana cannabinoids - oral and transdermal methods

Saturday, December 17, 2011 by: Mark Sircus., AC, OMD

(NaturalNews) (NaturalNews )The research indicates that cannabinoids hold the secret to helping heal many of the chronic diseases we are facing. From cancer to diabetes, and from autism to Alzheimer's, medical marijuana helps, and sometimes dramatically so. Cannabinoid medicine holds a great power to alleviate human suffering. There are no words to describe how important this substance is for our race in terms of sanity, compassion and highly rational medicine.

Although medical marijuana is nontoxic, smoking it can be hazardous over the long term because toxic compounds are created in the combustion process. Fortunately there are options for the administration of cannabis but in general all different ways of administrating hemp oil or raw marijuana can be combined with no harmful side effects. Also there are vaporizers that allow for inhalation or what amounts to transdermal treatments into the lungs without burning the marijuana. It's a cool clean smoke of powerful medicine.

Smoking marijuana has limited medical value when used exclusively, especially when it is inhaled through burning. It can reduce blood sugar; it can also help reduce ocular pressure for people with glaucoma. Most people know of marijuana's ability to reduce nausea, and smoking marijuana will often reduce the pain associated with many medical conditions. Smoking "grass" does make a person relax, which in itself can be quite beneficial. Smoking does help reduce the symptoms of many conditions but in general it does not work on a curative level like oral consumption does.

Rick Simpson, the most courageous medical marijuana expert of them all, says, "Smoking is the least effective method of using hemp as a medicine. The power of hemp medicine is magnified many times when the concentrated essential oil of the hemp plant is produced. If you want to see the real medicinal magic in the hemp plant, start ingesting high-grade hemp oil. When one starts ingesting the raw, unburned THC and its associated cannabinoids, medical miracles often occur. When a person smokes a joint, over 90% of the medicinal aspect of the plant material goes up in smoke. It's ironic to see people who have taken chemotherapy smoke hemp to reduce their nausea. They are smoking the very substance that, if taken properly, could cure them."

Cannabis, or marijuana, has been utilized as an ingredient in food and drink for thousands of years. Recipes were often recorded in rhyme, assisting in the memorization process. One such recipe, Bhang (a milk-based drink), dates back to 800 B.C. when it was first concocted in India. The Chinese use of cannabis as a staple food source -- for both humans and animals -- dates back to the 7th century B.C. Gathered for their exceptional nutritional value, cannabis seeds provided an exceptional source of protein and nutrients.

Oral Cannabis

When we ingest marijuana it is absorbed via the intestines and then passes through the liver, which processes the THC into a byproduct called 11-hydroxy-THC, which then travels to the bloodstream and then on to our brains. 11-hydroxy THC is thought to be four to five times more potent than regular THC. This is one reason why edibles are known to be more potent when compared to inhaled cannabis. Edibles are also thought to be strong sedatives and many patients use them for treatment of insomnia.

Marijuana taken in edible form usually takes from 40 minutes to one hour to start working and the peak effect is at two hours. The effects last though from six to eight hours, which is very convenient for those patients who want to sleep or have longer control of pain.

The key to proper use of oral marijuana is to know how much to eat so as to get the best medicinal effect without taking too much. The general rule is, if you buy an edible product from a registered marijuana dispensary, cut the edible product into four pieces and eat one piece to start. Wait at least one hour. If you feel braver start with half! If you feel the effects of the medication, do not eat any more. If you do not feel the effects of the medication, you can eat another piece. There have been patients who unknowingly have ingested too much and have felt "too high," nausea, vomiting, and very groggy, so it's best to start out slow in the beginning. If you do not feel much at a full dose than try a dose and a half or even two doses.

Transdermal Marijuana

Marijuana is lipophilic, which means that it can be dissolved into a fat-soluble substance and readily enter cell membranes. In other words, it can be effective when applied topically on the skin. Marijuana can be used transdermally to relieve pain from many conditions. Medical marijuana can be a balm, lotion, ointment or rubbing alcohol solution. In the old days when people only had plants to use for medication, many patients would soak marijuana leaves in alcohol and apply them as a poultice to an arthritic or swollen joint.

Many substances pass easily through the skin and that is why transdermal medicine has been more evident in contemporary medicine. When it comes to marijuana's anti-inflammatory effect people have long experienced this in action when they have applied marijuana to their skin. Patients with arthritis, muscle and joint pain can testify to the easing of the aches and pains that they feel on a regular basis. Topical marijuana preparations usually provide only local relief and do not have effect on the brain, meaning there is usually no high. This is helpful for those times when marijuana use is inappropriate (like when you have to drive your car) and you still need pain relief! Topical preparations can be purchased or made at home.

Transdermal medicine is ideal for pain management as well as sports and pediatric medicine. In fact it is one of the best ways to administer medicines quickly and effectively. Transdermal methods of delivery are widely used because they allow the absorption of medicine directly through the skin. Gels, emulsion creams, sprays and lip balm stick applicators are easy to use and are effective in getting medicine into the bloodstream quickly.

Traditional methods of administering medicine such as tablets or capsules get watered down and become much less effective due to stomach acids and digestive enzymes before they eventually get into the bloodstream. Bypassing the stomach and liver means a much greater percentage of the active ingredient goes straight into the bloodstream where it's needed. In many cases, transdermal methods are used to help avoid potential side effects such as stomach upset or drowsiness. The full potential for transdermal medicine has not been explored by modern medicine though it has been practiced for thousands of years in hot springs around the world.

Of course the use of magnesium oil for these same effects is also recommended and using topical magnesium and marijuana together in combination is excellent for difficult, stubborn pain. One of the main points for everyone to understand is that when we are thrust back to simpler lives, having access to versatile medicines without cost is important. If the governments would get off their people's backs, marijuana would be legal and virtually free because it's so easily grown.

It is highly regrettable that the deficiency of such an inexpensive,

low-toxicity nutrient like magnesium results in diseases that

cause incalculable suffering and expense throughout the world.

Dr. Steven Johnson

Bottom line, when it comes to pain medications that work on the source of pain and disease, there is nothing like magnesium chloride and nothing like cannabinoid medicine. Together they are the Batman and Robin superhero medical team for the world of pain, heavy emotional upset, and the general treatment of disease. Add sodium bicarbonate (baking soda) and iodine and you already have a full medical team at your fingertips.

Hemp Salves and Oils Offer Potent Solutions

One hospital pathologist cut his finger during an autopsy; bacteria resistant to antibiotics infected the wound and it seemed that an amputation was going to be inevitable. Then someone had the idea to ask Prof. Kabelik, who was known for his research on the medicinal use of cannabis, for help. He applied his hemp salve and two days later the wound was already healing and the amputation was avoided.

Topical Solution Uses

Arthritis ---------------------------- Pain

Dry/chapped skin ---------------- Rashes

Eczema ---------------------------- Rheumatism

Headaches or migraines --------- Swelling

Insect bites ----------------------- Sunburns

Burns ------------------------------ Stiff neck

Muscle soreness ----------------- Tendonitis

A Seattle company is reportedly developing a medical marijuana patch for pets, calling it a "question of quality of life." Jim Alekson's Medical Marijuana Delivery Systems, LLC has patented the patch, called Tetracan, and says it could be used on dogs, cats, and even horses. The patch would be available for human use as well. According to Alekson, "Dogs suffer from the same maladies that humans do," and pets can suffer greatly from pain -- everything from arthritis to cancer. He said that harsh pharmaceutical painkillers have proven harmful, sometimes fatal to animals.

In California an adult may grow, buy and smoke marijuana, all while remaining safely within the confines of state law. Dr. William Courtney tells his patients "Don't smoke the stuff. Eat it!" It won't get you high eaten raw, and juiced with a handful of carrots to cut the bitter taste, its leaves and buds may well offer an important contribution to getting people well.

Courtney juices carrots to cut the harsh taste of the ingredients

largely absent in the psychotropic variety of cannabis.

Karl Vick for The Washington Post

Kristen Peskuski summarized her return to near-full health -- including debilitating lupus, interstitial cystitis, rheumatoid arthritis and 40 medications a day -- after juicing fresh pot leaves over a 30-month period. Courtney's approach promotes marijuana as a good-for-you vegetable like spinach.

Raw bud has a high concentration of cannabinoids and is excellent for consumption. When consumed, raw marijuana generally does not make a person high. The main psychoactive compound in dried, aged cannabis is delta-9 THC, which is absent in the raw, fresh leaf. However, the other compounds, such as the terpenes, may have an effect on mood or energy levels. Raw leaf contains mainly THC acid (not THC) unless you are using a strain that is much higher in CBD. In that case, you will be getting some CBD from the leaf. Leaves are picked from a plant that is about three months of age. Buds should be at the state where the trichomes are fully present but not yet amber (i.e. cloudy).

Some of the benefits of raw cannabis include:

Immune modulating ----------- Anti-diabetic

Anti-inflammatory ------------- Neuroprotective

Antioxidant --------------------- Antispasmodic

Anti-tumor/anti-cancer ------- Anti-anxiety

Bone stimulation -------------- Antibacterial

Pain-relieving

What are the "active" ingredients in raw cannabis if there is no delta-9 THC?

Terpenes ---------------------- Cannabigerol (CBG)

Flavonoids -------------------- Cannabidivarin (CBDV)

Phytocannabinoids ---------- Cannabichromene (CBC)

Cannabinol (CBN) ----------- CBD Acid

Cannabidiol (CBD) ---------- THC Acid

Cannabigerol (CBG)

There are more than 525 molecules found in raw cannabis, some with synergistic effects. According to Dr. Courtney it takes about 4-8 weeks before full clinical benefit is reached. It takes that long to fully saturate the fat tissue with phyto-cannabinoids. Phyto-cannabinoids are fat molecules that are stored in the adipose or fat tissue similar to the fat-soluble vitamins A, D, E and K. It appears that a wheat grass juicer is probably the best method of breaking up the cannabis plant cells. Mix with a minimal amount of organic fruit or vegetable juice -- just enough to cut the bitter taste of the raw cannabis. Choose lower sugar juices to minimize your ingestion of simple sugars. Store leaves in a green bag in the refrigerator; do not rinse until immediately before using. Dr. Courtney recommends soaking leaves in water for five minutes before juicing.

Use organic cannabis that does not have any pesticides applied at any point in its life cycle. Dr. Courtney recommends using ten large fan leaves per day in juice, salsa, pesto, salad, etc. If you have access to fresh bud, he recommends one bud/day.

Cannabinoids and THCA are cleared rapidly from the blood, so frequent consumption of a small amount of juice is ideal. Split the juice into five parts for five divided doses per day.

Special Note: Part two of this essay Rick Simpson on Hemp Oil and Marijuana Tinctures is coming soon.

For all the references, sources and more articles, please visit Dr. Mark Sircus blog.

About the author:

About the author:

Mark A. Sircus, Ac., OMD, is director of the International Medical Veritas Association (IMVA) http://www.imva.info/.

Dr. Sircus was trained in acupuncture and oriental medicine at the Institute of Traditional Medicine in Sante Fe, N.M., and at the School of Traditional Medicine of New England in Boston. He served at the Central Public Hospital of Pochutla in Mexico, and was awarded the title of doctor of oriental medicine for his work. He was one of the first nationally certified acupuncturists in the United States. Dr. Sircus's IMVA is dedicated to unifying the various disciplines in medicine with the goal of creating a new dawn in healthcare.

He is particularly concerned about the effect vaccinations have on vulnerable infants and is identifying the common thread of many toxic agents that are dramatically threatening present and future generations of children. His book, The Terror of Pediatric Medicine, is a free e-book offered on his web site. Humane Pediatrics will be an e-book available early in 2011 and then quickly as possible put into print.

Dr. Sircus is a most prolific and courageous writer and one can read through hundreds of pages on his various web sites.

He has recently released a number of e-books including Winning the War Against Cancer, Survival Medicine for the 21st Century, Sodium Bicarbonate, Rich Man’s Poor Man’s Cancer Treatment, New Paradigms in Diabetic Care and Bringing Back the Universal Medicine: IODINE.

Dr. Sircus is a pioneer in the area of natural detoxification and chelation of toxic chemicals and heavy metals. He is also a champion of the medicinal value of minerals and seawater.

Transdermal Magnesium Therapy, his first published work, offers a stunning breakthrough in medicine, an entirely new way to supplement magnesium that naturally increases DHEA levels, brings cellular magnesium levels up quickly, relieves pain, brings down blood pressure and pushes cell physiology in a positive direction. Magnesium chloride delivered transdermally brings a quick release from a broad range of conditions. His second edition of Transdermal Magnesium Therapy will be out shortly. In addition he writes critically about the political and financial crises occurring around us.

International Medical Veritas Association: http://www.imva.info/

http://publications.imva.info/

Stay informed! FREE subscription to the Health Ranger's email newsletter

Get breaking health news + a LIFETIME 7% discount on everything at the NaturalNews Store

Join two million monthly readers. Email privacy 100% protected. Unsubscribe at any time.

Articles Related to This Article:

• PBS documentary highlights marijuana's amazing ability to treat disease

• Denied: DEA refuses to reclassify marijuana, claims it's as dangerous as heroin

• Willie Nelson pot possession charge shows ludicrousness of marijuana prohibition

• Calls for Further Research into Medicinal Marijuana Gain Momentum

• Medical Marijuana Debate: Science is Ignored

• Cannabinoid Medicine

• PBS documentary highlights marijuana's amazing ability to treat disease

• Denied: DEA refuses to reclassify marijuana, claims it's as dangerous as heroin

• Willie Nelson pot possession charge shows ludicrousness of marijuana prohibition

• Calls for Further Research into Medicinal Marijuana Gain Momentum

• Medical Marijuana Debate: Science is Ignored

• Cannabinoid Medicine

Take Action: Support NaturalNews.com

Email this article to a friend

Share this article on: NewsVine
digg
del.icio.us

Permalink to this article:

http://www.naturalnews.com/034425_marijuana_cannabinoids_medicine.html

Reprinting this article: Non-commercial use OK, cite NaturalNews.com with clickable link.

Embed article link: (copy HTML code below):

Marijuana cannabinoids - oral and transdermal methods

Most Popular

Today
Week
Month
Year

Pepsi's lawyers say Mountain Dew can dissolve a mouse

Juicing medical marijuana the latest trend in amazing cures

Five practical ways to raise your consciousness in 2012 (and beyond)

Eating healthy on a budget

Weight Watchers says eat at McDonald's to lose weight (opinion)

How to detox aluminum and why it's necessary

Why McDonald's Happy Meal hamburgers won't decompose - the real story behind the story

Homeopathic alternatives to antidepressant drugs

Study: Fukushima killed at least 14,000 people in the US, mostly babies, in weeks following disaster

Mediterranean diet and reduced calorie intake promote brain health and longevity

Proteins, not sugar, increase energy expenditure

Vitamin C mega-dosing continues to unleash healing miracles around the world

25 predictions for 2012 - 2015 (plus five things that won't happen)

Pepsi's lawyers say Mountain Dew can dissolve a mouse

R.I.P. Bill of Rights 1789 - 2011

Study: Fukushima killed at least 14,000 people in the US, mostly babies, in weeks following disaster

Myth busted: Yes, the NDAA does apply to Americans, and here's the text that says so

Juicing medical marijuana the latest trend in amazing cures

IBM helped automate Hitler's holocaust death machine, author reveals

Weight Watchers says eat at McDonald's to lose weight (opinion)

Woman files class action lawsuit against Frito-Lay for marketing genetically-modified snacks as 'all natural'

Mediterranean diet and reduced calorie intake promote brain health and longevity

Eating healthy on a budget

Vitamin C mega-dosing continues to unleash healing miracles around the world

R.I.P. Bill of Rights 1789 - 2011

Should you leave the USA before the collapse? Words of wisdom from someone who tried

Artificial Sweetener Disease; a new breed of sickness

Myth busted: Yes, the NDAA does apply to Americans, and here's the text that says so

No longer just theories: The top 10 conspiracy facts of 2011

Collecting rainwater now illegal in many states as Big Government claims ownership over our water

25 predictions for 2012 - 2015 (plus five things that won't happen)

The top 10 most censored Natural News stories of 2011

How to heal a cavity naturally and nutritionally without the need for 'drilling and filling'

Pepsi's lawyers say Mountain Dew can dissolve a mouse

America's farmlands to be carpet-bombed with Vietnam-era Agent Orange chemical if Dow petition approved

Obama to fill Gitmo with Americans as NDAA law passes

R.I.P. Bill of Rights 1789 - 2011

FDA finally admits chicken meat contains cancer-causing arsenic (but keep eating it, yo!)

14 signs that the collapse of our modern world has already begun

Forensic evidence emerges that European e.coli superbug was bioengineered to produce human fatalities

7 surprising things you're not supposed to know about sunscreen and sunlight exposure

Collecting rainwater now illegal in many states as Big Government claims ownership over our water

Anti-foaming agent found in Chicken McNuggets

CDC warns Americans to prepare for zombie apocalypse (really)

Should you leave the USA before the collapse? Words of wisdom from someone who tried

Artificial Sweetener Disease; a new breed of sickness

Shock finding: More than 75 percent of all 'honey' sold in grocery stores contains no honey at all, by definition (Updated)

Thirty-six predictions for the world: 2010 - 2012

See all Top Headlines...

Now Available from NaturalNews.TV

Across the Web

THERMONUCLEAR WAR: Wall Street denizens threaten lawsuit or quitting if yearly bonuses aren't same or better than previous year (New York Post)

MUST READ: Insecticide, Flame Retardant, Jet Fuel Chemicals in Top Selling Supplement Brands (Activist Post)

FASCINATING: A Medical Tell-All Can Be Found in Urine (New York Times)

VITAL READ: Strategies For Survival: Are You Going To Be A Refugee Or Evacuee? (Codgerville)

SATAN SKATES: W. Virginia ruling leaves dioxin cleanup out of Monsanto trial (Saturday Gazette-Mail)

U.S. tightens fishing policy, setting 2012 catch limits for all managed species (Washington Post)

What Really Causes Crooked Teeth? (Healthy Home Economist)

Glass of Red Wine a Day Could Keep Breast Cancer Away, New Cedars-Sinai Research Shows (The Informer)

Fraud and folly: The untold story of General Electric's subprime debacle (iWatch News)

For Kids With ADHD, Some Foods May Complement Treatment (NPR)

MUST READ: Why the Wealthy Own Gold (Goldseek)

By the Pricking of Equity's Thumbs, Something Wicked This Way Comes (Of Two Minds)

Complex Systems, Dysfunctional Industries, and Catastrophic Collapse (Dollar Collapse)

IMPRESSIVE: Ford pushes the 2013 Fusion hybrid to 100 mpg (Yahoo)

Things That Make You Go Hmmm.... (Zero Hedge)

SHOCK: Report Finds Only 1 out of 7 Errors at Hospitals Go Unreported! (New York Times)

EXCELLENT: Unemployment Drop Masks Ongoing Decline (USA Watchdog)

FBI pushes to classify undercover factory farm animal abuse investigations as terrorism (Natural News)

Homeopathic alternatives to antidepressant drugs (Natural News)

Less Bloat, More Gloat: Using Chinese Medicine to Fight Winter Fat (Huff Post)

Healthy Processed Foods: Do They Exist? (Huff Post)

How Yoga Can Wreck Your Body (New York Times)

The Fall of Ireland's Mighty Quinn (New York Times)

Top 20 fitness trends of 2012 (CNN)

BIG PHARMA SCAM UNRAVELS: Nicotine Gum, Patch Don't Help Smokers Quit Long Term; No Better Than Cold Turkey (Time Healthland)

More News...

Also on NaturalNews:

Advertise with NaturalNews...

Most Popular Stories

Collecting rainwater now illegal in many states as Big Government claims ownership over our water 99K

Share

FDA finally admits chicken meat contains cancer-causing arsenic (but keep eating it, yo!) 80K

Share

Senate Bill S 510 Food Safety Modernization Act vote imminent: Would outlaw gardening and saving seeds 76K

Share

Anti-foaming agent found in Chicken McNuggets 50K

Share

R.I.P. Bill of Rights 1789 - 2011 37K

Share

Court rules organic farmers can sue conventional, GMO farmers whose pesticides 'trespass' and contaminate their fields 36K

Share

Federal agents raid Mormon food storage facility, demand list of customers storing emergency food 33K

Share

Why McDonald's Happy Meal hamburgers won't decompose - the real story behind the story 32K

Share

14 signs that the collapse of our modern world has already begun 31K

Share

H1N1 vaccine linked to 700 percent increase in miscarriages 31K

Share

Forensic evidence emerges that European e.coli superbug was bioengineered to produce human fatalities 30K

Share

Artificial Sweetener Disease; a new breed of sickness 29K

Share

The NaturalNews Store

Huge discounts on supplements, raw foods, botanicals and healthly personal care products. Save up to 50%! Click here to see the current sale items

Health Ranger Storable Organics

GMO-free, chemical-free foods and superfoods for long-term storage and preparedness. Bulk pricing! Shipping immediately. See selection at www.StorableOrganics.com

25 Amazing Facts About Food

This FREE downloadable report unveils a collection of astonishing and little-known facts about the food we eat very day. Click here to read it now...

Resveratrol and its Effects on Human Health and Longevity - Myth or Miracle.

Unlock the secrets of cellular health with the "miracle" nutrient Resveratrol Click here to read it now...

Nutrition Can Save America

FREE online report shows how we can save America through a nutrition health care revolution. "Eating healthy is patriotic!" Click here to read it now...

The Healing Power of Sunlight and Vitamin D

In this exclusive interview, Dr. Michael Holick reveals fascinating facts on how vitamin D is created and used in the human body to ward off chronic diseases like cancer, osteoporosis, mental disorders and more. Click here to read it now...

Vaccines: Get the Full Story

The International Medical Council on Vaccination has released, exclusively through NaturalNews.com, a groundbreaking document containing the signatures of physicians, brain surgeons and professors, all of which have signed on to a document stating that vaccines pose a significant risk of harm to the health of children. Click here to read it now.

This site is part of the Natural News Network © 2011 All Rights Reserved. Privacy
Terms All content posted on this site is commentary or opinion and is protected under Free Speech. Truth Publishing International, LTD. is not responsible for content written by contributing authors. The information on this site is provided for educational and entertainment purposes only. It is not intended as a substitute for professional advice of any kind. Truth Publishing assumes no responsibility for the use or misuse of this material. Your use of this website indicates your agreement to these terms and those published here. All trademarks, registered trademarks and servicemarks mentioned on this site are the property of their respective owners.

Learn more: http://www.naturalnews.com/034425_marijuana_cannabinoids_medicine.html#ixzz1j53Mr4U3

Most Shocking WikiLeaks Yet

2012-01-09T09:12:00.000-08:00

http://youtu.be/F_h3kLV3C1c

Forty per cent increase in Brain cells with cannabis use.

Peer Reviewed Cannabis and Cancer References

2012-01-07T07:47:00.000-08:00

Peer Reviewed Cannabis and Cancer References

1. Argaw, A. et al. Concerted Action of CB1 Cannabinoid Receptor and Deleted in

Colorectal Cancer in Axon Guidance. J Neurosci 31, 1489-1499 (2011).

2. Malfitano, A. M. et al. Update on the endocannabinoid system as an anticancer

target. Expert Opin Ther Targets (2011).

3. Lorente, M. et al. Stimulation of the midkine/ALK axis renders glioma cells

resistant to cannabinoid antitumoral action. Cell Death Differ (2011).

4. Karasu, T., Marczylo, T. H., Maccarrone, M. & Konje, J. C. The role of sex steroid

hormones, cytokines and the endocannabinoid system in female fertility. Hum

Reprod Update (2011).

5. Torres, S. et al. A Combined Preclinical Therapy of Cannabinoids and

Temozolomide against Glioma. Mol Cancer Ther 10, 90-103 (2011).

6. Hsu, E. S. A review of granisetron, 5-hydroxytryptamine3 receptor antagonists, and

other antiemetics. Am J Ther 17, 476-486 (2010).

7. Van Ryckeghem, F. & Van Belle, S. Management of chemotherapy-induced nausea

and vomiting. Acta Clin Belg 65, 305-310 (2010).

8. Jordan, K. et al. Antiemetics in children receiving chemotherapy. MASCC/ESMO

guideline update 2009. Support Care Cancer (2010).

9. Liu, W. M., Fowler, D. W. & Dalgleish, A. G. Cannabis-Derived Substances in

Cancer Therapy - an Emerging Anti-Inflammatory Role for the Cannabinoids. Curr

Clin Pharmacol (2010).

10. Larrinaga, G. et al. Cannabinoid CB1 Receptor Is Down-regulated in Clear Cell

Renal Cell Carcinoma. J Histochem Cytochem (2010).

11. Lam, P. M., Marczylo, T. H. & Konje, J. C. Simultaneous measurement of three Nacylethanolamides

in human bio-matrices using ultra performance liquid

chromatography-tandem mass spectrometry. Anal Bioanal Chem (2010).

12. Tazi, E. & Errihani, H. Treatment of cachexia in oncology. Indian J Palliat Care

16, 129-137 (2010).

13. Thapa, D. et al. Novel hexahydrocannabinol analogs as potential anti-cancer agents

inhibit cell proliferation and tumor angiogenesis. Eur J Pharmacol (2010).

14. Amoako, A. A. et al. Quantitative analysis of anandamide and related

acylethanolamides in human seminal plasma by ultra performance liquid

chromatography tandem mass spectrometry. J Chromatogr B Analyt Technol

Biomed Life Sci (2010).

15. Peat, S. Using cannabinoids in pain and palliative care. Int J Palliat Nurs 16, 481-

485 (2010).

16. Hu, G., Ren, G. & Shi, Y. The putative cannabinoid receptor GPR55 promotes

cancer cell proliferation. Oncogene (2010).

17. Preet, A. et al. Cannabinoid Receptors, CB1 and CB2, as Novel Targets for

Inhibition of Non-Small Cell Lung Cancer Growth and Metastasis. Cancer Prev

Res (Phila) (2010).

18. Saghafi, N., Lam, D. K. & Schmidt, B. L. Cannabinoids Attenuate Cancer Pain and

Proliferation in a Mouse Model. Neurosci Lett (2010).

19. Karschner, E. L., Darwin, W. D., Goodwin, R. S., Wright, S. & Huestis, M. A.

Plasma Cannabinoid Pharmacokinetics following Controlled Oral {Delta}9-

Tetrahydrocannabinol and Oromucosal Cannabis Extract Administration. Clin

Chem (2010).

20. Lin, H. C. et al. The relationship between endotoxemia and hepatic

endocannabinoids in cirrhotic rats with portal hypertension. J Hepatol (2010).

21. Duran, M. et al. Preliminary efficacy and safety of an oromucosal standardized

cannabis extract in chemotherapy-induced nausea and vomiting. Br J Clin

Pharmacol 70, 656-663 (2010).

22. Lee, T. Y., Lee, K. C. & Chang, H. H. Modulation of the cannabinoid receptors by

andrographolide attenuates hepatic apoptosis following bile duct ligation in rats

with fibrosis. Apoptosis (2010).

23. Yang, Q., Liu, H. Y., Zhang, Y. W., Wu, W. J. & Tang, W. X. Anandamide induces

cell death through lipid rafts in hepatic stellate cells. J Gastroenterol Hepatol

(2010).

24. Labar, G., Wouters, J. & Lambert, D. M. A Review on the Monoacylglycerol

Lipase: At the Interface between Fat and Endocannabinoid Signalling. Curr Med

Chem (2010).

25. Frampton, G., Coufal, M., Li, H., Ramirez, J. & Demorrow, S. Opposing actions of

endocannabinoids on cholangiocarcinoma growth is via the differential activation of

Notch signaling. Exp Cell Res (2010).

26. Xian, X. S. et al. Effect of a synthetic cannabinoid agonist on the proliferation and

invasion of gastric cancer cells. J Cell Biochem (2010).

27. Jesus, M. L. et al. Opposite changes in cannabinoid CB(1) and CB(2) receptor

expression in human gliomas. Neurochem Int (2010).

28. Laezza, C. et al. Inhibition of HMG-CoA reductase activity and of Ras

farnesylation mediate antitumor effects of anandamide in human breast cancer cell.

Endocr Relat Cancer (2010).

29. Wu, W. J. et al. [Membrane cholesterol mediates the endocannabinoids-anandamide

effection on HepG2 cells.]. Zhonghua Gan Zang Bing Za Zhi 18, 204-208 (2010).

30. Fonseca, B. M. et al. N-Acylethanolamine Levels and Expression of Their

Metabolizing Enzymes during Pregnancy. Endocrinology (2010).

31. Fernandez-Solari, J., Prestifilippo, J. P., Ossola, C. A., Rettori, V. & Elverdin, J. C.

Participation of the endocannabinoid system in lipopolysaccharide-induced

inhibition of salivary secretion. Arch Oral Biol (2010).

32. Whyte, D. A. et al. Cannabinoids Inhibit Cellular Respiration of Human Oral

Cancer Cells. Pharmacology 85, 328-335 (2010).

33. Soneji, N. D., Paule, C. C., Mlynarczyk, M. & Nagy, I. Effects of cannabinoids on

capsaicin receptor activity following exposure of primary sensory neurons to

inflammatory mediators. Life Sci (2010).

34. Reiss, C. S. Cannabinoids and Viral Infections. Pharmaceuticals (Basel) 3, 1873-

1886 (2010).

35. Santha, P., Jenes, A., Somogyi, C. & Nagy, I. The endogenous cannabinoid

anandamide inhibits transient receptor potential vanilloid type 1 receptor-mediated

currents in rat cultured primary sensory neurons. Acta Physiol Hung 97, 149-158

(2010).

36. Ford, L. A. et al. A role for L-alpha-lysophosphatidylinositol and GPR55 in the

modulation of migration, orientation and polarization of human breast cancer cells.

Br J Pharmacol 160, 762-771 (2010).

37. Brown, I. et al. Cannabinoid receptor dependent and independent anti-proliferative

effects of omega-3 ethanolamides in androgen receptor positive and negative

prostate cancer cell lines. Carcinogenesis (2010).

38. Caffarel, M. M. et al. Cannabinoids reduce ErbB2-driven breast cancer progression

through Akt inhibition. Mol Cancer 9, 196 (2010).

39. Park, J. Y. et al. Alcohol intake and risk of colorectal cancer: Results from the UK

Dietary Cohort Consortium. Br J Cancer (2010).

40. Linsalata, M. et al. Effects of anandamide on polyamine levels and cell growth in

human colon cancer cells. Anticancer Res 30, 2583-2589 (2010).

41. Marcu, J. P. et al. Cannabidiol Enhances the Inhibitory Effects of {Delta}9-

Tetrahydrocannabinol on Human Glioblastoma Cell Proliferation and Survival. Mol

Cancer Ther (2010).

42. Petrosino, S. & Di Marzo, V. FAAH and MAGL inhibitors: therapeutic

opportunities from regulating endocannabinoid levels. Curr Opin Investig Drugs

11, 51-62 (2010).

43. Patel, K. D., Davison, J. S., Pittman, Q. J. & Sharkey, K. A. Cannabinoid CB(2)

Receptors in Health and Disease. Curr Med Chem (2010).

44. Martini, L., Thompson, D., Kharazia, V. & Whistler, J. L. Differential Regulation

of Behavioral Tolerance to WIN55,212-2 by GASP1. Neuropsychopharmacology

(2010).

45. Gao, M., Wang, M., Miller, K. D., Hutchins, G. D. & Zheng, Q. H. Synthesis and in

vitro biological evaluation of carbon-11-labeled quinoline derivatives as new

candidate PET radioligands for cannabinoid CB2 receptor imaging. Bioorg Med

Chem (2010).

46. Zoppi, S. et al. Regulatory Role of Cannabinoid Receptor 1 in Stress-Induced

Excitotoxicity and Neuroinflammation. Neuropsychopharmacology (2010).

47. Cui, J. H. et al. Antinociceptive effect of intrathecal cannabinoid receptor agonist

WIN 55,212-2 in a rat bone tumor pain model. Neurosci Lett (2010).

48. Kalifa, S., Polston, E. K., Allard, J. S. & Manaye, K. F. Distribution Patterns of

Cannabinoid CB1 receptors in the hippocampus of APP(swe)/PS1(DeltaE9) double

transgenic mice. Brain Res (2010).

49. De Petrocellis, L. et al. Effects of cannabinoids and cannabinoid-enriched Cannabis

extracts on TRP channels and endocannabinoid metabolic enzymes. Br J

Pharmacol (2010).

50. Miro, A. M. et al. 17beta-Estradiol regulates oxidative stress in prostate cancer cell

lines according to ERalpha/ERbeta ratio. J Steroid Biochem Mol Biol (2010).

51. Nithipatikom, K., Isbell, M. A., Endsley, M. P., Woodliff, J. E. & Campbell, W. B.

Anti-proliferative Effect of a Putative Endocannabinoid; 2-Arachidonylglyceryl

Ether in Prostate Carcinoma Cells. Prostaglandins Other Lipid Mediat (2010).

52. Nunez, M., Perdomo, S., Moreta, J., Santos-Briz, A. & Gonzalez-Sarmiento, R. The

G1359A-CNR1 gene polymorphism is associated to glioma in Spanish patients.

Clin Transl Oncol 12, 825-828 (2010).

53. Ward, H., Luben, R. N., Wareham, N. J. & Khaw, K. T. CHD risk in relation to

alcohol intake from categorical and open-ended dietary instruments. Public Health

Nutr 1-8 (2010).

54. Yang, Y. Y., Liu, H., Nam, S. W., Kunos, G. & Lee, S. S. Mechanisms of

TNFalpha-induced cardiac dysfunction in cholestatic bile duct-ligated mice:

interaction between TNFalpha and endocannabinoids. J Hepatol 53, 298-306

(2010).

55. Miranville, A., Herling, A. W., Biemer-Daub, G. & Voss, M. D. Reversal of

Inflammation-Induced Impairment of Glucose Uptake in Adipocytes by Direct

Effect of CB1 Antagonism on Adipose Tissue Macrophages. Obesity (Silver

Spring) (2010).

56. Kawamata, T., Niiyama, Y., Yamamoto, J. & Furuse, S. Reduction of bone cancer

pain by CB1 activation and TRPV1 inhibition. J Anesth (2010).

57. Fowler, C. J. et al. Targeting the Endocannabinoid System for the Treatment of

Cancer - A Practical View. Curr Top Med Chem (2010).

58. Taylor, A. H., Abbas, M. S., Habiba, M. A. & Konje, J. C. Histomorphometric

evaluation of cannabinoid receptor and anandamide modulating enzyme expression

in the human endometrium through the menstrual cycle. Histochem Cell Biol

(2010).

59. Gallotta, D. et al. Rimonabant-induced apoptosis in leukemia cell lines: activation

of caspase-dependent and -independent pathways. Biochem Pharmacol (2010).

60. Mukhopadhyay, B. et al. Transcriptional regulation of cannabinoid receptor-1

expression in the liver by retinoic acid acting via retinoic acid receptor-{gamma}. J

Biol Chem (2010).

61. De Laurentiis, A., Fernandez Solari, J., Mohn, C., Zorrilla Zubilete, M. & Rettori,

V. Endocannabinoid System Participates in Neuroendocrine Control of

Homeostasis. Neuroimmunomodulation 17, 153-156 (2010).

62. Thors, L. et al. Fatty Acid Amide Hydrolase in Prostate Cancer: Association with

Disease Severity and Outcome, CB(1) Receptor Expression and Regulation by IL-4.

PLoS One 5, (2010).

63. Phillips, R. S. et al. Antiemetic medication for prevention and treatment of

chemotherapy induced nausea and vomiting in childhood. Cochrane Database Syst

Rev 9, CD007786 (2010).

64. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. The

cannabinoid R(+)methanandamide induces IL-6 secretion by prostate cancer PC3

cells. J Immunotoxicol (2009).

65. Izzo, A. A., Borrelli, F., Capasso, R., Di Marzo, V. & Mechoulam, R. Nonpsychotropic

plant cannabinoids: new therapeutic opportunities from an ancient

herb. Trends Pharmacol Sci (2009).

66. Wainwright, C. & McGrath, J. Editorial. Br J Pharmacol 158, 393-394 (2009).

67. Guindon, J. & Hohmann, A. G. The Endocannabinoid System and Pain. CNS

Neurol Disord Drug Targets (2009).

68. Horn, C. C., Still, L., Fitzgerald, C. & Friedman, M. I. Food restriction, refeeding,

and gastric fill fail to affect emesis in musk shrews. Am J Physiol Gastrointest Liver

Physiol (2009).

69. Freimuth, N., Ramer, R. & Hinz, B. Antitumorigenic effects of cannabinoids

beyond apoptosis. J Pharmacol Exp Ther (2009).

70. Tournier, N. et al. Interaction of drugs of abuse and maintenance treatments with

human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). Int

J Neuropsychopharmacol 1-11 (2009).

71. Johnson, J. R. et al. Multicenter, Double-Blind, Randomized, Placebo-Controlled,

Parallel-Group Study of the Efficacy, Safety, and Tolerability of THC:CBD Extract

and THC Extract in Patients With Intractable Cancer-Related Pain. J Pain Symptom

Manage (2009).

72. Qamri, Z. et al. Synthetic cannabinoid receptor agonists inhibit tumor growth and

metastasis of breast cancer. Mol Cancer Ther (2009).

73. Rask-Andersen, M., Olszewski, P. K., Levine, A. S. & Schioth, H. B. Molecular

mechanisms underlying anorexia nervosa: Focus on human gene association studies

and systems controlling food intake. Brain Res Rev (2009).

74. De Filippis, D. et al. LEVELS OF ENDOCANNABINOIDs AND

PALMITOYLETHANOLAMIDE AND THEIR PHARMACOLOGICAL

MANIPULATION IN CHRONIC GRANULOMATOUS INFLAMMATION IN

RATs. Pharmacol Res (2009).

75. Leelawat, S., Leelawat, K., Narong, S. & Matangkasombut, O. The Dual Effects of

Delta(9)-Tetrahydrocannabinol on Cholangiocarcinoma Cells: Anti-Invasion

Activity at Low Concentration and Apoptosis Induction at High Concentration.

Cancer Invest (2009).

76. Ramer, R., Merkord, J., Rohde, H. & Hinz, B. Cannabidiol Inhibits Cancer Cell

Invasion Via Upregulation Of Tissue Inhibitor Of Matrix Metalloproteinases-1.

Biochem Pharmacol (2009).

77. Brighton, P. J. et al. Characterization of anandamide-stimulated cannabinoid

receptor signaling in human ULTR myometrial smooth muscle cells. Mol

Endocrinol (2009).

78. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids, their congeners and

COX-2 metabolites. J Chromatogr B Analyt Technol Biomed Life Sci (2009).

79. Takeda, S., Yamamoto, I. & Watanabe, K. Modulation of Delta(9)-

tetrahydrocannabinol-induced MCF-7 breast cancer cell growth by cyclooxygenase

and aromatase. Toxicology 259, 25-32 (2009).

80. Cotter, J. Efficacy of Crude Marijuana and Synthetic Delta-9-Tetrahydrocannabinol

as Treatment for Chemotherapy-Induced Nausea and Vomiting: A Systematic

Literature Review. Oncol Nurs Forum 36, 345-352 (2009).

81. Wegener, N. & Koch, M. Neurobiology and Systems Physiology of the

Endocannabinoid System. Pharmacopsychiatry 42, S79-S86 (2009).

82. Brizzi, A. et al. New Resorcinol-Anandamide "Hybrids" as Potent Cannabinoid

Receptor Ligands Endowed with Antinociceptive Activity in Vivo. J Med Chem

(2009).

83. Izzo, A. A. & Camilleri, M. Cannabinoids in intestinal inflammation and cancer.

Pharmacol Res (2009).

84. Yin, H. et al. Lipid G-protein-coupled Receptor Ligand Identification Using beta -

arrestin Pathhunter Assay. J Biol Chem (2009).

85. Villanueva, A. et al. Central Cannabinoid-1 Receptor Antagonist Administration

Prevents Endotoxic Hypotension Affecting Norepinephrine Release in the Preoptic

Anterior Hypothalamic Area. Shock (2009).

86. Farquhar-Smith, W. P. Do cannabinoids have a role in cancer pain management?

Curr Opin Support Palliat Care 3, 7-13 (2009).

87. Navari, R. M. Antiemetic control: toward a new standard of care for emetogenic

chemotherapy. Expert Opin Pharmacother 10, 629-644 (2009).

88. Oesch, S. et al. Cannabinoid receptor 1 is a potential drug target for treatment of

translocation-positive rhabdomyosarcoma. Mol Cancer Ther (2009).

89. Furuse, S. et al. Reduction of Bone Cancer Pain by Activation of Spinal

Cannabinoid Receptor 1 and Its Expression in the Superficial Dorsal Horn of the

Spinal Cord in a Murine Model of Bone Cancer Pain. Anesthesiology (2009).

90. Schley, M. et al. Predominant CB2 receptor expression in endothelial cells of

glioblastoma in humans. Brain Res Bull 79, 333-337 (2009).

91. Udler, M. S. et al. Common germline polymorphisms in COMT, CYP19A1, ESR1,

PGR, SULT1E1 and STS and survival after a diagnosis of breast cancer. Int J

Cancer (2009).

92. Luca, T. et al. The CB(1)/CB(2) receptor agonist WIN-55,212-2 reduces viability of

human Kaposi's sarcoma cells in vitro. Eur J Pharmacol (2009).

93. Galal, A. M. et al. Naturally Occurring and Related Synthetic Cannabinoids and

their Potential Therapeutic Applications. Recent Pat CNS Drug Discov 4, 112-136

(2009).

94. Liang, C. et al. A Population-Based Case-Control Study of Marijuana Use and Head

and Neck Squamous Cell Carcinoma. Cancer Prev Res (Phila Pa) (2009).

95. Surtees, P. G., Wainwright, N. W., Luben, R. N., Khaw, K. T. & Bingham, S. A.

No evidence that social stress is associated with breast cancer incidence. Breast

Cancer Res Treat (2009).

96. Biro, T., Toth, B. I., Hasko, G., Paus, R. & Pacher, P. The endocannabinoid system

of the skin in health and disease: novel perspectives and therapeutic opportunities.

Trends Pharmacol Sci (2009).

97. Han, K. H. et al. CB1 and CB2 Cannabinoid Receptors Differentially Regulate the

Production of Reactive Oxygen Species by Macrophages. Cardiovasc Res (2009).

98. Oesch, S. & Gertsch, J. Cannabinoid receptor ligands as potential anticancer agents

- high hopes for new therapies? J Pharm Pharmacol 61, 839-853 (2009).

99. Gustafsson, K., Sander, B., Bielawski, J., Hannun, Y. A. & Flygare, J. Potentiation

of cannabinoid-induced cytotoxicity in mantle cell lymphoma through modulation

of ceramide metabolism. Mol Cancer Res 7, 1086-1098 (2009).

100. Ramesh, Shukla, N. K. & Bhatnagar, S. Phantom breast syndrome. Indian J Palliat

Care 15, 103-107 (2009).

101. Surtees, P. G. et al. No association between APOE and major depressive disorder in

a community sample of 17,507 adults. J Psychiatr Res (2009).

102. Dunning, A. M. et al. Association of ESR1 gene tagging SNPs with breast cancer

risk. Hum Mol Genet (2009).

103. Van Dross, R. T. Metabolism of anandamide by COX-2 is necessary for

endocannabinoid-induced cell death in tumorigenic keratinocytes. Mol Carcinog

(2009).

104. Lorente, M. et al. Amphiregulin is a factor for resistance of glioma cells to

cannabinoid-induced apoptosis. Glia (2009).

105. Pisanti, S. et al. Use of cannabinoid receptor agonists in cancer therapy as palliative

and curative agents. Best Pract Res Clin Endocrinol Metab 23, 117-131 (2009).

106. Froger, N. et al. Cannabinoids prevent the opposite regulation of astroglial

connexin43 hemichannels and gap junction channels induced by pro-inflammatory

treatments. J Neurochem 111, 1383-1397 (2009).

107. Madeddu, C. & Mantovani, G. An update on promising agents for the treatment of

cancer cachexia. Curr Opin Support Palliat Care (2009).

108. Mantovani, G. & Madeddu, C. Cancer cachexia: medical management. Support

Care Cancer (2009).

109. Olea-Herrero, N., Vara, D., Malagarie-Cazenave, S. & Diaz-Laviada, I. Inhibition

of human tumour prostate PC-3 cell growth by cannabinoids R(+)-Methanandamide

and JWH-015: Involvement of CB(2). Br J Cancer (2009).

110. Zhao, P., Leonoudakis, D., Abood, M. E. & Beattie, E. Cannabinoid Receptor

Activation Reduces TNFalpha-Induced Surface Localization of AMPAR-Type

Glutamate Receptors and Excitotoxicity. Neuropharmacology (2009).

111. Pisanti, S. & Bifulco, M. Endocannabinoid system modulation in cancer biology

and therapy. Pharmacol Res 60, 107-116 (2009).

112. Moayyeri, A. et al. Estimation of absolute fracture risk among middle-aged and

older men and women: the EPIC-Norfolk population cohort study. Eur J Epidemiol

(2009).

113. Santoro, A. et al. Rimonabant inhibits human colon cancer cell growth and reduces

the formation of precancerous lesions in the mouse colon. Int J Cancer (2009).

114. Wang, Q. et al. Pretreatment With Electroacupuncture Induces Rapid Tolerance to

Focal Cerebral Ischemia Through Regulation of Endocannabinoid System. Stroke

(2009).

115. Gallant, M., Odei-Addo, F., Frost, C. L. & Levendal, R. A. Biological effects of

THC and a lipophilic cannabis extract on normal and insulin resistant 3T3-L1

adipocytes. Phytomedicine (2009).

116. Salazar, M. et al. Cannabinoid action induces autophagy-mediated cell death

through stimulation of ER stress in human glioma cells. J Clin Invest (2009).

117. El-Talatini, M. R. et al. Localisation and function of the endocannabinoid system in

the human ovary. PLoS ONE 4, e4579 (2009).

118. Keeley, P. W. Nausea and vomiting in people with cancer and other chronic

diseases. Clin Evid (Online) 2009, (2009).

119. Alpini, G. & Demorrow, S. Chapter 18 Changes in the Endocannabinoid System

May Give Insight into new and Effective Treatments for Cancer. Vitam Horm 81C,

469-485 (2009).

120. Bifulco, M., Santoro, A., Laezza, C. & Malfitano, A. M. Chapter 7 Cannabinoid

Receptor CB1 Antagonists State of the Art and Challenges. Vitam Horm 81, 159-

189 (2009).

121. Wang, J. et al. Expression and secretion of N-acylethanolamine-hydrolyzing acid

amidase in human prostate cancer cells. J Biochem (2008).

122. Zuardi, A. W. Cannabidiol: from an inactive cannabinoid to a drug with wide

spectrum of action. Rev Bras Psiquiatr 30, 271-280 (2008).

123. Khasabova, I. A. et al. A decrease in anandamide signaling contributes to the

maintenance of cutaneous mechanical hyperalgesia in a model of bone cancer pain.

J Neurosci 28, 11141-11152 (2008).

124. Eichele, K., Ramer, R. & Hinz, B. R(+)-Methanandamide-Induced Apoptosis of

Human Cervical Carcinoma Cells Involves A Cyclooxygenase-2-Dependent

Pathway. Pharm Res (2008).

125. Demorrow, S. et al. Anandamide inhibits cholangiocyte hyperplastic proliferation

via activation of thioredoxin 1/redox factor 1 and AP-1 activation. Am J Physiol

Gastrointest Liver Physiol 294, G506-19 (2008).

126. Van der Kooy, F., Pomahacova, B. & Verpoorte, R. Cannabis Smoke Condensate

II: Influence of Tobacco on Tetrahydrocannabinol Levels. Inhal Toxicol 1 (2008).

127. Burstein, S. & Salmonsen, R. Acylamido analogs of endocannabinoids selectively

inhibit cancer cell proliferation. Bioorg Med Chem (2008).

128. Czifra, G. et al. Increased expressions of cannabinoid receptor-1 and transient

receptor potential vanilloid-1 in human prostate carcinoma. J Cancer Res Clin

Oncol (2008).

129. Lissoni, P. et al. The endocannabinoid anandamide neither impairs in vitro T-cell

function nor induces regulatory T-cell generation. Anticancer Res 28, 3743-3748

(2008).

130. Giuliano, M. et al. Apoptosis induced in HepG2 cells by the synthetic cannabinoid

WIN: Involvement of the transcription factor PPARgamma. Biochimie (2008).

131. Purohit, V., Gao, B. & Song, B. J. Molecular Mechanisms of Alcoholic Fatty Liver.

Alcohol Clin Exp Res (2008).

132. Caffarel, M. M. et al. JunD is involved in the antiproliferative effect of Delta(9)-

tetrahydrocannabinol on human breast cancer cells. Oncogene (2008).

133. Casida, J. E., Nomura, D. K., Vose, S. C. & Fujioka, K. Organophosphate-sensitive

lipases modulate brain lysophospholipids, ether lipids and endocannabinoids. Chem

Biol Interact (2008).

134. Buznikov, G. A. et al. Amyloid Precursor Protein 96-110 and Beta-amyloid 1-42

Elicit Developmental Anomalies in Sea Urchin Embryos and Larvae That Are

Alleviated By Neurotransmitter Analogs for Acetylcholine, Serotonin and

Cannabinoids. Neurotoxicol Teratol (2008).

135. Zheng, D. et al. The cannabinoid receptors are required for ultraviolet-induced

inflammation and skin cancer development. Cancer Res 68, 3992-3998 (2008).

136. Deutsch, S. I. et al. Current Status of Cannabis Treatment of Multiple Sclerosis with

an Illustrative Case Presentation of a Patient with MS, Complex Vocal Tics,

Paroxysmal Dystonia, and Marijuana Dependence Treated with Dronabinol. CNS

Spectr 13, 393-403 (2008).

137. Surtees, P. G. et al. Psychological distress, major depressive disorder, and risk of

stroke. Neurology 70, 788-794 (2008).

138. De Petrocellis, L. et al. Plant-derived cannabinoids modulate the activity of

transient receptor potential channels of ankyrin type-1 (TRPA1) and melastatin

type-8 (TRPM-8). J Pharmacol Exp Ther (2008).

139. Blazquez, C. et al. Cannabinoids inhibit glioma cell invasion by down-regulating

matrix metalloproteinase-2 expression. Cancer Res 68, 1945-1952 (2008).

140. Endsley, M. P. et al. Expression and Function of Fatty Acid Amide Hydrolase in

Prostate Cancer. Int J Cancer (2008).

141. Iribarne, M. et al. Cannabinoid Receptors in Conjunctival Epithelium: Identification

and Functional Properties. Invest Ophthalmol Vis Sci (2008).

142. Gustafsson, K. et al. Expression of Cannabinoid Receptors Type 1 and Type 2 in

Non-hodkin Lymphoma: Growth Inhibition By Receptor Activation. Int J Cancer

(2008).

143. Bifulco, M., Malfitano, A. M., Pisanti, S. & Laezza, C. Endocannabinoids in

endocrine and related tumours. Endocr Relat Cancer 15, 391-408 (2008).

144. Widmer, M., Hanemann, O. & Zajicek, J. High concentrations of cannabinoids

activate apoptosis in human U373MG glioma cells. J Neurosci Res (2008).

145. Habayeb, O. M., Taylor, A. H., Bell, S. C., Taylor, D. J. & Konje, J. C. Expression

of the Endocannabinoid System in Human First Trimester Placenta and its Role in

Trophoblast Proliferation. Endocrinology (2008).

146. Machado Rocha, F. C., Stefano, S. C., DE Cassia Haiek, R., Rosa Oliveira, L. M. &

DA Silveira, D. X. Therapeutic use of Cannabis sativa on chemotherapy-induced

nausea and vomiting among cancer patients: systematic review and meta-analysis.

Eur J Cancer Care (Engl) (2008).

147. Rahn, E. J. et al. Selective Activation of Cannabinoid CB2 Receptors Suppresses

Neuropathic Nociception Induced by Treatment with the Chemotherapeutic Agent

Paclitaxel in Rats. J Pharmacol Exp Ther (2008).

148. van Diepen, H., Schlicker, E. & Michel, M. C. Prejunctional and peripheral effects

of the cannabinoid CB(1) receptor inverse agonist rimonabant (SR 141716).

Naunyn Schmiedebergs Arch Pharmacol (2008).

149. Gustafsson, S. B., Lindgren, T., Jonsson, M. & Jacobsson, S. O. Cannabinoid

receptor-independent cytotoxic effects of cannabinoids in human colorectal

carcinoma cells: synergism with 5-fluorouracil. Cancer Chemother Pharmacol

(2008).

150. von Bueren, A. O., Schlumpf, M. & Lichtensteiger, W. Delta(9)-

tetrahydrocannabinol inhibits 17beta-estradiol-induced proliferation and fails to

activate androgen and estrogen receptors in MCF7 human breast cancer cells.

Anticancer Res 28, 85-89 (2008).

151. Ramer, R. & Hinz, B. Inhibition of cancer cell invasion by cannabinoids via

increased expression of tissue inhibitor of matrix metalloproteinases-1. J Natl

Cancer Inst 100, 59-69 (2008).

152. Sarfaraz, S., Adhami, V. M., Syed, D. N., Afaq, F. & Mukhtar, H. Cannabinoids for

cancer treatment: progress and promise. Cancer Res 68, 339-342 (2008).

153. Warr, D. G. Chemotherapy- and cancer-related nausea and vomiting. Curr Oncol

15, S4-9 (2008).

154. Jones, J. D., Carney, S. T., Vrana, K. E., Norford, D. C. & Howlett, A. C.

Cannabinoid receptor-mediated translocation of NO-sensitive guanylyl cyclase and

production of cyclic GMP in neuronal cells. Neuropharmacology 54, 23-30 (2008).

155. Bari, M. et al. Type-1 cannabinoid receptors colocalize with caveolin-1 in neuronal

cells. Neuropharmacology 54, 45-50 (2008).

156. Blazquez, C. et al. Down-regulation of tissue inhibitor of metalloproteinases-1 in

gliomas: a new marker of cannabinoid antitumoral activity? Neuropharmacology

54, 235-243 (2008).

157. Notarnicola, M. et al. Estrogenic induction of cannabinoid CB1 receptor in human

colon cancer cell lines. Scand J Gastroenterol 43, 66-72 (2008).

158. Shi, Y. et al. Cannabinoid 2 receptor induction by IL-12 and its potential as a

therapeutic target for the treatment of anaplastic thyroid carcinoma. Cancer Gene

Ther 15, 101-107 (2008).

159. Massi, P. et al. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the

antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem

104, 1091-1100 (2008).

160. Rudolph, M. I. et al. The Influence of Mast Cell Mediators on Migration of SW756

Cervical Carcinoma Cells. J Pharmacol Sci 106, 208-218 (2008).

161. Ware1, M. A., Daeninck, P. & Maida, V. A review of nabilone in the treatment of

chemotherapy-induced nausea and vomiting. Ther Clin Risk Manag 4, 99-107

(2008).

162. Russo, E. B. Cannabinoids in the management of difficult to treat pain. Ther Clin

Risk Manag 4, 245-259 (2008).

163. Diaz, P. et al. 6-Methoxy-N-alkyl Isatin Acylhydrazone Derivatives as a Novel

Series of Potent Selective Cannabinoid Receptor 2 Inverse Agonists: Design,

Synthesis, and Binding Mode Prediction. J Med Chem (2008).

164. Sugamura, K. et al. Activated Endocannabinoid System in Coronary Artery Disease

and Antiinflammatory Effects of Cannabinoid 1 Receptor Blockade on

Macrophages. Circulation (2008).

165. Chung, S. C. et al. A high cannabinoid CB(1) receptor immunoreactivity is

associated with disease severity and outcome in prostate cancer. Eur J Cancer

(2008).

166. Cianchi, F. et al. Cannabinoid Receptor Activation Induces Apoptosis through

Tumor Necrosis Factor {alpha}-Mediated Ceramide De novo Synthesis in Colon

Cancer Cells. Clin Cancer Res 14, 7691-7700 (2008).

167. Anand, P., Whiteside, G., Fowler, C. J. & Hohmann, A. G. Targeting CB(2)

receptors and the endocannabinoid system for the treatment of pain. Brain Res Rev

(2008).

168. Yazulla, S. Endocannabinoids in the retina: From marijuana to neuroprotection.

Prog Retin Eye Res (2008).

169. Wang, D. et al. Loss of cannabinoid receptor 1 accelerates intestinal tumor growth.

Cancer Res 68, 6468-6476 (2008).

170. Santoro, A. et al. Reply to the letter to the editor "Long-term cannabinoid receptor

(CB1) blockade in obesity: Implications for the development of colorectal cancer".

Int J Cancer (2008).

171. Potenzieri, C., Harding-Rose, C. & Simone, D. A. The cannabinoid receptor

agonist, WIN 55, 212-2, attenuates tumor-evoked hyperalgesia through peripheral

mechanisms. Brain Res (2008).

172. Ernst, G. & Kongsgaard, U. E. [Use of cannabinoids in palliative medicine.].

Tidsskr Nor Laegeforen 128, 822-825 (2008).

173. DUBOIS. Turned-off Cannabinoid Receptor Turns on Colorectal Tumor Growth.

Newswise (2008).

174. Bilsland, L. G. & Greensmith, L. The endocannabinoid system in amyotrophic

lateral sclerosis. Curr Pharm Des 14, 2306-2316 (2008).

175. Massi, P., Valenti, M., Bolognini, D. & Parolaro, D. Expression and function of the

endocannabinoid system in glial cells. Curr Pharm Des 14, 2289-2298 (2008).

176. Galanti, G. et al. Delta 9-tetrahydrocannabinol inhibits cell cycle progression by

downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol 47,

1062-1070 (2008).

177. Izzo, A. A. et al. Increased endocannabinoid levels reduce the development of

precancerous lesions in the mouse colon. J Mol Med (2007).

178. Izzo, A. A. The cannabinoid CB(2) receptor: a good friend in the gut.

Neurogastroenterol Motil 19, 704-708 (2007).

179. Peters, M. & Kogan, N. M. HU-331: a cannabinoid quinone, with uncommon

cytotoxic properties and low toxicity. Expert Opin Investig Drugs 16, 1405-1413

(2007).

180. Michalski, C. W. et al. Cannabinoids in pancreatic cancer: Correlation with survival

and pain. Int J Cancer (2007).

181. Holland, M. L., Lau, D. T., Allen, J. D. & Arnold, J. C. The multidrug transporter

ABCG2 (BCRP) is inhibited by plant-derived cannabinoids. Br J Pharmacol

(2007).

182. Mukhopadhyay, S. & Tulis, D. A. Endocannabinoid regulation of matrix

metalloproteinases: implications in ischemic stroke. Cardiovasc Hematol Agents

Med Chem 5, 311-318 (2007).

183. Gary-Bobo, M. et al. Rimonabant reduces obesity-associated hepatic steatosis and

features of metabolic syndrome in obese Zucker fa/fa rats. Hepatology (2007).

184. Seamon, M. J., Fass, J. A., Maniscalco-Feichtl, M. & Abu-Shraie, N. A. Medical

marijuana and the developing role of the pharmacist. Am J Health Syst Pharm 64,

1037-1044 (2007).

185. Varvel, S. A., Martin, B. R. & Lichtman, A. H. Lack of behavioral sensitization

after repeated exposure to THC in mice and comparison to methamphetamine.

Psychopharmacology (Berl) (2007).

186. Slatkin, N. E. Cannabinoids in the treatment of chemotherapy-induced nausea and

vomiting: beyond prevention of acute emesis. J Support Oncol 5, 1-9 (2007).

187. Tham, C. S., Whitaker, J., Luo, L. & Webb, M. Inhibition of microglial fatty acid

amide hydrolase modulates LPS stimulated release of inflammatory mediators.

FEBS Lett 581, 2899-2904 (2007).

188. Taylor, A. H., Ang, C., Bell, S. C. & Konje, J. C. The role of the endocannabinoid

system in gametogenesis, implantation and early pregnancy. Hum Reprod Update

(2007).

189. Greenhough, A., Patsos, H. A., Williams, A. C. & Paraskeva, C. The cannabinoid

delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival

signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int J

Cancer (2007).

190. Gkoumassi, E. et al. Virodhamine and CP55,940 modulate cAMP production and

IL-8 release in human bronchial epithelial cells. Br J Pharmacol (2007).

191. Preet, A., Ganju, R. K. & Groopman, J. E. Delta(9)-Tetrahydrocannabinol inhibits

epithelial growth factor-induced lung cancer cell migration in vitro as well as its

growth and metastasis in vivo. Oncogene (2007).

192. Vila, A., Rosengarth, A., Piomelli, D., Cravatt, B. & Marnett, L. J. Hydrolysis of

Prostaglandin Glycerol Esters by the Endocannabinoid-Hydrolyzing Enzymes,

Monoacylglycerol Lipase and Fatty Acid Amide Hydrolase. Biochemistry (2007).

193. Udler, M. et al. Common germline genetic variation in antioxidant defense genes

and survival after diagnosis of breast cancer. J Clin Oncol 25, 3015-3023 (2007).

194. Schramm-Sapyta, N. L. et al. Differential anxiogenic, aversive, and locomotor

effects of THC in adolescent and adult rats. Psychopharmacology (Berl) S (2007).

195. Jordan, K., Schmoll, H. J. & Aapro, M. S. Comparative activity of antiemetic drugs.

Crit Rev Oncol Hematol S (2007).

196. Aguado, T. et al. Cannabinoids induce glioma stem-like cell differentiation and

inhibit gliomagenesis. J Biol Chem S (2007).

197. Demorrow, S. et al. Opposing actions of endocannabinoids on cholangiocarcinoma

growth: Recruitment of fas and fas ligand to lipid rafts. J Biol Chem S (2007).

198. Bifulco, M., Grimaldi, C., Gazzerro, P., Pisanti, S. & Santoro, A. Rimonabant: Just

an Anti-obesity Drug? Current Evidence on Its Pleiotropic Effects. Mol Pharmacol

(2007).

199. Darmani, N. A., Janoyan, J. J., Crim, J. & Ramirez, J. Receptor mechanism and

antiemetic activity of structurally-diverse cannabinoids against radiation-induced

emesis in the least shrew. Eur J Pharmacol S (2007).

200. Fogarty, A. et al. Marijuana as therapy for people living with HIV/AIDS: Social

and health aspects. AIDS Care S 19, 295-301 (2007).

201. Athanasiou, A. et al. Cannabinoid receptor agonists are mitochondrial inhibitors: A

unified hypothesis of how cannabinoids modulate mitochondrial function and

induce cell death. Biochem Biophys Res Commun 364, 131-137 (2007).

202. Takeda, S. et al. Delta(9)-Tetrahydrocannabinol enhances MCF-7 cell proliferation

via cannabinoid receptor-independent signaling. Toxicology (2007).

203. Flygare, J. & Sander, B. The endocannabinoid system in cancer-Potential

therapeutic target? Semin Cancer Biol (2007).

204. Engels, F. K. et al. Medicinal cannabis in oncology. Eur J Cancer 43, 2638-2644

(2007).

205. Russo, E. B., Guy, G. W. & Robson, P. J. Cannabis, Pain, and Sleep: Lessons from

Therapeutic Clinical Trials of Sativex((R)), a Cannabis-Based Medicine. Chem

Biodivers 4, 1729-1743 (2007).

206. Zhang, X., Wang, J. F., Kunos, G. & Groopman, J. E. Cannabinoid Modulation of

Kaposi's Sarcoma Associated Herpesvirus Infection and Transformation. Cancer

Res 67, 7230-7237 (2007).

207. Kempf, K. et al. Immune-mediated Activation of the Endocannabinoid System in

Visceral Adipose Tissue in Obesity. Horm Metab Res 39, 596-600 (2007).

208. Batkai, S. et al. Decreased age-related cardiac dysfunction, myocardial nitrative

stress, inflammatory gene expression, and apoptosis in mice lacking fatty acid

amide hydrolase. Am J Physiol Heart Circ Physiol 293, H909-18 (2007).

209. Velasco, G. et al. Cannabinoids and gliomas. Mol Neurobiol 36, 60-67 (2007).

210. De Filippis, D. et al. Local administration of WIN 55,212-2 reduces chronic

granuloma-associated angiogenesis in rat by inhibiting NF-kappaB activation. J

Mol Med (2007).

211. Bifulco, M., Laezza, C., Gazzerro, P. & Pentimalli, F. Endocannabinoids as

emerging suppressors of angiogenesis and tumor invasion (Review). Oncol Rep 17,

813-816 (2007).

212. D'Souza, D. C. Cannabinoids and psychosis. Int Rev Neurobiol S 78, 289-326

(2007).

213. Whiteside, G. T., Lee, G. P. & Valenzano, K. J. The role of the cannabinoid CB2

receptor in pain transmission and therapeutic potential of small molecule CB2

receptor agonists. Curr Med Chem 14, 917-936 (2007).

214. Sunil K. Aggarwal, M. S. I. I. I., PhC, BS, BA, Muraco Kyashna-Tocha, PhD;

Gregory T. Carter, MD, MS. Dosing Medical Marijuana: Rational Guidelines on

Trial in Washington State. (2007).

215. Kingsley, P. J. & Marnett, L. J. LC-MS-MS Analysis of Neutral Eicosanoids.

Methods Enzymol 433, 91-112 (2007).

216. Kogan, N. M. & Mechoulam, R. Cannabinoids in health and disease. Dialogues

Clin Neurosci 9, 413-430 (2007).

217. Goanvic, D. L. & Tius, M. A. Oxaza adamantyl cannabinoids. A new class of

cannabinoid receptor probes. J Org Chem 71, 7800-7804 (2006).

218. Pacher, P., Batkai, S. & Kunos, G. The endocannabinoid system as an emerging

target of pharmacotherapy. Pharmacol Rev 58, 389-462 (2006).

219. Karanian, D. A. & Bahr, B. A. Cannabinoid drugs and enhancement of

endocannabinoid responses: strategies for a wide array of disease states. Curr Mol

Med 6, 677-684 (2006).

220. Ziring, D. et al. Formation of B and T cell subsets require the cannabinoid receptor

CB2. Immunogenetics 58, 714-725 (2006).

221. Ligresti, A. et al. Antitumor activity of plant cannabinoids with emphasis on the

effect of cannabidiol on human breast carcinoma. J Pharmacol Exp Ther 318, 1375-

1387 (2006).

222. Sarfaraz, S., Afaq, F., Adhami, V. M., Malik, A. & Mukhtar, H. Cannabinoid

receptor agonist induced apoptosis of human prostate cancer cells LNCaP proceeds

through sustained activation of ERK1/2 leading to G1 cell cycle arrest. J Biol Chem

(2006).

223. Blazquez, C. et al. Cannabinoid receptors as novel targets for the treatment of

melanoma. FASEB J (2006).

224. Stokes, A. et al. TRPA1 is a substrate for de-ubiquitination by the tumor suppressor

CYLD. Cell Signal 18, 1584-1594 (2006).

225. De Lago, E. et al. Acyl-based anandamide uptake inhibitors cause rapid toxicity to

C6 glioma cells at pharmacologically relevant concentrations. J Neurochem 99,

677-688 (2006).

226. Xu, X. et al. Overexpression of cannabinoid receptors CB1 and CB2 correlates with

improved prognosis of patients with hepatocellular carcinoma. Cancer Genet

Cytogenet 171, 31-38 (2006).

227. Fernandez-Solari, J., Prestifilippo, J. P., Bornstein, S. R., McCann, S. M. & Rettori,

V. Participation of the Endocannabinoid System in the Effect of TNF-{alpha} on

Hypothalamic Release of Gonadotropin-Releasing Hormone. Ann N Y Acad Sci S

1088, 238-250 (2006).

228. Mormina, M. E., Thakur, S., Molleman, A., Whelan, C. J. & Baydoun, A. R.

Cannabinoid signalling in TNF-alpha induced IL-8 release. Eur J Pharmacol

(2006).

229. Raduner, S. et al. Alkylamides from Echinacea Are a New Class of

Cannabinomimetics: CANNABINOID TYPE 2 RECEPTOR-DEPENDENT AND -

INDEPENDENT IMMUNOMODULATORY EFFECTS. J Biol Chem 281, 14192-

14206 (2006).

230. Alsasua Del Valle, A. Implication of Cannabinoids in Neurological Diseases. Cell

Mol Neurobiol (2006).

231. Bifulco, M., Laezza, C., Pisanti, S. & Gazzerro, P. Cannabinoids and cancer: pros

and cons of an antitumour strategy. Br J Pharmacol 148, 123-135 (2006).

232. Kogan, N. M. et al. A Cannabinoid Quinone Inhibits Angiogenesis by Targeting

Vascular Endothelial Cells. Mol Pharmacol (2006).

233. Fogli, S. et al. Cannabinoid derivatives induce cell death in pancreatic MIA PaCa-2

cells via a receptor-independent mechanism. FEBS Lett 580, 1733-1739 (2006).

234. Bari, M., Battista, N., Fezza, F., Gasperi, V. & Maccarrone, M. New insights into

endocannabinoid degradation and its therapeutic potential. Mini Rev Med Chem 6,

257-268 (2006).

235. Fernandez-Lopez, D. et al. Characterization of the Neuroprotective Effect of the

Cannabinoid Agonist WIN-55212 in an In Vitro Model of Hypoxic-Ischemic Brain

Damage in Newborn Rats. Pediatr Res (2006).

236. Guzman, M. et al. A pilot clinical study of Delta(9)-tetrahydrocannabinol in

patients with recurrent glioblastoma multiforme. Br J Cancer (2006).

237. Sarnataro, D. et al. The Cannabinoid CB1 Receptor Antagonist Rimonabant

(SR141716) Inhibits Human Breast Cancer Cell Proliferation Through A Lipid

Rafts Mediated Mechanism. Mol Pharmacol (2006).

238. Strasser, F. et al. Comparison of orally administered cannabis extract and delta-9-

tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia

syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled

clinical trial from the Cannabis-In-Cachexia-Study-Group. J Clin Oncol 24, 3394-

3400 (2006).

239. Carracedo, A. et al. Cannabinoids Induce Apoptosis of Pancreatic Tumor Cells via

Endoplasmic Reticulum Stress-Related Genes. Cancer Res 66, 6748-6755 (2006).

240. Caffarel, M. M., Sarrio, D., Palacios, J., Guzman, M. & Sanchez, C. Delta}9-

Tetrahydrocannabinol Inhibits Cell Cycle Progression in Human Breast Cancer

Cells through Cdc2 Regulation. Cancer Res 66, 6615-6621 (2006).

241. Guagnini, F. et al. Neural contractions in colonic strips from patients with

diverticular disease: role of endocannabinoids and substance P. Gut 55, 946-953

(2006).

242. Roberts, J. D., Gennings, C. & Shih, M. Synergistic affective analgesic interaction

between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 530, 54-58

(2006).

243. Eichele, K., Weinzierl, U., Ramer, R., Brune, K. & Hinz, B. R(+)-methanandamide

elicits a cyclooxygenase-2-dependent mitochondrial apoptosis signaling pathway in

human neuroglioma cells. Pharm Res 23, 90-94 (2006).

244. Rao, G. K. & Kaminski, N. E. Induction of intracellular calcium elevation by

Delta9-tetrahydrocannabinol in T cells involves TRPC1 channels. J Leukoc Biol 79,

202-213 (2006).

245. Ben-Shabat, S., Hanus, L. O., Katzavian, G. & Gallily, R. New cannabidiol

derivatives: synthesis, binding to cannabinoid receptor, and evaluation of their

antiinflammatory activity. J Med Chem 49, 1113-1117 (2006).

246. Grimaldi, C. et al. Anandamide inhibits adhesion and migration of breast cancer

cells. Exp Cell Res 312, 363-373 (2006).

247. Vignot, S. et al. [Cannabis and cancer]. Bull Cancer 93, 163-170 (2006).

248. Shmist, Y. A. et al. Delta-9-tetrahydrocannabinol protects cardiac cells from

hypoxia via CB2 receptor activation and nitric oxide production. Mol Cell Biochem

283, 75-83 (2006).

249. Hamamoto, D. T., Giridharagopalan, S. & Simone, D. A. Acute and chronic

administration of the cannabinoid receptor agonist CP 55,940 attenuates tumorevoked

hyperalgesia. Eur J Pharmacol S (2006).

250. Pisanti, S. et al. Antiangiogenic activity of the endocannabinoid anandamide:

Correlation to its tumor-suppressor efficacy. J Cell Physiol S (2006).

251. Ellert-Miklaszewska, A., Grajkowska, W., Gabrusiewicz, K., Kaminska, B. &

Konarska, L. Distinctive pattern of cannabinoid receptor type II (CB2) expression

in adult and pediatric brain tumors. Brain Res S (2006).

252. Huang, H., Nishi, K., Tsai, H. J. & Hammock, B. D. Development of highly

sensitive fluorescent assays for fatty acid amide hydrolase. Anal Biochem SO - Anal

Biochem. 2006 Dec 20;d (2006).

253. Davis, M., Maida, V., Daeninck, P. & Pergolizzi, J. The emerging role of

cannabinoid neuromodulators in symptom management. Support Care Cancer

(2006).

254. Wang, H. et al. Fatty acid amide hydrolase deficiency limits early pregnancy

events. J Clin Invest 116, 2122-2131 (2006).

255. Jia, W. et al. Delta}9-Tetrahydrocannabinol-Induced Apoptosis in Jurkat Leukemia

T Cells Is Regulated by Translocation of Bad to Mitochondria. Mol Cancer Res 4,

549-562 (2006).

256. Held-Feindt, J., Dorner, L., Sahan, G., Mehdorn, H. M. & Mentlein, R.

Cannabinoid receptors in human astroglial tumors. J Neurochem 98, 886-893

(2006).

257. Perez, J. Combined cannabinoid therapy via an oromucosal spray. Drugs Today

(Barc) 42, 495-503 (2006).

258. Matias, I. et al. Regulation, function, and dysregulation of endocannabinoids in

models of adipose and beta-pancreatic cells and in obesity and hyperglycemia. J

Clin Endocrinol Metab 91, 3171-3180 (2006).

259. Ben Amar, M. Cannabinoids in medicine: A review of their therapeutic potential. J

Ethnopharmacol 105, 1-25 (2006).

260. Herrera, B. et al. The CB(2) cannabinoid receptor signals apoptosis via ceramidedependent

activation of the mitochondrial intrinsic pathway. Exp Cell Res (2006).

261. Holland, M. L. et al. The effects of cannabinoids on P-glycoprotein transport and

expression in multidrug resistant cells. Biochem Pharmacol 71, 1146-1154 (2006).

262. Carracedo, A. et al. The stress-regulated protein p8 mediates cannabinoid-induced

apoptosis of tumor cells. Cancer Cell 9, 301-312 (2006).

263. Verhoeckx, K. C. et al. Unheated Cannabis sativa extracts and its major compound

THC-acid have potential immuno-modulating properties not mediated by CB1 and

CB2 receptor coupled pathways. Int Immunopharmacol 6, 656-665 (2006).

264. Singh, J. & Budhiraja, S. Therapeutic potential of cannabinoid receptor ligands:

current status. Methods Find Exp Clin Pharmacol 28, 177-183 (2006).

265. Russo, E. & Guy, G. W. A tale of two cannabinoids: the therapeutic rationale for

combining tetrahydrocannabinol and cannabidiol. Med Hypotheses 66, 234-246

(2006).

266. Vidinsky, B., Gal, P. & Mojzis, J. [Different views on the association between

cannabinoids and cancer]. Cas Lek Cesk 145, 453-7; discussion 458-9 (2006).

267. Massi, P., Vaccani, A. & Parolaro, D. Cannabinoids, immune system and cytokine

network. Curr Pharm Des 12, 3135-3146 (2006).

268. Huskey, A. Cannabinoids in cancer pain management. J Pain Palliat Care

Pharmacother 20, 43-46 (2006).

269. Melamede, R. J. Endocannabinoids: Multi-scaled, Global Homeostatic Regulators

of Cells and Society. Interjournal Complex Systems 1669 (2006).

270. Sancho, R. et al. Mechanisms of HIV-1 inhibition by the lipid mediator Narachidonoyldopamine.

J Immunol 175, 3990-3999 (2005).

271. Melamede, R. Cannabis and tobacco smoke are not equally carcinogenic. Harm

Reduct J 2, 21 (2005).

272. Sun, Y. X. et al. Involvement of N-acylethanolamine-hydrolyzing acid amidase in

the degradation of anandamide and other N-acylethanolamines in macrophages.

Biochim Biophys Acta 1736, 211-220 (2005).

273. Kogan, N. M. Cannabinoids and cancer. Mini Rev Med Chem 5, 941-952 (2005).

274. Sarnataro, D. et al. Plasma membrane and lysosomal localization of CB1

cannabinoid receptor are dependent on lipid rafts and regulated by anandamide in

human breast cancer cells. FEBS Lett 579, 6343-6349 (2005).

275. Klein, T. W. Cannabinoid-based drugs as anti-inflammatory therapeutics. Nat Rev

Immunol 5, 400-411 (2005).

276. McKallip, R. J., Nagarkatti, M. & Nagarkatti, P. S. Delta-9-tetrahydrocannabinol

enhances breast cancer growth and metastasis by suppression of the antitumor

immune response. J Immunol 174, 3281-3289 (2005).

277. Tashkin, D. P. Smoked marijuana as a cause of lung injury. Monaldi Arch Chest

Dis 63, 93-100 (2005).

278. Bari, M., Paradisi, A., Pasquariello, N. & Maccarrone, M. Cholesterol-dependent

modulation of type 1 cannabinoid receptors in nerve cells. J Neurosci Res 81, 275-

283 (2005).

279. Nithipatikom, K. et al. A new class of inhibitors of 2-arachidonoylglycerol

hydrolysis and invasion of prostate cancer cells. Biochem Biophys Res Commun

332, 1028-1033 (2005).

280. Watanabe, K. et al. Marijuana extracts possess the effects like the endocrine

disrupting chemicals. Toxicology 206, 471-478 (2005).

281. Sheng, W. S. et al. Synthetic cannabinoid WIN55,212-2 inhibits generation of

inflammatory mediators by IL-1beta-stimulated human astrocytes. Glia 49, 211-219

(2005).

282. Ellert-Miklaszewska, A., Kaminska, B. & Konarska, L. Cannabinoids downregulate

PI3K/Akt and Erk signalling pathways and activate proapoptotic function

of Bad protein. Cell Signal 17, 25-37 (2005).

283. Chung, K. F. Drugs to suppress cough. Expert Opin Investig Drugs 14, 19-27

(2005).

284. Hall, W., Christie, M. & Currow, D. Cannabinoids and cancer: causation,

remediation, and palliation. Lancet Oncol 6, 35-42 (2005).

285. Ramirez, B. G., Blazquez, C., Gomez del Pulgar, T., Guzman, M. & de Ceballos,

M. L. Prevention of Alzheimer's disease pathology by cannabinoids:

neuroprotection mediated by blockade of microglial activation. J Neurosci 25,

1904-1913 (2005).

286. Powles, T. et al. Cannabis-induced cytotoxicity in leukemic cell lines: the role of

the cannabinoid receptors and the MAPK pathway. Blood 105, 1214-1221 (2005).

287. Radbruch, L. & Elsner, F. Emerging analgesics in cancer pain management. Expert

Opin Emerg Drugs 10, 151-171 (2005).

288. Sharma, R., Tobin, P. & Clarke, S. J. Management of chemotherapy-induced

nausea, vomiting, oral mucositis, and diarrhoea. Lancet Oncol 6, 93-102 (2005).

289. Roila, F. et al. Antiemetics in children receiving chemotherapy. Support Care

Cancer 13, 129-131 (2005).

290. Kishimoto, S. et al. Endogenous cannabinoid receptor ligand induces the migration

of human natural killer cells. J Biochem (Tokyo) 137, 217-223 (2005).

291. Flygare, J., Gustafsson, K., Kimby, E., Christensson, B. & Sander, B. Cannabinoid

receptor ligands mediate growth inhibition and cell death in mantle cell lymphoma.

FEBS Lett 579, 6885-6889 (2005).

292. Lee, S. Y., Oh, S. M., Lee, S. K. & Chung, K. H. Antiestrogenic effects of

marijuana smoke condensate and cannabinoid compounds. Arch Pharm Res 28,

1365-1375 (2005).

293. Patsos, H. A., Hicks, D. J., Greenhough, A., Williams, A. C. & Paraskeva, C.

Cannabinoids and cancer: potential for colorectal cancer therapy. Biochem Soc

Trans 33, 712-714 (2005).

294. Ortega-Gutierrez, S. et al. Activation of the endocannabinoid system as therapeutic

approach in a murine model of multiple sclerosis. FASEB J 19, 1338-1340 (2005).

295. Lombard, C., Nagarkatti, M. & Nagarkatti, P. S. Targeting cannabinoid receptors to

treat leukemia: role of cross-talk between extrinsic and intrinsic pathways in

Delta9-tetrahydrocannabinol (THC)-induced apoptosis of Jurkat cells. Leuk Res 29,

915-922 (2005).

296. McAllister, S. D. et al. Cannabinoids selectively inhibit proliferation and induce

death of cultured human glioblastoma multiforme cells. J Neurooncol 74, 31-40

(2005).

297. Myrianthefs, P. M. & Batistaki, C. Cancer cachexia and immunomodulation. J

BUON 10, 181-188 (2005).

298. Bari, M., Battista, N., Fezza, F., Finazzi-Agro, A. & Maccarrone, M. Lipid rafts

control signaling of type-1 cannabinoid receptors in neuronal cells. Implications for

anandamide-induced apoptosis. J Biol Chem 280, 12212-12220 (2005).

299. Fride, E., Bregman, T. & Kirkham, T. C. Endocannabinoids and food intake:

newborn suckling and appetite regulation in adulthood. Exp Biol Med (Maywood)

230, 225-234 (2005).

300. Vaccani, A., Massi, P., Colombo, A., Rubino, T. & Parolaro, D. Cannabidiol

inhibits human glioma cell migration through a cannabinoid receptor-independent

mechanism. Br J Pharmacol 144, 1032-1036 (2005).

301. Guzman, M. Effects on cell viability. Handb Exp Pharmacol 627-642 (2005).

302. Izzo, A. A. & Coutts, A. A. Cannabinoids and the digestive tract. Handb Exp

Pharmacol 573-598 (2005).

303. Burstein, S. Ajulemic acid (IP-751): synthesis, proof of principle, toxicity studies,

and clinical trials. AAPS J 7, E143-8 (2005).

304. Carlini, E. A. The good and the bad effects of (-) trans-delta-9-tetrahydrocannabinol

(Delta 9-THC) on humans. Toxicon 44, 461-467 (2004).

305. Medveczky, M. M., Sherwood, T. A., Klein, T. W., Friedman, H. & Medveczky, P.

G. Delta-9 tetrahydrocannabinol (THC) inhibits lytic replication of gamma

oncogenic herpesviruses in vitro. BMC Med 2, 34 (2004).

306. Contassot, E. et al. Arachidonylethanolamide induces apoptosis of human glioma

cells through vanilloid receptor-1. J Neuropathol Exp Neurol 63, 956-963 (2004).

307. Juttler, E. et al. The cannabinoid dexanabinol is an inhibitor of the nuclear factorkappa

B (NF-kappa B). Neuropharmacology 47, 580-592 (2004).

308. Velasco, G., Galve-Roperh, I., Sanchez, C., Blazquez, C. & Guzman, M.

Hypothesis: cannabinoid therapy for the treatment of gliomas? Neuropharmacology

47, 315-323 (2004).

309. Inui, A. [Pathogenesis and treatment of cancer anorexia-cachexia, with special

emphasis on aged patients]. Nippon Ronen Igakkai Zasshi 41, 460-467 (2004).

310. Bifulco, M. et al. A new strategy to block tumor growth by inhibiting

endocannabinoid inactivation. FASEB J 18, 1606-1608 (2004).

311. Hinz, B., Ramer, R., Eichele, K., Weinzierl, U. & Brune, K. R(+)-methanandamideinduced

cyclooxygenase-2 expression in H4 human neuroglioma cells: possible

involvement of membrane lipid rafts. Biochem Biophys Res Commun 324, 621-626

(2004).

312. Rukwied, R., Gauter, B., Schley, M. & Konrad, C. [Cannabinoids-signal

transduction and mode of action.]. Schmerz (2004).

313. Carter, G. T. & Ugalde, V. Medical marijuana: emerging applications for the

management of neurologic disorders. Phys Med Rehabil Clin N Am 15, 943-54, ix

(2004).

314. Fowler, C. J., Tiger, G., Ligresti, A., Lopez-Rodriguez, M. L. & Di Marzo, V.

Selective inhibition of anandamide cellular uptake versus enzymatic hydrolysis--a

difficult issue to handle. Eur J Pharmacol 492, 1-11 (2004).

315. Carter, G. T., Weydt, P., Kyashna-Tocha, M. & Abrams, D. I. Medicinal cannabis:

rational guidelines for dosing. IDrugs 7, 464-470 (2004).

316. Matias, I. et al. Prostaglandin ethanolamides (prostamides): in vitro pharmacology

and metabolism. J Pharmacol Exp Ther 309, 745-757 (2004).

317. Duran, M., Laporte, J. R. & Capella, D. [News about therapeutic use of Cannabis

and endocannabinoid system]. Med Clin (Barc) 122, 390-398 (2004).

318. Hart, S., Fischer, O. M. & Ullrich, A. Cannabinoids induce cancer cell proliferation

via tumor necrosis factor alpha-converting enzyme (TACE/ADAM17)-mediated

transactivation of the epidermal growth factor receptor. Cancer Res 64, 1943-1950

(2004).

319. Massi, P. et al. Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid,

on human glioma cell lines. J Pharmacol Exp Ther 308, 838-845 (2004).

320. Carracedo, A. et al. Ceramide sensitizes astrocytes to oxidative stress: protective

role of cannabinoids. Biochem J 380, 435-440 (2004).

321. Kraft, B. & Kress, H. G. [Cannabinoids and the immune system. Of men, mice and

cells]. Schmerz 18, 203-210 (2004).

322. Nauck, F. & Klaschik, E. Cannabinoids in the treatment of the cachexia-anorexia

syndrome in palliative care patients. Schmerz 18, 197-202 (2004).

323. Martin, B. R. & Wiley, J. L. Mechanism of action of cannabinoids: how it may lead

to treatment of cachexia, emesis, and pain. J Support Oncol 2, 305-14; discussion

314-6 (2004).

324. Kogan, N. M. et al. Synthesis and antitumor activity of quinonoid derivatives of

cannabinoids. J Med Chem 47, 3800-3806 (2004).

325. Derkinderen, P., Valjent, E., Darcel, F., Damier, P. & Girault, J. A. [Cannabis and

cannabinoid receptors: from pathophysiology to therapeutic options]. Rev Neurol

(Paris) 160, 639-649 (2004).

326. Rubovitch, V., Gafni, M. & Sarne, Y. The involvement of VEGF receptors and

MAPK in the cannabinoid potentiation of Ca2+ flux into N18TG2 neuroblastoma

cells. Brain Res Mol Brain Res 120, 138-144 (2004).

327. Desreumaux, P., Thuru, X. & Philippe, D. [Control of secretory diarrhea and

colorectal cancer growth by cannabinoids in the gut]. Gastroenterol Clin Biol 28,

97 (2004).

328. Leggett, J. D. et al. Oleamide is a selective endogenous agonist of rat and human

CB1 cannabinoid receptors. Br J Pharmacol 141, 253-262 (2004).

329. Sancho, R. et al. Immunosuppressive activity of endovanilloids: N-arachidonoyldopamine

inhibits activation of the NF-kappa B, NFAT, and activator protein 1

signaling pathways. J Immunol 172, 2341-2351 (2004).

330. Cabral, G. A. & Marciano-Cabral, F. Cannabinoid-mediated exacerbation of brain

infection by opportunistic amebae. J Neuroimmunol 147, 127-130 (2004).

331. Fowler, C. J. Possible involvement of the endocannabinoid system in the actions of

three clinically used drugs. Trends Pharmacol Sci 25, 59-61 (2004).

332. Liang, Y. C., Huang, C. C. & Hsu, K. S. Therapeutic potential of cannabinoids in

trigeminal neuralgia. Curr Drug Targets CNS Neurol Disord 3, 507-514 (2004).

333. Coutts, A. A. & Izzo, A. A. The gastrointestinal pharmacology of cannabinoids: an

update. Curr Opin Pharmacol 4, 572-579 (2004).

334. Blazquez, C. et al. Cannabinoids inhibit the vascular endothelial growth factor

pathway in gliomas. Cancer Res 64, 5617-5623 (2004).

335. Joseph, J., Niggemann, B., Zaenker, K. S. & Entschladen, F. Anandamide is an

endogenous inhibitor for the migration of tumor cells and T lymphocytes. Cancer

Immunol Immunother 53, 723-728 (2004).

336. Kalant, H. Adverse effects of cannabis on health: an update of the literature since

1996. Prog Neuropsychopharmacol Biol Psychiatry 28, 849-863 (2004).

337. Contassot, E., Tenan, M., Schnuriger, V., Pelte, M. F. & Dietrich, P. Y.

Arachidonyl ethanolamide induces apoptosis of uterine cervix cancer cells via

aberrantly expressed vanilloid receptor-1. Gynecol Oncol 93, 182-188 (2004).

338. Maccarrone, M. et al. The endocannabinoid system in human keratinocytes.

Evidence that anandamide inhibits epidermal differentiation through CB1 receptordependent

inhibition of protein kinase C, activation protein-1, and transglutaminase.

J Biol Chem 278, 33896-33903 (2003).

339. Vannacci, A., Giannini, L., Masini, E. & Mannaioni, P. F. Cannabinoid-induced

activation of ERK and AKT in mast cells may be mediated by intracellular NO

production. J Immunol 171, 2767 (2003).

340. Fowler, C. J. et al. Inhibition of C6 glioma cell proliferation by anandamide, 1-

arachidonoylglycerol, and by a water soluble phosphate ester of anandamide:

variability in response and involvement of arachidonic acid. Biochem Pharmacol

66, 757-767 (2003).

341. Sanchez, M. G., Ruiz-Llorente, L., Sanchez, A. M. & Diaz-Laviada, I. Activation of

phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid

receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and

NGF induction. Cell Signal 15, 851-859 (2003).

342. Portella, G. et al. Inhibitory effects of cannabinoid CB1 receptor stimulation on

tumor growth and metastatic spreading: actions on signals involved in angiogenesis

and metastasis. FASEB J 17, 1771-1773 (2003).

343. Ligresti, A. et al. Possible endocannabinoid control of colorectal cancer growth.

Gastroenterology 125, 677-687 (2003).

344. Croci, T., Landi, M., Galzin, A. M. & Marini, P. Role of cannabinoid CB1

receptors and tumor necrosis factor-alpha in the gut and systemic anti-inflammatory

activity of SR 141716 (rimonabant) in rodents. Br J Pharmacol 140, 115-122

(2003).

345. Klein, T. W. et al. The cannabinoid system and immune modulation. J Leukoc Biol

74, 486-496 (2003).

346. Guzman, M. Cannabinoids: potential anticancer agents. Nat Rev Cancer 3, 745-755

(2003).

347. Gardner, B., Zhu, L. X., Sharma, S., Tashkin, D. P. & Dubinett, S. M.

Methanandamide increases COX-2 expression and tumor growth in murine lung

cancer. FASEB J 17, 2157-2159 (2003).

348. Ramer, R., Weinzierl, U., Schwind, B., Brune, K. & Hinz, B. Ceramide is involved

in r(+)-methanandamide-induced cyclooxygenase-2 expression in human

neuroglioma cells. Mol Pharmacol 64, 1189-1198 (2003).

349. Wrobleski, S. T. et al. Rational design and synthesis of an orally active

indolopyridone as a novel conformationally constrained cannabinoid ligand

possessing antiinflammatory properties. J Med Chem 46, 2110-2116 (2003).

350. Samson, M. T. et al. Differential roles of CB1 and CB2 cannabinoid receptors in

mast cells. J Immunol 170, 4953-4962 (2003).

351. Kehl, L. J. et al. A cannabinoid agonist differentially attenuates deep tissue

hyperalgesia in animal models of cancer and inflammatory muscle pain. Pain 103,

175-186 (2003).

352. Bifulco, M. & Di Marzo, V. [The endocannabinoid system as a target for the

development of new drugs for cancer therapy]. Recenti Prog Med 94, 194-198

(2003).

353. Vandevoorde, S., Lambert, D. M., Smart, D., Jonsson, K. O. & Fowler, C. J. NMorpholino-

and N-diethyl-analogues of palmitoylethanolamide increase the

sensitivity of transfected human vanilloid receptors to activation by anandamide

without affecting fatty acid amidohydrolase activity. Bioorg Med Chem 11, 817-825

(2003).

354. Upham, B. L. et al. Cannabinoids inhibit gap junctional intercellular

communication and activate ERK in a rat liver epithelial cell line. Int J Cancer 104,

12-18 (2003).

355. Kingsley, P. J. & Marnett, L. J. Analysis of endocannabinoids by Ag+ coordination

tandem mass spectrometry. Anal Biochem 314, 8-15 (2003).

356. Blazquez, C. et al. Inhibition of tumor angiogenesis by cannabinoids. FASEB J 17,

529-531 (2003).

357. New toke on treating skin cancer. Lab Anim (NY) 32, 12 (2003).

358. Ware, M. A., Doyle, C. R., Woods, R., Lynch, M. E. & Clark, A. J. Cannabis use

for chronic non-cancer pain: results of a prospective survey. Pain 102, 211-216

(2003).

359. Parker, L. A. et al. Effects of cannabinoids on lithium-induced conditioned rejection

reactions in a rat model of nausea. Psychopharmacology (Berl) 166, 156-162

(2003).

360. Walsh, D., Nelson, K. A. & Mahmoud, F. A. Established and potential therapeutic

applications of cannabinoids in oncology. Support Care Cancer 11, 137-143

(2003).

361. Bruera, E. & Castro, M. Cannabinoids in supportive care: are they necessary?

Support Care Cancer 11, 133-134 (2003).

362. Tarzia, G. et al. Design, synthesis, and structure-activity relationships of

alkylcarbamic acid aryl esters, a new class of fatty acid amide hydrolase inhibitors.

J Med Chem 46, 2352-2360 (2003).

363. Klegeris, A., Bissonnette, C. J. & McGeer, P. L. Reduction of human monocytic

cell neurotoxicity and cytokine secretion by ligands of the cannabinoid-type CB2

receptor. Br J Pharmacol 139, 775-786 (2003).

364. Bash, R., Rubovitch, V., Gafni, M. & Sarne, Y. The stimulatory effect of

cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and

cAMP formation. Neurosignals 12, 39-44 (2003).

365. Facchinetti, F., Del Giudice, E., Furegato, S., Passarotto, M. & Leon, A.

Cannabinoids ablate release of TNFalpha in rat microglial cells stimulated with

lypopolysaccharide. Glia 41, 161-168 (2003).

366. Ihenetu, K., Molleman, A., Parsons, M. E. & Whelan, C. J. Inhibition of

interleukin-8 release in the human colonic epithelial cell line HT-29 by

cannabinoids. Eur J Pharmacol 458, 207-215 (2003).

367. Casanova, M. L. et al. Inhibition of skin tumor growth and angiogenesis in vivo by

activation of cannabinoid receptors. J Clin Invest 111, 43-50 (2003).

368. Zurier, R. B., Rossetti, R. G., Burstein, S. H. & Bidinger, B. Suppression of human

monocyte interleukin-1beta production by ajulemic acid, a nonpsychoactive

cannabinoid. Biochem Pharmacol 65, 649-655 (2003).

369. Sarafian, T. et al. Clarifying Cb2 Receptor-dependent and Independent Effects of

Thc on Human Lung Epithelial Cells. Toxicol Appl Pharmacol (2008).

370. Davis, M. I., Ronesi, J. & Lovinger, D. M. A predominant role for inhibition of the

adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid

receptor 1 in N1E-115 neuroblastoma cells. J Biol Chem 278, 48973-48980 (2003).

371. Sanchez, M. G., Sanchez, A. M., Ruiz-Llorente, L. & Diaz-Laviada, I.

Enhancement of androgen receptor expression induced by (R)-methanandamide in

prostate LNCaP cells. FEBS Lett 555, 561-566 (2003).

372. Lavon, I. et al. A novel synthetic cannabinoid derivative inhibits inflammatory liver

damage via negative cytokine regulation. Mol Pharmacol 64, 1334-1341 (2003).

373. Grotenhermen, F. & Muller-Vahl, K. IACM 2nd Conference on Cannabinoids in

Medicine. Expert Opin Pharmacother 4, 2367-2371 (2003).

374. Keren, O. & Sarne, Y. Multiple mechanisms of CB1 cannabinoid receptors

regulation. Brain Res 980, 197-205 (2003).

375. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Prudhomme, D. R. & Marnett,

L. J. Amino acid determinants in cyclooxygenase-2 oxygenation of the

endocannabinoid anandamide. Biochemistry 42, 9041-9049 (2003).

376. Gilgun-Sherki, Y., Melamed, E., Mechoulam, R. & Offen, D. The CB1 cannabinoid

receptor agonist, HU-210, reduces levodopa-induced rotations in 6-

hydroxydopamine-lesioned rats. Pharmacol Toxicol 93, 66-70 (2003).

377. Radbruch, L. & Nauck, F. [A review of side effects and complications with

cannabinoid treatment]. Schmerz 17, 274-279 (2003).

378. Glaser, S. T. et al. Evidence against the presence of an anandamide transporter.

Proc Natl Acad Sci U S A 100, 4269-4274 (2003).

379. Jonsson, K. O. et al. AM404 and VDM 11 non-specifically inhibit C6 glioma cell

proliferation at concentrations used to block the cellular accumulation of the

endocannabinoid anandamide. Arch Toxicol 77, 201-207 (2003).

380. Hinz, B., Ramer, R. & Brune, K. Induction of COX-2 expression by the

endocannabinoid derivative R(+)-methanandamide. Adv Exp Med Biol 525, 145-

152 (2003).

381. Grotenhermen, F. Pharmacokinetics and pharmacodynamics of cannabinoids. Clin

Pharmacokinet 42, 327-360 (2003).

382. Croxford, J. L. Therapeutic potential of cannabinoids in CNS disease. CNS Drugs

17, 179-202 (2003).

383. Reggio, P. H. Pharmacophores for ligand recognition and activation/inactivation of

the cannabinoid receptors. Curr Pharm Des 9, 1607-1633 (2003).

384. Cannabis-based medicines--GW pharmaceuticals: high CBD, high THC, medicinal

cannabis--GW pharmaceuticals, THC:CBD. Drugs R D 4, 306-309 (2003).

385. Gallily, R. et al. gamma-Irradiation Enhances Apoptosis Induced by Cannabidiol, a

Non-psychotropic Cannabinoid, in Cultured HL-60 Myeloblastic Leukemia Cells.

Leuk Lymphoma 44, 1767-1773 (2003).

386. Gomez Del Pulgar, T., De Ceballos, M. L., Guzman, M. & Velasco, G.

Cannabinoids protect astrocytes from ceramide-induced apoptosis through the

phosphatidylinositol 3-kinase/protein kinase B pathway. J Biol Chem 277, 36527-

36533 (2002).

387. Kozak, K. R. Metabolism of the endocannabinoids, 2-arachidonylglycerol and

anandamide, into prostaglandin, thromboxane, and prostacyclin glycerol esters and

ethanolamides. J Biol Chem 277, 44877-44885 (2002).

388. Hashibe, M., Ford, D. E. & Zhang, Z. F. Marijuana smoking and head and neck

cancer. J Clin Pharmacol 42, 103S-107S (2002).

389. Rubovitch, V., Gafni, M. & Sarne, Y. The cannabinoid agonist DALN positively

modulates L-type voltage-dependent calcium-channels in N18TG2 neuroblastoma

cells. Brain Res Mol Brain Res 101, 93-102 (2002).

390. Hinnebusch, B. F., Meng, S., Wu, J. T., Archer, S. Y. & Hodin, R. A. The effects of

short-chain fatty acids on human colon cancer cell phenotype are associated with

histone hyperacetylation. J Nutr 132, 1012-1017 (2002).

391. Inui, A. Cancer anorexia-cachexia syndrome: current issues in research and

management. CA Cancer J Clin 52, 72-91 (2002).

392. Carter, G. T. & Weydt, P. Cannabis: old medicine with new promise for

neurological disorders. Curr Opin Investig Drugs 3, 437-440 (2002).

393. Germain, N., Boichot, E., Advenier, C., Berdyshev, E. V. & Lagente, V. Effect of

the cannabinoid receptor ligand, WIN 55,212-2, on superoxide anion and TNFalpha

production by human mononuclear cells. Int Immunopharmacol 2, 537-543

(2002).

394. Smith, P. F. Cannabinoids in the treatment of pain and spasticity in multiple

sclerosis. Curr Opin Investig Drugs 3, 859-864 (2002).

395. Bifulco, M. & Di Marzo, V. Targeting the endocannabinoid system in cancer

therapy: a call for further research. Nat Med 8, 547-550 (2002).

396. Sarafian, T. A., Kouyoumjian, S., Tashkin, D. & Roth, M. D. Synergistic

cytotoxicity of Delta(9)-tetrahydrocannabinol and butylated hydroxyanisole.

Toxicol Lett 133, 171-179 (2002).

397. McKallip, R. J. et al. Targeting CB2 cannabinoid receptors as a novel therapy to

treat malignant lymphoblastic disease. Blood 100, 627-634 (2002).

398. Parolaro, D., Massi, P., Rubino, T. & Monti, E. Endocannabinoids in the immune

system and cancer. Prostaglandins Leukot Essent Fatty Acids 66, 319-332 (2002).

399. Fernandez-Ruiz, J., Lastres-Becker, I., Cabranes, A., Gonzalez, S. & Ramos, J. A.

Endocannabinoids and basal ganglia functionality. Prostaglandins Leukot Essent

Fatty Acids 66, 257-267 (2002).

400. Kozak, K. R. & Marnett, L. J. Oxidative metabolism of endocannabinoids.

Prostaglandins Leukot Essent Fatty Acids 66, 211-220 (2002).

401. Pertwee, R. G. & Ross, R. A. Cannabinoid receptors and their ligands.

Prostaglandins Leukot Essent Fatty Acids 66, 101-121 (2002).

402. Esposito, G. et al. The endocannabinoid system protects rat glioma cells against

HIV-1 Tat protein-induced cytotoxicity. Mechanism and regulation. J Biol Chem

277, 50348-50354 (2002).

403. Galve-Roperh, I., Rueda, D., Gomez del Pulgar, T., Velasco, G. & Guzman, M.

Mechanism of extracellular signal-regulated kinase activation by the CB(1)

cannabinoid receptor. Mol Pharmacol 62, 1385-1392 (2002).

404. Maccarrone, M., Pauselli, R., Di Rienzo, M. & Finazzi-Agro, A. Binding,

degradation and apoptotic activity of stearoylethanolamide in rat C6 glioma cells.

Biochem J 366, 137-144 (2002).

405. van der Stelt, M. et al. Oxygenated metabolites of anandamide and 2-

arachidonoylglycerol: conformational analysis and interaction with cannabinoid

receptors, membrane transporter, and fatty acid amide hydrolase. J Med Chem 45,

3709-3720 (2002).

406. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated tyrosine

phosphorylation of focal adhesion kinase-related non-kinase. FEBS Lett 525, 164-

168 (2002).

407. Ek, S., Hogerkorp, C. M., Dictor, M., Ehinger, M. & Borrebaeck, C. A. Mantle cell

lymphomas express a distinct genetic signature affecting lymphocyte trafficking

and growth regulation as compared with subpopulations of normal human B cells.

Cancer Res 62, 4398-4405 (2002).

408. De Petrocellis, L. et al. Effect on cancer cell proliferation of palmitoylethanolamide,

a fatty acid amide interacting with both the cannabinoid and vanilloid signalling

systems. Fundam Clin Pharmacol 16, 297-302 (2002).

409. Ishii, I. & Chun, J. Anandamide-induced neuroblastoma cell rounding via the CB1

cannabinoid receptors. Neuroreport 13, 593-596 (2002).

410. Jorda, M. A. et al. Hematopoietic cells expressing the peripheral cannabinoid

receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood

99, 2786-2793 (2002).

411. Gomez del Pulgar, T., Velasco, G., Sanchez, C., Haro, A. & Guzman, M. De novosynthesized

ceramide is involved in cannabinoid-induced apoptosis. Biochem J 363,

183-188 (2002).

412. Zurcher, G. [Anorectic syndrome]. Z Gastroenterol 40 Suppl 1, S71-S5 (2002).

413. Melck, D. et al. Cannabimimetic eicosanoids in cancer and inflammation: an

update. Adv Exp Med Biol 507, 381-386 (2002).

414. Kalant, H. Medicinal use of cannabis: history and current status. Pain Res Manag 6,

80-91 (2001).

415. Walker, J. M., Strangman, N. M. & Huang, S. M. Cannabinoids and pain. Pain Res

Manag 6, 74-79 (2001).

416. Mechoulam, R. & Hanu, L. The cannabinoids: an overview. Therapeutic

implications in vomiting and nausea after cancer chemotherapy, in appetite

promotion, in multiple sclerosis and in neuroprotection. Pain Res Manag 6, 67-73

(2001).

417. Ramer, R., Brune, K., Pahl, A. & Hinz, B. R(+)-methanandamide induces

cyclooxygenase-2 expression in human neuroglioma cells via a non-cannabinoid

receptor-mediated mechanism. Biochem Biophys Res Commun 286, 1144-1152

(2001).

418. Recht, L. D. et al. Antitumor effects of ajulemic acid (CT3), a synthetic nonpsychoactive

cannabinoid. Biochem Pharmacol 62, 755-763 (2001).

419. ElSohly, M. A., deWit, H., Wachtel, S. R., Feng, S. & Murphy, T. P. Delta9-

tetrahydrocannabivarin as a marker for the ingestion of marijuana versus Marinol:

results of a clinical study. J Anal Toxicol 25, 565-571 (2001).

420. Jamshidi, N. & Taylor, D. A. Anandamide administration into the ventromedial

hypothalamus stimulates appetite in rats. Br J Pharmacol 134, 1151-1154 (2001).

421. Roth, M. D. et al. Induction and regulation of the carcinogen-metabolizing enzyme

CYP1A1 by marijuana smoke and delta (9)-tetrahydrocannabinol. Am J Respir Cell

Mol Biol 24, 339-344 (2001).

422. Tashkin, D. P. Airway effects of marijuana, cocaine, and other inhaled illicit agents.

Curr Opin Pulm Med 7, 43-61 (2001).

423. Pagotto, U. et al. Normal human pituitary gland and pituitary adenomas express

cannabinoid receptor type 1 and synthesize endogenous cannabinoids: first evidence

for a direct role of cannabinoids on hormone modulation at the human pituitary

level. J Clin Endocrinol Metab 86, 2687-2696 (2001).

424. Day, T. A., Rakhshan, F., Deutsch, D. G. & Barker, E. L. Role of fatty acid amide

hydrolase in the transport of the endogenous cannabinoid anandamide. Mol

Pharmacol 59, 1369-1375 (2001).

425. Campbell, F. A. et al. Are cannabinoids an effective and safe treatment option in the

management of pain? A qualitative systematic review. BMJ 323, 13-16 (2001).

426. Moody, J. S., Kozak, K. R., Ji, C. & Marnett, L. J. Selective oxygenation of the

endocannabinoid 2-arachidonylglycerol by leukocyte-type 12-lipoxygenase.

Biochemistry 40, 861-866 (2001).

427. Maccarrone, M., Attina, M., Cartoni, A., Bari, M. & Finazzi-Agro, A. Gas

chromatography-mass spectrometry analysis of endogenous cannabinoids in healthy

and tumoral human brain and human cells in culture. J Neurochem 76, 594-601

(2001).

428. Velasco, L., Ruiz, L., Sanchez, M. G. & Diaz-Laviada, I. delta(9)-

Tetrahydrocannabinol increases nerve growth factor production by prostate PC-3

cells. Involvement of CB1 cannabinoid receptor and Raf-1. Eur J Biochem 268,

531-535 (2001).

429. Darmani, N. A. Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent

emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR

141716A. Neuropsychopharmacology 24, 198-203 (2001).

430. Bifulco, M. et al. Control by the endogenous cannabinoid system of ras oncogenedependent

tumor growth. FASEB J 15, 2745-2747 (2001).

431. Jacobsson, S. O., Wallin, T. & Fowler, C. J. Inhibition of rat C6 glioma cell

proliferation by endogenous and synthetic cannabinoids. Relative involvement of

cannabinoid and vanilloid receptors. J Pharmacol Exp Ther 299, 951-959 (2001).

432. Smith, S. R., Terminelli, C. & Denhardt, G. Modulation of cytokine responses in

Corynebacterium parvum-primed endotoxemic mice by centrally administered

cannabinoid ligands. Eur J Pharmacol 425, 73-83 (2001).

433. Di Marzo, V. et al. Palmitoylethanolamide inhibits the expression of fatty acid

amide hydrolase and enhances the anti-proliferative effect of anandamide in human

breast cancer cells. Biochem J 358, 249-255 (2001).

434. Zhou, D. & Song, Z. H. CB1 cannabinoid receptor-mediated neurite remodeling in

mouse neuroblastoma N1E-115 cells. J Neurosci Res 65, 346-353 (2001).

435. Kozak, K. R., Prusakiewicz, J. J., Rowlinson, S. W., Schneider, C. & Marnett, L. J.

Amino acid determinants in cyclooxygenase-2 oxygenation of the endocannabinoid

2-arachidonylglycerol. J Biol Chem 276, 30072-30077 (2001).

436. Sanchez, C. et al. Inhibition of glioma growth in vivo by selective activation of the

CB(2) cannabinoid receptor. Cancer Res 61, 5784-5789 (2001).

437. Sarafian, T. A., Tashkin, D. P. & Roth, M. D. Marijuana smoke and Delta(9)-

tetrahydrocannabinol promote necrotic cell death but inhibit Fas-mediated

apoptosis. Toxicol Appl Pharmacol 174, 264-272 (2001).

438. Esposito, G., Izzo, A. A., Di Rosa, M. & Iuvone, T. Selective cannabinoid CB1

receptor-mediated inhibition of inducible nitric oxide synthase protein expression in

C6 rat glioma cells. J Neurochem 78, 835-841 (2001).

439. Jonsson, K. O., Vandevoorde, S., Lambert, D. M., Tiger, G. & Fowler, C. J. Effects

of homologues and analogues of palmitoylethanolamide upon the inactivation of the

endocannabinoid anandamide. Br J Pharmacol 133, 1263-1275 (2001).

440. Jacobsson, S. O. & Fowler, C. J. Characterization of palmitoylethanolamide

transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia

cells: comparison with anandamide. Br J Pharmacol 132, 1743-1754 (2001).

441. Bisogno, T. et al. The uptake by cells of 2-arachidonoylglycerol, an endogenous

agonist of cannabinoid receptors. Eur J Biochem 268, 1982-1989 (2001).

442. Ripamonti, C. & Dickerson, E. D. Strategies for the treatment of cancer pain in the

new millennium. Drugs 61, 955-977 (2001).

443. Guzman, M., Sanchez, C. & Galve-Roperh, I. Control of the cell survival/death

decision by cannabinoids. J Mol Med 78, 613-625 (2001).

444. Kaferstein, H. & Sticht, G. Comparison of nonradioactive microtiter plate enzyme

immunoassays for the sensitive detection of fentanyl. Forensic Sci Int 113, 353-357

(2000).

445. Di, M., Bisogno, T. & De Petrocellis, L. Endocannabinoids: new targets for drug

development. Curr Pharm Des 6, 1361-1380 (2000).

446. Gallily, R., Breuer, A. & Mechoulam, R. 2-Arachidonylglycerol, an endogenous

cannabinoid, inhibits tumor necrosis factor-alpha production in murine

macrophages, and in mice. Eur J Pharmacol 406, R5-7 (2000).

447. Maccarrone, M., Lorenzon, T., Bari, M., Melino, G. & Finazzi-Agro, A.

Anandamide induces apoptosis in human cells via vanilloid receptors. Evidence for

a protective role of cannabinoid receptors. J Biol Chem 275, 31938-31945 (2000).

448. Klein, T. W., Lane, B., Newton, C. A. & Friedman, H. The cannabinoid system and

cytokine network. Proc Soc Exp Biol Med 225, 1-8 (2000).

449. Carriot, F. & Sasco, A. J. [Cannabis and cancer]. Rev Epidemiol Sante Publique 48,

473-483 (2000).

450. Maccarrone, M., Salvati, S., Bari, M. & Finazzi-Agro. Anandamide and 2-

arachidonoylglycerol inhibit fatty acid amide hydrolase by activating the

lipoxygenase pathway of the arachidonate cascade. Biochem Biophys Res Commun

278, 576-583 (2000).

451. De Petrocellis, L., Melck, D., Bisogno, T. & Di Marzo, V. Endocannabinoids and

fatty acid amides in cancer, inflammation and related disorders. Chem Phys Lipids

108, 191-209 (2000).

452. Ho, B. Y. et al. Cannabinoid CB1 receptor-mediated inhibition of prolactin release

and signaling mechanisms in GH4C1 cells. Endocrinology 141, 1675-1685 (2000).

453. MacCarrone, M. et al. Down-regulation of anandamide hydrolase in mouse uterus

by sex hormones. Eur J Biochem 267, 2991-2997 (2000).

454. Molnar, J. et al. Membrane associated antitumor effects of crocine-, ginsenosideand

cannabinoid derivates. Anticancer Res 20, 861-867 (2000).

455. Galve-Roperh, I. et al. Anti-tumoral action of cannabinoids: involvement of

sustained ceramide accumulation and extracellular signal-regulated kinase

activation. Nat Med 6, 313-319 (2000).

456. Zhu, L. X. et al. Delta-9-tetrahydrocannabinol inhibits antitumor immunity by a

CB2 receptor-mediated, cytokine-dependent pathway. J Immunol 165, 373-380

(2000).

457. Puffenbarger, R. A., Boothe, A. C. & Cabral, G. A. Cannabinoids inhibit LPSinducible

cytokine mRNA expression in rat microglial cells. Glia 29, 58-69 (2000).

458. Melck, D. et al. Suppression of nerve growth factor Trk receptors and prolactin

receptors by endocannabinoids leads to inhibition of human breast and prostate

cancer cell proliferation. Endocrinology 141, 118-126 (2000).

459. Yea, S. S., Yang, K. H. & Kaminski, N. E. Role of nuclear factor of activated Tcells

and activator protein-1 in the inhibition of interleukin-2 gene transcription by

cannabinol in EL4 T-cells. J Pharmacol Exp Ther 292, 597-605 (2000).

460. Jacobsson, S. O., Rongard, E., Stridh, M., Tiger, G. & Fowler, C. J. Serumdependent

effects of tamoxifen and cannabinoids upon C6 glioma cell viability.

Biochem Pharmacol 60, 1807-1813 (2000).

461. Rubino, T. et al. Chronic delta-9-tetrahydrocannabinol treatment increases cAMP

levels and cAMP-dependent protein kinase activity in some rat brain regions.

Neuropharmacology 39, 1331-1336 (2000).

462. Gomez del Pulgar, T., Velasco, G. & Guzman, M. The CB1 cannabinoid receptor is

coupled to the activation of protein kinase B/Akt. Biochem J 347, 369-373 (2000).

463. Han, D. S. et al. Synthesis and cytotoxic effects of deoxy-tomentellin. Arch Pharm

Res 23, 121-127 (2000).

464. Benard, J. [Cannabinoids, among others, send malignant glial tumors to nirvana.].

Bull Cancer 87, 299-300 (2000).

465. Muthian, S., Nithipatikom, K., Campbell, W. B. & Hillard, C. J. Synthesis and

characterization of a fluorescent substrate for the N-arachidonoylethanolamine

(anandamide) transmembrane carrier. J Pharmacol Exp Ther 293, 289-295 (2000).

466. Smith, S. R., Terminelli, C. & Denhardt, G. Effects of cannabinoid receptor agonist

and antagonist ligands on production of inflammatory cytokines and antiinflammatory

interleukin-10 in endotoxemic mice. J Pharmacol Exp Ther 293, 136-

150 (2000).

467. Di Marzo, V., Melck, D., De Petrocellis, L. & Bisogno, T. Cannabimimetic fatty

acid derivatives in cancer and inflammation. Prostaglandins Other Lipid Mediat 61,

43-61 (2000).

468. Lorenzo Fernandez, P. [Potential therapeutic usefulness of cannabis and

cannabinoids]. An R Acad Nac Med (Madr) 117, 595-605; discussion 616-24

(2000).

469. Ruiz, L., Miguel, A. & Diaz-Laviada, I. Delta9-tetrahydrocannabinol induces

apoptosis in human prostate PC-3 cells via a receptor-independent mechanism.

FEBS Lett 458, 400-404 (1999).

470. Lambert, D. M. et al. Analogues and homologues of N-palmitoylethanolamide, a

putative endogenous CB(2) cannabinoid, as potential ligands for the cannabinoid

receptors. Biochim Biophys Acta 1440, 266-274 (1999).

471. Gorter, R. W. Cancer cachexia and cannabinoids. Forsch Komplementarmed 6

Suppl 3, 21-22 (1999).

472. Mechoulam, R. Recent advantages in cannabinoid research. Forsch

Komplementarmed 6 Suppl 3, 16-20 (1999).

473. listed], [N. a. Studies of high-dose chemotherapy with stem cell support for breast

cancer. Am J Health Syst Pharm 56, 940 (1999).

474. Valk, P. J. et al. Retroviral insertions in Evi12, a novel common virus integration

site upstream of Tra1/Grp94, frequently coincide with insertions in the gene

encoding the peripheral cannabinoid receptor Cnr2. J Virol 73, 3595-3602 (1999).

475. Mukhopadhyay, S., Cowsik, S. M., Lynn, A. M., Welsh, W. J. & Howlett, A. C.

Regulation of Gi by the CB1 cannabinoid receptor C-terminal juxtamembrane

region: structural requirements determined by peptide analysis. Biochemistry 38,

3447-3455 (1999).

476. Sarafian, T. A., Magallanes, J. A., Shau, H., Tashkin, D. & Roth, M. D. Oxidative

stress produced by marijuana smoke. An adverse effect enhanced by cannabinoids.

Am J Respir Cell Mol Biol 20, 1286-1293 (1999).

477. Basavarajappa, B. S. & Hungund, B. L. Chronic ethanol increases the cannabinoid

receptor agonist anandamide and its precursor Narachidonoylphosphatidylethanolamine

in SK-N-SH cells. J Neurochem 72, 522-

528 (1999).

478. Melck, D. et al. Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs):

vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to

CB1 cannabinoid receptors. Biochem Biophys Res Commun 262, 275-284 (1999).

479. Kenney, S. P. et al. Cannabinoid receptors and their role in the regulation of the

serotonin transporter in human placenta. Am J Obstet Gynecol 181, 491-497 (1999).

480. Masset, D., Bourdon, J. H., Arditti-Djiane, J. & Jouglard, J. [Impact of delta-9-

tetrahydrocannabinol and its metabolites on the immune system]. Acta Clin Belg

Suppl 1, 39-43 (1999).

481. Berglund, B. A., Boring, D. L. & Howlett, A. C. Investigation of structural analogs

of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid

receptors in rat brain and human tonsils. Adv Exp Med Biol 469, 527-533 (1999).

482. Sanchez, C., Galve-Roperh, I., Canova, C., Brachet, P. & Guzman, M. Delta9-

tetrahydrocannabinol induces apoptosis in C6 glioma cells. FEBS Lett 436, 6-10

(1998).

483. Di Marzo, V. et al. Interactions between synthetic vanilloids and the endogenous

cannabinoid system. FEBS Lett 436, 449-454 (1998).

484. Maccarrone, M. et al. Anandamide hydrolysis by human cells in culture and brain. J

Biol Chem 273, 32332-32339 (1998).

485. Srivastava, M. D., Srivastava, B. I. & Brouhard, B. Delta9 tetrahydrocannabinol

and cannabidiol alter cytokine production by human immune cells.

Immunopharmacology 40, 179-185 (1998).

486. Herrstedt, J., Aapro, M. S., Smyth, J. F. & Del Favero, A. Corticosteroids,

dopamine antagonists and other drugs. Support Care Cancer 6, 204-214 (1998).

487. Bisogno, T. et al. Biosynthesis and degradation of bioactive fatty acid amides in

human breast cancer and rat pheochromocytoma cells--implications for cell

proliferation and differentiation. Eur J Biochem 254, 634-642 (1998).

488. Baek, S. H. et al. Boron trifluoride etherate on silica-A modified Lewis acid reagent

(VII). Antitumor activity of cannabigerol against human oral epitheloid carcinoma

cells. Arch Pharm Res 21, 353-356 (1998).

489. Bruera, E. & Neumann, C. M. The uses of psychotropics in symptom management

in advanced cancer. Psychooncology 7, 346-358 (1998).

490. De Petrocellis, L. et al. The endogenous cannabinoid anandamide inhibits human

breast cancer cell proliferation. Proc Natl Acad Sci U S A 95, 8375-8380 (1998).

491. Bisogno, T. et al. Arachidonoylserotonin and other novel inhibitors of fatty acid

amide hydrolase. Biochem Biophys Res Commun 248, 515-522 (1998).

492. Zurier, R. B. et al. Dimethylheptyl-THC-11 oic acid: a nonpsychoactive

antiinflammatory agent with a cannabinoid template structure. Arthritis Rheum 41,

163-170 (1998).

493. Derocq, J. M. et al. The endogenous cannabinoid anandamide is a lipid messenger

activating cell growth via a cannabinoid receptor-independent pathway in

hematopoietic cell lines. FEBS Lett 425, 419-425 (1998).

494. Di Marzo, V., Bisogno, T., Sugiura, T., Melck, D. & De Petrocellis, L. The novel

endogenous cannabinoid 2-arachidonoylglycerol is inactivated by neuronal- and

basophil-like cells: connections with anandamide. Biochem J 331, 15-19 (1998).

495. Di Toro, R., Campana, G., Sciarretta, V., Murari, G. & Spampinato, S. Regulation

of delta opioid receptors by delta9-tetrahydrocannabinol in NG108-15 hybrid cells.

Life Sci 63, PL197-204 (1998).

496. Ongradi, J., Specter, S., Horvath, A. & Friedman, H. Combined in vitro effect of

marijuana and retrovirus on the activity of mouse natural killer cells. Pathol Oncol

Res 4, 191-199 (1998).

497. Bisogno, T., Sepe, N., De Petrocellis, L., Mechoulam, R. & Di Marzo, V. The sleep

inducing factor oleamide is produced by mouse neuroblastoma cells. Biochem

Biophys Res Commun 239, 473-479 (1997).

498. Molina-Holgado, F., Lledo, A. & Guaza, C. Anandamide suppresses nitric oxide

and TNF-alpha responses to Theiler's virus or endotoxin in astrocytes. Neuroreport

8, 1929-1933 (1997).

499. Voth, E. A. & Schwartz, R. H. Medicinal applications of delta-9-

tetrahydrocannabinol and marijuana. Ann Intern Med 126, 791-798 (1997).

500. McPartland, J. M. & Pruitt, P. L. Medical marijuana and its use by the

immunocompromised. Altern Ther Health Med 3, 39-45 (1997).

501. Bisogno, T. et al. Biosynthesis, release and degradation of the novel endogenous

cannabimimetic metabolite 2-arachidonoylglycerol in mouse neuroblastoma cells.

Biochem J 322, 671-677 (1997).

502. Abood, M. E., Ditto, K. E., Noel, M. A., Showalter, V. M. & Tao, Q. Isolation and

expression of a mouse CB1 cannabinoid receptor gene. Comparison of binding

properties with those of native CB1 receptors in mouse brain and N18TG2

neuroblastoma cells. Biochem Pharmacol 53, 207-214 (1997).

503. Ruh, M. F., Taylor, J. A., Howlett, A. C. & Welshons, W. V. Failure of cannabinoid

compounds to stimulate estrogen receptors. Biochem Pharmacol 53, 35-41 (1997).

504. Deutsch, D. G. et al. Fatty acid sulfonyl fluorides inhibit anandamide metabolism

and bind to the cannabinoid receptor. Biochem Biophys Res Commun 231, 217-221

(1997).

505. Schatz, A. R., Lee, M., Condie, R. B., Pulaski, J. T. & Kaminski, N. E. Cannabinoid

receptors CB1 and CB2: a characterization of expression and adenylate cyclase

modulation within the immune system. Toxicol Appl Pharmacol 142, 278-287

(1997).

506. Sanchez, C., Velasco, G. & Guzman, M. Delta9-tetrahydrocannabinol stimulates

glucose utilization in C6 glioma cells. Brain Res 767, 64-71 (1997).

507. Axelrod, R. S. Antiemetic therapy. Compr Ther 23, 539-545 (1997).

508. Goodman, M. Risk factors and antiemetic management of chemotherapy-induced

nausea and vomiting. Oncol Nurs Forum 24, 20-32 (1997).

509. Hunter, S. A. & Burstein, S. H. Receptor mediation in cannabinoid stimulated

arachidonic acid mobilization and anandamide synthesis. Life Sci 60, 1563-1573

(1997).

510. Di Marzo, V., De Petrocellis, L., Sugiura, T. & Waku, K. Potential biosynthetic

connections between the two cannabimimetic eicosanoids, anandamide and 2-

arachidonoyl-glycerol, in mouse neuroblastoma cells. Biochem Biophys Res

Commun 227, 281-288 (1996).

511. Lew, G. M. Tau protein after delta-9-tetrahydrocannabinol in a human

neuroblastoma cell line. Gen Pharmacol 27, 1141-1143 (1996).

512. NIH. NTP Toxicology and Carcinogenesis Studies of 1-Trans-Delta(9)-

Tetrahydrocannabinol (CAS No. 1972-08-3) in F344 Rats and B6C3F1 Mice

(Gavage Studies). Natl Toxicol Program Tech Rep Ser S 446, 1-317 (1996).

513. Bhargava, H. N., House, R. V., Thorat, S. N. & Thomas, P. T. Cellular immune

function in mice tolerant to or abstinent from l-trans-delta 9-tetrahydrocannabinol.

Pharmacology 52, 271-282 (1996).

514. Chan, P. C., Sills, R. C., Braun, A. G., Haseman, J. K. & Bucher, J. R. Toxicity and

carcinogenicity of delta 9-tetrahydrocannabinol in Fischer rats and B6C3F1 mice.

Fundam Appl Toxicol 30, 109-117 (1996).

515. Di Marzo, V., De Petrocellis, L., Sepe, N. & Buono, A. Biosynthesis of anandamide

and related acylethanolamides in mouse J774 macrophages and N18 neuroblastoma

cells. Biochem J 316, 977-984 (1996).

516. Ho, B. Y. & Zhao, J. Determination of the cannabinoid receptors in mouse x rat

hybridoma NG108-15 cells and rat GH4C1 cells. Neurosci Lett 212, 123-126

(1996).

517. Zheng, Z. M. & Specter, S. C. Delta-9-tetrahydrocannabinol suppresses tumor

necrosis factor alpha maturation and secretion but not its transcription in mouse

macrophages. Int J Immunopharmacol 18, 53-68 (1996).

518. Abood, M. E. & Martin, B. R. Molecular neurobiology of the cannabinoid receptor.

Int Rev Neurobiol 39, 197-221 (1996).

519. Mackie, K., Lai, Y., Westenbroek, R. & Mitchell, R. Cannabinoids activate an

inwardly rectifying potassium conductance and inhibit Q-type calcium currents in

AtT20 cells transfected with rat brain cannabinoid receptor. J Neurosci 15, 6552-

6561 (1995).

520. Burnette-Curley, D. & Cabral, G. A. Differential inhibition of RAW264.7

macrophage tumoricidal activity by delta 9tetrahydrocannabinol. Proc Soc Exp Biol

Med 210, 64-76 (1995).

521. Burstein, S. H. & Hunter, S. A. Stimulation of anandamide biosynthesis in N-

18TG2 neuroblastoma cells by delta 9-tetrahydrocannabinol (THC). Biochem

Pharmacol 49, 855-858 (1995).

522. Klein, T. W., Newton, C., Zhu, W., Daaka, Y. & Friedman, H. delta 9-

Tetrahydrocannabinol, cytokines, and immunity to Legionella pneumophila. Proc

Soc Exp Biol Med 209, 205-212 (1995).

523. Fride, E. et al. Low doses of anandamides inhibit pharmacological effects of delta

9-tetrahydrocannabinol. J Pharmacol Exp Ther 272, 699-707 (1995).

524. Gibertini, M., Newton, C., Friedman, H. & Klein, T. W. IL-1 beta and TNF alpha

modulate delta 9-tetrahydrocannabinol-induced catalepsy in mice. Pharmacol

Biochem Behav 50, 141-146 (1995).

525. Hirst, R. A. & Lambert, D. G. Do SH-SY5Y human neuroblastoma cells express

cannabinoid receptors? Biochem Soc Trans 23, 418S (1995).

526. Cabral, G. A., Toney, D. M., Fischer-Stenger, K., Harrison, M. P. & Marciano-

Cabral, F. Anandamide inhibits macrophage-mediated killing of tumor necrosis

factor-sensitive cells. Life Sci 56, 2065-2072 (1995).

527. Nelson, K., Walsh, D., Deeter, P. & Sheehan, F. A phase II study of delta-9-

tetrahydrocannabinol for appetite stimulation in cancer-associated anorexia. J

Palliat Care 10, 14-18 (1994).

528. Koutek, B. et al. Inhibitors of arachidonoyl ethanolamide hydrolysis. J Biol Chem

269, 22937-22940 (1994).

529. Kusher, D. I., Dawson, L. O., Taylor, A. C. & Djeu, J. Y. Effect of the psychoactive

metabolite of marijuana, delta 9-tetrahydrocannabinol (THC), on the synthesis of

tumor necrosis factor by human large granular lymphocytes. Cell Immunol 154, 99-

108 (1994).

530. Zheng, Z. M. & Specter, S. Suppression by delta-9-tetrahydrocannabinol of

lipopolysaccharide-induced and intrinsic tyrosine phosphorylation and protein

expression in mouse peritoneal macrophages. Biochem Pharmacol 47, 2243-2252

(1994).

531. Trisler, K. & Specter, S. Delta-9-tetrahydrocannabinol treatment results in a

suppression of interleukin-2-induced cellular activities in human and murine

lymphocytes. Int J Immunopharmacol 16, 593-603 (1994).

532. Vigano, A., Watanabe, S. & Bruera, E. Anorexia and cachexia in advanced cancer

patients. Cancer Surv 21, 99-115 (1994).

533. Cabral, G. A. & Fischer-Stenger, K. Inhibition of macrophage inducible protein

expression by delta-9-tetrahydrocannabinol. Life Sci 54, 1831-1844 (1994).

534. Shivers, S. C., Newton, C., Friedman, H. & Klein, T. W. delta 9-

Tetrahydrocannabinol (THC) modulates IL-1 bioactivity in human

monocyte/macrophage cell lines. Life Sci 54, 1281-1289 (1994).

535. Munro, S., Thomas, K. L. & Abu-Shaar, M. Molecular Characterization of a

Peripheral Receptor for Cannabinoids. Nature 365, 61-65 (1993).

536. Mackie, K., Devane, W. A. & Hille, B. Anandamide, an endogenous cannabinoid,

inhibits calcium currents as a partial agonist in N18 neuroblastoma cells. Mol

Pharmacol 44, 498-503 (1993).

537. Klein, T. W., Newton, C., Widen, R. & Friedman, H. Delta 9-tetrahydrocannabinol

injection induces cytokine-mediated mortality of mice infected with Legionella

pneumophila. J Pharmacol Exp Ther 267, 635-640 (1993).

538. Melvin, L. S. et al. Structure-activity relationships for cannabinoid receptor-binding

and analgesic activity: studies of bicyclic cannabinoid analogs. Mol Pharmacol 44,

1008-1015 (1993).

539. Bruera, E. Is the pharmacological treatment of cancer cachexia possible? Support

Care Cancer 1, 298-304 (1993).

540. Bouaboula, M. et al. Cannabinoid-receptor expression in human leukocytes. Eur J

Biochem 214, 173-180 (1993).

541. Fischer-Stenger, K., Dove Pettit, D. A. & Cabral, G. A. Delta 9-

tetrahydrocannabinol inhibition of tumor necrosis factor-alpha: suppression of posttranslational

events. J Pharmacol Exp Ther 267, 1558-1565 (1993).

542. Burnette-Curley, D., Marciano-Cabral, F., Fischer-Stenger, K. & Cabral, G. A.

delta-9-Tetrahydrocannabinol inhibits cell contact-dependent cytotoxicity of

Bacillus Calmette-Guerin-activated macrophages. Int J Immunopharmacol 15, 371-

382 (1993).

543. Tchekmedyian, N. S., Halpert, C., Ashley, J. & Heber, D. Nutrition in advanced

cancer: anorexia as an outcome variable and target of therapy. JPEN J Parenter

Enteral Nutr 16, 88S-92S (1992).

544. Zheng, Z. M., Specter, S. & Friedman, H. Inhibition by delta-9-

tetrahydrocannabinol of tumor necrosis factor alpha production by mouse and

human macrophages. Int J Immunopharmacol 14, 1445-1452 (1992).

545. Mackie, K. & Hille, B. Cannabinoids inhibit N-type calcium channels in

neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 89, 3825-3829 (1992).

546. Mitchelson, F. Pharmacological agents affecting emesis. A review (Part I). Drugs

43, 295-315 (1992).

547. Caulfield, M. P. & Brown, D. A. Cannabinoid receptor agonists inhibit Ca current

in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J

Pharmacol 106, 231-232 (1992).

548. Bruera, E. Current pharmacological management of anorexia in cancer patients.

Oncology (Huntingt) 6, 125-30; discussion 132, 137 (1992).

549. Campbell, M. & Bateman, D. N. Pharmacokinetic optimisation of antiemetic

therapy. Clin Pharmacokinet 23, 147-160 (1992).

550. Nahas, G. & Latour, C. The human toxicity of marijuana. Med J Aust 156, 495-497

(1992).

551. Bruera, E. Clinical management of anorexia and cachexia in patients with advanced

cancer. Oncology 49 Suppl 2, 35-42 (1992).

552. Turkanis, S. A., Karler, R. & Partlow, L. M. Differential effects of delta-9-

tetrahydrocannabinol and its 11-hydroxy metabolite on sodium current in

neuroblastoma cells. Brain Res 560, 245-250 (1991).

553. Wang, M., Richards, A. L., Friedman, H. & Djeu, J. Y. Selective inhibition of

natural killer but not natural cytotoxic activity in a cloned cell line by delta-9-

tetrahydrocannabinol. J Leukoc Biol 50, 192-197 (1991).

554. Watzl, B., Scuderi, P. & Watson, R. R. Influence of marijuana components (THC

and CBD) on human mononuclear cell cytokine secretion in vitro. Adv Exp Med

Biol 288, 63-70 (1991).

555. Watzl, B., Scuderi, P. & Watson, R. R. Marijuana components stimulate human

peripheral blood mononuclear cell secretion of interferon-gamma and suppress

interleukin-1 alpha in vitro. Int J Immunopharmacol 13, 1091-1097 (1991).

556. Tashkin, D. P. Pulmonary complications of smoked substance abuse. West J Med

152, 525-530 (1990).

557. Johnson, B. A. Psychopharmacological effects of cannabis. Br J Hosp Med 43, 114-

6, 118-20, 122 (1990).

558. Stewart, D. J. Cancer therapy, vomiting, and antiemetics. Can J Physiol Pharmacol

68, 304-313 (1990).

559. Tortorice, P. V. & O'Connell, M. B. Management of chemotherapy-induced nausea

and vomiting. Pharmacotherapy 10, 129-145 (1990).

560. Howlett, A. C., Scott, D. K. & Wilken, G. H. Regulation of adenylate cyclase by

cannabinoid drugs. Insights based on thermodynamic studies. Biochem Pharmacol

38, 3297-3304 (1989).

561. Shook, J. E. & Burks, T. F. Psychoactive cannabinoids reduce gastrointestinal

propulsion and motility in rodents. J Pharmacol Exp Ther 249, 444-449 (1989).

562. Grunberg, S. M. Advances in the management of nausea and vomiting induced by

non-cisplatin containing chemotherapeutic regimens. Blood Rev 3, 216-221 (1989).

563. McCabe, M. et al. Efficacy of tetrahydrocannabinol in patients refractory to

standard antiemetic therapy. Invest New Drugs 6, 243-246 (1988).

564. Dill, J. A. & Howlett, A. C. Regulation of adenylate cyclase by chronic exposure to

cannabimimetic drugs. J Pharmacol Exp Ther 244, 1157-1163 (1988).

565. Kawakami, Y. et al. Suppression by delta-9-tetrahydrocannabinol of interleukin 2-

induced lymphocyte proliferation and lymphokine-activated killer cell activity. Int J

Immunopharmacol 10, 485-488 (1988).

566. Triozzi, P. L. & Laszlo, J. Optimum management of nausea and vomiting in cancer

chemotherapy. Drugs 34, 136-149 (1987).

567. Little, P. J., Kaplan, N. C. & Martin, B. R. Pharmacological profile of delta 9-THC

carbamate. Alcohol Drug Res 7, 517-523 (1987).

568. Howlett, A. C. Regulation of adenylate cyclase in a cultured neuronal cell line by

marijuana constituents, metabolites of delta-9-tetrahydrocannabinol, and synthetic

analogs having psychoactivity. NIDA Res Monogr 79, 148-157 (1987).

569. Roffman, R. A. Stress inoculation training in the control of THC toxicities. Int J

Addict 21, 883-896 (1986).

570. Specter, S. C. et al. Marijuana effects on immunity: suppression of human natural

killer cell activity of delta-9-tetrahydrocannabinol. Int J Immunopharmacol 8, 741-

745 (1986).

571. Dodds, L. J. The control of cancer chemotherapy-induced nausea and vomiting. J

Clin Hosp Pharm 10, 143-166 (1985).

572. Citron, M. L. et al. Antiemetic efficacy of levonantradol compared to delta-9-

tetrahydrocannabinol for chemotherapy-induced nausea and vomiting. Cancer Treat

Rep 69, 109-112 (1985).

573. Perlin, E. et al. Disposition and bioavailability of various formulations of

tetrahydrocannabinol in the rhesus monkey. J Pharm Sci 74, 171-174 (1985).

574. Ungerleider, J. T. et al. THC or Compazine for the cancer chemotherapy patient--

the UCLA study. Part II: Patient drug preference. Am J Clin Oncol 8, 142-147

(1985).

575. Bakowski, M. T. Advances in anti-emetic therapy. Cancer Treat Rev 11, 237-256

(1984).

576. Kaplan, N. C. Dichloroethyl carbamoyl ester of delta-9-tetrahydrocannabinol.

Chemical synthesis and biological testing and evaluation as a potentially sitespecific

anti-tumor agent. Sci Sin [B] 27, 1048-1058 (1984).

577. Hiller, E. & Gerhartz, H. [New aspects in the antiemetic therapy of cytostatic druginduced

vomiting]. Klin Wochenschr 62, 441-445 (1984).

578. Stoudemire, A., Cotanch, P. & Laszlo, J. Recent advances in the pharmacologic and

behavioral management of chemotherapy-induced emesis. Arch Intern Med 144,

1029-1033 (1984).

579. Eyre, H. J. & Ward, J. H. Control of cancer chemotherapy-induced nausea and

vomiting. Cancer 54, 2642-2648 (1984).

580. Frytak, S., Moertel, C. G. & Rubin, J. Metabolic studies of delta-9-

tetrahydrocannabinol in cancer patients. Cancer Treat Rep 68, 1427-1431 (1984).

581. Hogan, P., Sharpe, M., Smedley, H. & Sikora, K. Cannabinoids and hCG levels in

patients with testicular cancer. Lancet 2(8359), 1144 (1983).

582. Treffert, D. A. & Joranson, D. E. delta 9-Tetrahydrocannabinol and therapeutic

research legislation for cancer patients. JAMA 249, 1469-1472 (1983).

583. Carey, M. P., Burish, T. G. & Brenner, D. E. Delta-9-tetrahydrocannabinol in

cancer chemotherapy: research problems and issues. Ann Intern Med 99, 106-114

(1983).

584. Laszlo, J. Nausea and vomiting as major complications of cancer chemotherapy.

Drugs 25 Suppl 1, 1-7 (1983).

585. Heim, M. E. [Cannabis and cannabinoids. Possibilities of their therapeutic use].

Fortschr Med 100, 343-346 (1982).

586. Tetrahydrocannabinol (THC) for cancer patients. A review of the National Cancer

Institute program in Wisconsin. Wis Med J 81, 24 (1982).

587. Laszlo, J. Treatment of nausea and vomiting caused by cancer chemotherapy.

Cancer Treat Rev 9 Suppl B, 3-9 (1982).

588. Ungerleider, J. T. et al. Cannabis and cancer chemotherapy: a comparison of oral

delta-9-THC and prochlorperazine. Cancer 50, 636-645 (1982).

589. Joss, R. A. et al. Levonantradol, a new antiemetic with a high rate of side-effects for

the prevention of nausea and vomiting in patients receiving cancer chemotherapy.

Cancer Chemother Pharmacol 9, 61-64 (1982).

590. Goldstein, M. S. & Williams, F. F. How we comply with federal guidelines on THC

dispensing. Pharm Times 47, 32-36 (1981).

591. Poster, D. S., Penta, J. S., Bruno, S. & Macdonald, J. S. delta 9-

tetrahydrocannabinol in clinical oncology. JAMA 245, 2047-2051 (1981).

592. Anderson, P. O. & McGuire, G. G. Delta-9-tetrahydrocannabinol as an antiemetic.

Am J Hosp Pharm 38, 639-646 (1981).

593. Procedure for obtaining THC for cancer patients. JAMA 246, 15-19 (1981).

594. Sweet, D. L., Miller, N. J., Weddington, W., Senay, E. & Sushelsky, L. delta 9-

Tetrahydrocannabinol as an antiemetic for patients receiving cancer chemotherapy.

A pilot study. J Clin Pharmacol 21, 70S-75S (1981).

595. Garb, S. Cannabinoids in the management of severe nausea and vomiting from

cancer chemotherapy. Some additional considerations. J Clin Pharmacol 21, 57S-

59S (1981).

596. Benowitz, N. L. & Jones, R. T. Cardiovascular and metabolic considerations in

prolonged cannabinoid administration in man. J Clin Pharmacol 21, 214S-223S

(1981).

597. Dow, G. J. & Meyers, F. H. The California program for the investigational use of

THC and marihuana in heterogeneous populations experiencing nausea and

vomiting from anticancer therapy. J Clin Pharmacol 21, 128S-132S (1981).

598. Abraham, D., Pina, K. R. & Davignon, J. P. Mechanism for national distribution of

delta 9-tetrahydrocannabinol (NSC-134454). J Clin Pharmacol 21, 122S-127S

(1981).

599. Scigliano, J. A. THC therapeutic research by independent and state-sponsored

investigators: a historical review. J Clin Pharmacol 21, 113S-121S (1981).

600. Penta, J. S., Poster, D. S., Bruno, S. & Macdonald, J. S. Clinical trials with

antiemetic agents in cancer patients receiving chemotherapy. J Clin Pharmacol 21,

11S-22S (1981).

601. Levitt, M. et al. Physiologic observations in a controlled clinical trial of the

antiemetic effectiveness of 5, 10, and 15 mg of delta 9-tetrahydrocannabinol in

cancer chemotherapy. Ophthalmologic implications. J Clin Pharmacol 21, 103S-

109S (1981).

602. Gunby, P. Many cancer patients receiving THC as antiemetic. JAMA 245, 1515,

1518 (1981).

603. Chang, A. E. et al. A prospective evaluation of delta-9-tetrahydrocannabinol as an

antiemetic in patients receiving adriamycin and cytoxan chemotherapy. Cancer 47,

1746-1751 (1981).

604. Sallan, S. E. & Cronin, C. M. Is THC an effective antiemetic for cancer patients?

Opinion 2. CA Cancer J Clin 30, 283-285 (1980).

605. Frytak, S. Is THC an effective antiemetic for cancer patients? Opinion 1. CA

Cancer J Clin 30, 278-282 (1980).

606. Winokur, S. H., Baker, J. J., Lokey, J. L. & Price, N. A. Marijuana for nausea and

vomiting in cancer patients. J Med Assoc Ga 69, 919-920 (1980).

607. Lucas, V. S. J. & Laszlo, J. delta 9-Tetrahydrocannabinol for refractory vomiting

induced by cancer chemotherapy. JAMA 243, 1241-1243 (1980).

608. Sallan, S. E., Cronin, C., Zelen, M. & Zinberg, N. E. Antiemetics in patients

receiving chemotherapy for cancer: a randomized comparison of delta-9-

tetrahydrocannabinol and prochlorperazine. N Engl J Med 302, 135-138 (1980).

609. Levy, J. A. & Heppner, G. H. Immunosuppression by marihuana and its

cannabinoid constituents. J Immunopharmacol 2, 159-177 (1980).

610. Ekert, H., Waters, K. D., Jurk, I. H., Mobilia, J. & Loughnan, P. Amelioration of

cancer chemotherapy-induced nausea and vomiting by delta-9-

tetrahydrocannabinol. Med J Aust 2, 657-659 (1979).

611. Frytak, S. et al. Delta-9-tetrahydrocannabinol as an antiemetic for patients receiving

cancer chemotherapy. A comparison with prochlorperazine and a placebo. Ann

Intern Med 91, 825-830 (1979).

612. Chang, A. E. et al. Delata-9-tetrahydrocannabinol as an antiemetic in cancer

patients receiving high-dose methotrexate. A prospective, randomized evaluation.

Ann Intern Med 91, 819-824 (1979).

613. Mechoulam, R. & Carlini, E. A. Toward drugs derived from cannabis.

Naturwissenschaften 65, 174-179 (1978).

614. Warner, W., Harris, L. S. & Carchman, R. A. Inhibition of cortiocosteroidogenesis

by delta-9-tetrahydrocannabinol. Endocrinology 101, 1815-1820 (1977).

615. Friedman, M. A. In vivo effects of cannabinoids on macromolecular biosynthesis in

Lewis lung carcinomas. Cancer Biochem Biophys 2, 51-54 (1977).

616. White, A. C., Munson, J. A., Munson, A. E. & Carchman, R. A. Effects of delta9-

tetrahydrocannabinol in Lewis lung adenocarcinoma cells in tissue culture. J Natl

Cancer Inst 56, 655-658 (1976).

617. Carchman, R. A., Harris, L. S. & Munson, A. E. The inhibition of DNA synthesis

by cannabinoids. Cancer Res 36, 95-100 (1976).

618. Munson, A. E., Harris, L. S., Friedman, M. A., Dewey, W. L. & Carchman, R. A.

Antineoplastic activity of cannabinoids. J Natl Cancer Inst 55, 597-602 (1975).

619. Noyes, R. J., Brunk, S. F., Avery, D. A. & Canter, A. C. The analgesic properties of

delta-9-tetrahydrocannabinol and codeine. Clin Pharmacol Ther 18, 84-89 (1975).

620. Noyes, R. J., Brunk, S. F., Baram, D. A. & Canter, A. Analgesic effect of delta-9-

tetrahydrocannabinol. J Clin Pharmacol 15, 139-143 (1975).

Cannabis Plant Genetics Mapped

2012-01-07T03:22:00.000-08:00

Cannabis Plant Genetics Mapped

Posted on January 6, 2012

1 Vote

In 2011 we saw cannabis all over the news. We saw raids, booming industries, more states push for and more doctors taking a stand for legalization. Cannabis has been in use by humans since at least 2737 BCE with Chinese Emperor Shen-Nung recorded prescribing it for a number of ailments.

There are many mysteries and controversies surrounding the cannabis plant. Science has been trying to unravel them for years. In 2011 we had a monumental breakthrough that quite literally could change the course of history.

Kevin McKernan has stacked up a long list of big accomplishments at just 38. He is the owner of Medicinal Genomics with a lab in Amsterdam for researchers to freely study the cannabis plant. Kevin was part of the Human Genome Project for four years. He also worked on a robotic system that could handle He also developed methods to process DNA 100,000 times faster.

With a man who’s resume is that impressive you have to ask yourself why would a guy like that get into the business of studying cannabis. He did work on mapping tumors and after working with doctors and patients started to see that many cancer patients were using cannabis. After looking into cannabis he saw that there was much more to this plant and that it did have medicinal value.

While working with oncologist he found that if you sequence a tumors DNA as well as the patient you will discover the differences which can then become a target for drug therapies. With cannabis being mapped the same theory could apply, instead of using Big Pharma drugs you could use Cannabinoids.

With both the Indica and Cannabis plant genetics mapped science can now start to get a better grasp on how cannabinoids interact with our bodies. When we can successfully target each person illness with specific cannabinoids we will effectively understand the science behind the curing powers of cannabis.

Science will finally be able to confirm what millions have known for thousands of years. Today we know more about THC, the psychoactive ingredient and the CBD, non-psychoactive ingredient and how the synthases of each are the genes that code for an enzyme that helps fold the hydrocarbons into Cannabinoids.

What controls the other 83 cannabinoids and other hundreds of terpenes is still unknown.

Many genes that were bred out in search of higher THC content since the government prohibited cannabis use, will need to be brought back through selective breading.

This is one more step in our fight for legalization. With scientific proof the government will have no choice but to recognize cannabis has medicinal value.

Even the national Cancer Institute briefly posted a page that listed cannabis as a pain reliever and anti-nausea as well as possible anti-tumor effects. The government made them take it down since this has only been proven in cell cultures and rats although it is currently in human clinical trials.

When dealing with chemotherapeutic drugs there is a fine line between killing the tumor and killing the patient. Whats exciting about cannabis is that it is not fatal and very few drug therapies have such a forgiving window.

With all this new data in the coming years we will see our knowledge grow and hopefully result in legalization. It will take all of us making our voices heard, that we should have a natural choice when treating our illnesses. Kevin and his team have posted their findings online for all to look at. Please feel free to share ~ Cherry Girl

Related articles

■Endocannabinoid System, Cannabinoid Receptors, and Cannabinoids CURING Cancer (cherrygurl28.com)

■Cannabinoid Deficiency: Is It the Source of Your Illness? (cherrygurl28.com)

■Cash “Cashy” Hyde: Children’s Cancer and Cannabis (cherrygurl28.wordpress.com)

■How Cannabis Prohibition Effects All of Us (cherrygurl28.com)

■Newly Released Studies That Show Medical Value Of Cannabis 2011 (cherrygurl28.com)

US National Library of MedicineNational Institutes of Health

2012-01-05T09:30:00.000-08:00

US National Library of MedicineNational Institutes of Health

Search termSearch database

All DatabasesPubMedProteinNucleotideGSSESTStructureGenomeBioProjectBioSampleBioSystemsBooksCancerChromosomesConserved DomainsClonedbGaPdbVarEpigenomicsGeneGENSATGEO DataSetsGEO ProfilesHomoloGeneMeSHNCBI Web SiteNLM CatalogOMIAOMIMPMCPopSetProbeProtein ClustersPubChem BioAssayPubChem CompoundPubChem SubstanceSNPSRATaxonomyToolKitToolKitAllUniGeneUniSTS

Abstract

Health Technol Assess. 2006 Aug;10(28):iii-iv, xi-xiv, 1-183.

Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation.

Shepherd J, Jones J, Takeda A, Davidson P, Price A.

Source

Southampton Health Technology Assessments Centre, UK.

Abstract

OBJECTIVES:

To assess the clinical effectiveness and cost-effectiveness of adefovirdipivoxil (ADV) and pegylated interferon alfa-2a (PEG) for the treatment of adults with chronic hepatitis B infection (CHB).

DATA SOURCES:

Electronic databases for the period from 1995-6 to April 2005. Websites of the relevant organisations.

REVIEW METHODS:

Searches were made for studies of clinical effectiveness, cost-effectiveness, quality of life, resource use/costs and epidemiology/natural history. Randomised controlled trials (RCTs) were included that compared PEG and ADV with currently licensed treatments for CHB, including non-pegylated ('standard') interferon alfa (IFN), lamivudine (LAM), and best supportive care. The trials were reviewed in a narrative synthesis but meta-analysis was not undertaken owing to heterogeneity in the interventions and comparators evaluated. A model was developed to estimate the cost-effectiveness (cost-utility) of PEG and of ADV compared with IFN, LAM and best supportive care in a UK cohort of adults with CHB. The perspective of the cost-effectiveness analysis was that of the NHS and personal social services. A Markov state transition model was constructed, informed by a systematic search of the literature to identify source material on the natural history, epidemiology and treatment of CHB. Interventions were evaluated against their closest comparator (for PEG this is IFN, and for ADV this is LAM). In addition, the cost-effectiveness of sequential treatment scenarios was modelled.

RESULTS:

A total of 1086 references to clinical effectiveness studies were identified, of which seven fully published RCTs and one systematic review met the inclusion criteria. Four of the RCTs evaluated the effectiveness of ADV and three reported results for PEG. In addition, a conference abstract was included reporting interim results from an on-going Phase II RCT of ADV in combination with LAM. The published trials were of good quality, although details of randomisation and allocation of concealment were poorly reported. ADV was significantly more effective than placebo. Response rates were in the range 21-51% compared with 0%, respectively. For patients resistant to LAM, response rates were significantly higher for those treated with ADV in addition to on-going LAM (35-85%) than those who continued on LAM with placebo (0-11%). Significant alanine aminotransferase (ALT) reductions to normal levels were observed in all studies. For treatment-naive patients, seroconversion rates were 12-14% for ADV compared with 6% for placebo (statistically significant), rates were higher for LAM-resistant patients who received ADV in addition to on-going LAM (8%) than those who continued on LAM with placebo (2%) (no significance value was reported), and rates were higher for LAM-resistant patients who switched to ADV than those who continued on LAM with placebo (11 versus 0%, respectively; not statistically significant). HBsAg loss or seroconversion was observed in less than 5% of patients taking ADV. Two ADV studies reported changes in liver histology. In general, histological improvement and necroinflammatory activity/fibrosis scores were significantly better in ADV groups than in placebo groups. Dose discontinuations for safety reasons were low for patients receiving ADV. With the exception of headache, the most commonly reported adverse events were often seen in the placebo groups in similar proportions to the ADV groups, with different trials reporting conflicting results. PEG/LAM dual therapy and PEG monotherapy were similar in effect on HBV DNA and ALT levels, and both were significantly superior to LAM monotherapy. Response rates were higher for HBeAg-negative patients than for HBeAg-positive patients. HBeAg seroconversion rates at follow-up were significantly higher for PEG monotherapy patients than for those receiving either a combination of PEG and LAM or LAM monotherapy (32, 27 and 19%, respectively). For the comparison between PEG and IFN-2a, there was a significant difference in the combined outcome of ALT normalisation, HBV DNA response and HBeAg seroconversion at follow-up (24 versus 12%, respectively). Changes in liver histology were reported by two studies. There was no statistically significant difference in histological improvement between the PEG monotherapy groups, the LAM monotherapy groups and the dual therapy groups. Two PEG trials reported small percentages (up to 5%) of HBsAg loss or seroconversion among patients receiving PEG either as monotherapy or in combination with LAM, but no HBsAg loss or seroconversion was reported in those receiving LAM monotherapy. Health-related quality of life (HRQoL) scores, as measured by the Short Form with 36 Items, decreased during treatment, but returned to at least baseline levels at follow-up (based on unpublished data). For HBeAg-positive patients, there were no significant differences in scores between treatment groups. Dose discontinuations for safety reasons were significantly higher for patients receiving PEG than for patients receiving LAM monotherapy. The most commonly reported adverse events in the PEG studies were headache, pyrexia, fatigue, myalgia and alopecia. Only one fully published economic evaluation was identified, reporting a US cost-effectiveness study of ADV as salvage therapy for chronic hepatitis B with LAM resistance. A Markov model was used to estimate cost-effectiveness of interferon alfa (6-12 months), LAM and LAM followed by ADV when resistance occurs. ADV generated the most (undiscounted) life-years, but at highest costs, with an incremental cost-effectiveness ratio (ICER) of US$14,204 per life-year gained. Using our model, incremental cost per QALY estimates (baseline cohort of all patients) were: 5994 pounds for IFN compared with best supportive care, 6119 pounds for PEG compared with IFN, 3685 pounds for LAM compared with best supportive care, and 16,569 pounds for ADV compared with LAM. Incremental cost per QALY estimates (HBeAg-positive patients only) were: 7936 pounds for IFN (24 weeks) compared with best supportive care, 16,166 pounds for PEG (48 weeks) compared with IFN (24 weeks), 3489 pounds for LAM compared with best supportive care, and 15,289 pounds for ADV compared with LAM. Incremental cost per QALY estimates (HBeAg-negative patients only) were: 3922 pounds for IFN (48 weeks) compared with best supportive care, 2162 pounds for PEG (48 weeks) compared with IFN (24 weeks), 4131 pounds for LAM compared with best supportive care, and 18,620 pounds for ADV compared with LAM. For the sequential treatment strategies, incremental cost per QALY estimates ranged from 3604 pounds (IFN followed by LAM versus IFN alone) to 11,402 pounds (IFN followed by LAM with adefovir salvage versus IFN followed by LAM). In all of these cases, the ICERs are well within the range that would conventionally be regarded as being cost-effective. The probabilistic sensitivity analysis found that LAM is a cost-effective option at lower willingness-to-pay thresholds for health outcomes, but as the threshold is increased adefovir is increasingly likely to be the optimal intervention. Where a willingness-to-pay threshold of above 10,000 pounds per QALY is employed, PEG is highly likely to be the optimal intervention compared with IFN (based on a cohort of HBeAg-positive and -negative patients). Interferon alfa (non-pegylated or pegylated) followed by LAM would be the optimal strategy at lower willingness-to-pay thresholds. As the threshold increases, the sequential treatment strategy of PEG followed by LAM with adefovir added as salvage therapy is increasingly likely to be the optimal intervention.

CONCLUSIONS:

ADV and PEG are associated with significant improvements in a number of biochemical, virological and histological outcomes in both HBeAg-positive and -negative patients. For a small proportion of patients this is associated with resolution of infection. For another proportion it leads to remission and a reduced risk of progressing to cirrhosis, hepatocellular carcinoma, liver transplant and death. For others who do not respond or who relapse, retreatment with another agent is necessary. The results of our cost-effectiveness analysis demonstrate that incremental costs per QALY for a range of comparisons were between 5994 pounds and 16,569 pounds and within the range considered by NHS decision-makers to represent good value for money. When subjected to sensitivity analysis, most costs per QALY estimates remained under 30,000 pounds. Further RCT evidence of the effectiveness of anti-viral treatment is required, particularly for subgroups of patients with different genotypes, patients with cirrhosis, patients from different ethnic groups, patients with co-infections (e.g. HIV, HCV) and co-morbidities, liver transplant patients and children and adolescents.

PMID: 16904047 [PubMed - indexed for MEDLINE] Free full text

Publication Types, MeSH Terms, Substances

November 20, 2009 Irvin Rosenfeld, a Florida stockbroker, set the world record for the consumption of cannabis cigarettes.

2012-01-03T10:45:00.000-08:00

November 20, 2009 Irvin Rosenfeld, a Florida stockbroker, set the world record for the consumption of cannabis cigarettes.

The United States federal government has supplied Rosenfeld and three other US citizens for decades with a smokable cannabis medicine. Irv Rosenfeld has received his medicine for 27 years and is the longest known cannabis patient.

One of four patients intensely tested in 2001 by Patients Out of Time as part of the “Missoula Study” Irv was found to be in excellent health for a man of his age. All physiological systems were examined by neutral investigators since the US federal government had never required or requested such a complete overview to discover the efficacy of the plant product they were medically administering under the “Compassionate New Drug Program”of the FDA.

Irv will consume his number one hundred and fifteen thousand “joint” or marijuana cigarette sometime on November 20, 2009. All 115,000 cigarettes have been prescribed by US federally approved medical doctors from cannabis plants grown at the University of Mississippi in a test location and prepared for consumption in the research triangle area of North Carolina.

Speaking as a cannabis patient and Director of the cannabis patient advocacy organization Patients Out of Time Irv stated, “I cannot fathom the reluctance of my federal government to allow the use of medical cannabis for the sick and dying of the US. My experience of use, the calming of my negative symptoms, that has allowed me to be a useful, contributing member of society must be extended to all the ill based on the judgment of medical professionals and not guided or restrained by the dictates of law enforcement who have no empathy for the ill nor the education to appropriately enter into doctor-patient relationships and treatment options.”

115,000 and counting. When do the sick not named Rosenfeld, receive their cannabis medicine?

Illuminati Bloodlines (part 1)

2012-01-03T10:07:00.000-08:00

Illuminati Bloodlines (part 1)

TREKT UW PLANT SHOCKED BY STATEMENTS OF VICE-MINISTER DEVLIES - Encod.org

2011-12-31T04:22:00.000-08:00

TREKT UW PLANT SHOCKED BY STATEMENTS OF VICE-MINISTER DEVLIES - Encod.org

How the ILLUMINATI control cannabis

2011-12-24T23:40:00.000-08:00

http://www.youtube.com/watch?v=NC3KS

Copenhagen estimates cannabis sales as £200,000million (£2 Billion)

Here in the U.K we have figures (estimations only) that the U.K cannabis market could
earn around £17millions to £2billion in taxes.

At these estimations, we can see that the price of cannabis will make it a wealthy person's pastime.

And, it follows that if legal cannabis costs a high price, there will almost certainly be a black-market
that will undermine the whole enterprise. To counter any criminal gangs operating from greed and not from quality and a good product for the consumer the product i.e. cannabis must be very low in cost.
Thus making it a non-viable enterprise for criminals to bother themselves.

In Caliafornia cannabis costs around $600 per oz from dipensaries as long as one has a doctors recomendation for using cannabis, and must carry their card showing that they lawfully are allowed to carry and use cannabis.

The U.K and an all party parliamentary group as well as cannabis activists and supporters/campaigners whom in all other ways are in the main Law-abiding people, will be debating the issue of decriminalising or legalising cannabis in the House of Lords early in January 2012
.
However, criminalised by this law adults have to choose between what they think, have researched
and therefore, are informed of all the facts including the unjust fact of life that possession of cannabis is illegal in the U.K at this moment. irra

COPENHAGEN VOTES TO LEGALISE MARIJUANA

2011-12-24T09:19:00.000-08:00

CODE OF CONDUCT FOR EUROPEAN CANNABIS SOCIAL CLUBS

COPENHAGEN VOTES TO LEGALISE MARIJUANA

Published on Sunday 20 November 2011 21:15, by encod . Modified on Sunday 20 November 2011 21:15

All the versions of this article: [English] [Español] [Nederlands]

1

Source: The Telegraph

18 November 2011

The scheme, if approved by the Danish parliament at the start of next year, could make the city the first to fully legalise, rather than simply tolerate, marijuana consumption.

The drug is already sold openly on the streets of Christiania, a self-proclaimed ’free town’ in the city centre, despite the closure of the neighbourhood’s Amsterdam-style coffee shops in 2004.

But marijuana has never been officially decriminalised and those caught in possession of even small amounts face fines of up to £450.

"We are thinking of perhaps 30 to 40 public sales houses, where the people aren’t interested in selling you more, they’re interested in you," said Mikkel Warming, the Mayor in charge of Social Affairs at Copenhagen City Council. "Who is it better for youngsters to buy marijuana from? A drug pusher, who wants them to use more, who wants them to buy hard drugs, or a civil servant?"

The City Council voted on Thursday night, by a margin of 39 votes to nine, to empower Mr Warming’s Social Affairs committee to draw up a detailed outline of how the plan would work. Related Articles

The proposal will then be sent to to the Danish Parliament for approval early next year.

"We want to make it a little bit more concrete what kind of decriminalisation we want: should it be a public buying system, should there be an age limit?" Mr Warming explained.

He said he was opposed to instituting cannabis cafés, where marijuana use is tolerated, despite it remaining illegal to grow and import the drug.

This, he argued, would leave the revenues, which are estimated at £200m, in the control of the city’s notorious biker gangs.

"We don’t want an Amsterdam model. We want a way to make it legal to import or grow marijuana." he said.

Cannabis possession and production in the Netherlands are still technically punishable by fines. Its notorious coffee shops are also illegally but are tolerated.

The Danish parliament voted down a previous proposal submitted by Copenhagen City Council three years ago.

Share

Reply to this article

1 Message

COPENHAGEN VOTES TO LEGALISE MARIJUANA20 November 21:28, by Gart Valenc

I do not know how much support will the proposal carry within the Danish parliament, or whether the proposal itself is realistic in its plans to make it not only a public buying system but more significantly, to make the importation of marijuana legal . But if it manages to be passed, it would really represent a ground breaking scheme, for, as far as I know, it would be the first time marijuana will be allowed to be supplied by a foreign supplier. To say that I am intrigued by the idea, the mechanics and the practicalities of procuring it from outside Denmark would be an understatement of an understatement. One thing is for sure, the repercussions of such an scheme would be seismic and would deal a fatal blow to the prohibitionist regime. Gart Valenc http://www.stopthewarondrugs.org

Reply to this message

COMMENTS from www.infowars.com (AlexJones)

2011-12-24T08:36:00.000-08:00

beggarz says:

December 23, 2011 at 11:26 pm

Newt and his vile ilk need to trip into the dustbin of history, enough is enough.

The thing that no one blathering about the war on drugs wants to face is that, for an average kid today, DRUGS ARE ALREADY EFFECTIVELY LEGAL. Since I hit high school in 1978, they have been readily available with a few discreet queries.

But then, you’d get a little Columbian Gold, have a half a beer, laugh, fall down and get the munchies. I wouldn’t want to be a kid nowadays with what is out there, readily available, surrounded by mystique and danger – meth, cocaine, LSD, MDMA, GHB – all with the promise of cheap thrills and a badass image. Even the weed is literally ten times as strong in terms of thc content.

Making it illegal creates a profit motive, and an entire sub-culture by definition outside the law. The cost encourages young entrepreneurs to traffic, at first just for a party fund, but this can very quickly become a lifestyle. Taking people’s choices away from them, and terrorizing them in place of educating, only serves to infantilize the general public, and allows them to be victimized on many levels – you couldn’t have come up with a better plan if you had a team of psychologists on the case.

I know in Canada our liquor laws keep people in the bars – a decision to leave is a decision to terminate one’s alcohol supply, so it becomes part of the equation, and many people at least dawdle. Whereas, when I have stayed in NYC or other places that you can just buy a single beer at the bodega 24hrs, you’ll only stay in that bar if there is something interesting going on – good music or conversation, etc. Once you take away the pressure of availability, the binge drinking and other perverse behaviour surrounding alcohol clearly subsides.

I’m not sure what it would be like to be able to buy cocaine at the pharmacy, as I believe it was possible to do before 1900 – but I’m not sure that is what is being advocated. The point is, prohibition of alcohol didn’t work, and we figured something else out. Statistics I’ve seen indicate that legalization does not produce any more or less addicts – but it definitely cuts down on crime and loss of individual rights!

I mean, plenty of people get hooked on solvents, should they be outlawed too? I have a couple of cans of spraypaint, a can of WD40, and some paint thinner around here somewhere, so why am I not having a party?

For the same reason I’m not snorting some powdered coca leaves cured in gasoline – because it’s gross, it destroys your life from top to bottom, and in the end, it’s not even that fun.

Drugs are everywhere in our culture now – in the clubs, in movies, rock stars being idolized for their habits, even recently a rapper bragging that TSA found weed in his checked baggage and left him a smart-alec note instead of busting him! Meanwhile, people are cooling their heels in JAIL over this?!?!?

The war on drugs and prohibition as an idea utterly fails the general public on this issue of personal choice and responsibility. The ‘cool’ crowd expects you to ‘handle’ it, and if you go elsewhere for help you are often humiliated and even risk arrest.

For my generation, and even more so for every one after it, drugs are and have always been effectively legal, in that they are readily available. All the war on drugs does is drive the price up – which funds massive and powerful organized crime – and create a bizarre mystique combined with a fearful, almost siege mentality among the HUGE sub culture of users everywhere in the world today.

Shall we outlaw donuts, too? Has anyone done a statistical analysis of the burden put on our health care and other systems by unhealthy food?

But this isn’t just about people’s freedom of choice – the point is, prohibition creates at least as much damage and degradation for society as just letting people take responsibility for their own poor choices. It’s not helping anyone but the gangs who sell it, and those who profit from police, the prison system, and the cowed public forced to pay for it all.

Log in to Reply

The Avenger says:

December 23, 2011 at 11:21 pm

Yeah, and Newt and his supporters are for stuffing 2 cases of donuts into their fat faces every 20 minutes, getting screwed in the anus, robbing the poor to feed the rich, and worshipping Satan.

See?

We can play the same bullshit lying projection game too Newt, you fat rotten lying bastard!

Log in to Reply

GatorDude says:

December 23, 2011 at 11:16 pm

I do not use drugs. I do not smoke. I do not drink alcohol. But it’s up to individuals to choose to make their decisions and accept the consequences of their choices, NOT the government. If someone decides to have a beer, then a second beer, then a third, so one and so forth – THEN I REALLY DON’T CARE! But if that person decides to get behind a wheel and put others in jeapordy THEN I think the government should step in to regulate that type of behavior. I think government is TOO big right now. I support Dr. Ron Paul for President of the United States. He has sound policies that fall into my way of thinking and of course his great respect and support of the Constitution of the United States. IF WE TEACH CORRECT PRINCIPALS, PEOPLE CAN GOVERN THEMSELVES MORE EFFECTIVELY.

Log in to Reply

ChinaWildMan says:

December 23, 2011 at 11:04 pm

Gingrich is largely responsible for skyrocketing health care inflation in the U.S. today. In 2003, Gingrich founded The Center for Health Transformation, which was paid dues of $200,000 per year from health insurance providers and other health care firms. Those dues would provide health care companies with “access to Newt Gingrich” and “direct Newt interaction”, which everyone looks at as bribes that were paid to Gingrich by these health care giants to pass regulations that pushed health care costs through the roof.

Gingrich’s organization advocated that “anyone who earns more than $50,000 a year must purchase health insurance or post a bond.”It is unconstitutional for the government to force Americans to buy anything. This type of distortion of the free market by Gingrich is what has helped fuel massive health care inflation for the past decade.

On September 27th when Gingrich’s support was only 0.8%, Paul was beating him with support of 2.6%. Gingrich is the latest flavor of the month. We also saw huge spikes in support for Perry and Cain before their support collapsed back to below 2% as voters figured out the truth about them. Paul is the only candidate who has never been below 2% and has enjoyed a very large and solid support base that has been growing consistently.

Paul is currently second in Iowa and third nationwide and when voters realize he is the only candidate who will implement the changes that need to be made to save America from hyperinflation, Paul will be the only candidate left standing to take on Obama.

Log in to Reply

Marijuana : The Facts They Don't Want You To Hear

2011-12-19T09:44:00.000-08:00

Before You Vote in 2012, Watch This!

2011-12-19T09:36:00.000-08:00

http://youtu.be/JwYvFZdM_UM

Before You Vote in 2012, Watch This!

2011-12-19T09:35:00.000-08:00

http://youtu.be/JwYvFZdM_UM

What is Id Cop Plan?

2011-12-08T07:06:00.000-08:00

What Is Id Cop Plan?

The mnemonic ID COP PLAN is a Law governing the way arrests should be made in the UK. A police officer can only arrest if one of the following conditions applies: the investigation of the offence needs to be prompt and effective; the disappearance of the person will hinder the prosecution; to protect a child or other vulnerable person from the accused; to prevent the accused causing an unlawful obstruction of the highway; to prevent physical harm caused to any person and to prevent the accused from causing damage to property

Cannabis Cancer Drug Trials Underway in UK

2011-12-07T08:04:00.000-08:00

Home Green/Eco/Environment Green news Cannabis Cancer Drug Trials Underway in UK

Cannabis Cancer Drug Trials Underway in UK

1diggdigg

When Rick Simpson first announced he had cured cancer by using his home-grown cannabis oil, it would have been fair to expect fanfares and Nobel prizes at the very least.
Rick Simpson and his home grown cancer treatment
With Cancer expected to directly impact on 1 in 3 of our lives at some stage, it is in its self a huge proportion of the entire healthcare spend. So to suggest here was a substance which could reduce tumors for just a few pence/cents a dose, was big news. Or so you would have thought. What actually happened beggars belief.

Rick Simpson was arrested, branded a snake oil peddlar and cast off from his native Canadian homeland, forced to live in the US under the threat of re-arrest should he return to Canada.
	Today however its been announced the cannabis extract marketed by UK based biotech GW Pharmaceuticals is expected to achieve universal approval in the treatment of (wait for it) cancer.
Sativex was initially brought to market as a treatment for the spasticity associated with Multiple Sclerosis. But as more evidence becomes available its becoming apparent Rick Simpson was onto something with his cancer treatment. And with sales for the treatment of cancer expected to double the £150 million pounds it made as a MS treatment when licensing is completed, that would be a fair assumption. So are the cannabis laws really in place to 'save our children'? Or is there another, entirely more sinister agenda in play?]'' Read the entire Rick Simpson story, including step-by-step instructions on how to make your own cancer medicine at http://phoenixtears.ca/ Cannazine Cannabis News RELATED: UK's Largest Cannabis grower Identified Cannabis Creates New Jobs for UK Study Explains [exactly] How Cannabis Kills Cancer Cells

Dr. Nick Begich: HAARP, Secret Sciences & High Tech Mind Control 4/5

2011-12-02T08:17:00.001-08:00

2011-12-02T08:17:00.000-08:00

http://www.youtube.com/watch?feature=player_embedded&v=breFPBWh4GY#t=187s

Introduction to Cannabis:~ From Benediction to Condemnation.

2011-11-24T05:36:00.000-08:00

Introduction Cannabis: From Benediction to Condemnation

Introduction

Cannabis: From Benediction to Condemnation

Half a century ago, the judge presiding over the Moscow Trials, Andrei Vishinsky, made the doctrine

`the accused is guilty until proved innocent', the cornerstone of the judicial system of Communist

totalitarianism. Today, Gabriel Nahas and the rest of the modem witch-hunters have made the same

doctrine the cornerstone of the anti-drug hysteria, vociferously proclaiming that `marihuana should

remain guilty until proven innocent'.(1)

For thousands of years cannabis played a vital part in human survival, both as a source of energy, food,

and clothing, and also on account of its medicinal and euphoriant properties. Sixty years ago, however, it

suddenly became a threat to human existence, and a persecution campaign was launched against it.

Until 1937, people used cannabis for many of their daily needs. After 1937, self-serving, self-proclaimed

`protectors' of society turned it into the ultimate evil, banned its cultivation, and started to prosecute

users.

In 1875, cannabis was of such crucial importance for the economy and the survival of the US population

that in many states farmers who didn't grow it were punished with imprisonment or heavy fines. After

1937, people had to learn to live with the same sanctions hanging over their heads, but for precisely the

opposite reason: the cultivation or harvesting of a single shrub had been transformed from a patriotic

duty into an outrageous crime punishable by many years in prison.

Until 1937, the US government published special leaflets urging farmers to grow more cannabis. After

1937, it started producing propaganda to eradicate the plant and sending aeroplanes to spray cannabis

plantations in the US and in neighbouring countries with weed-killer.

Until 1937, the authorities described cannabis as a `valuable plant'. In 1937, they christened it an

`assassin of youth'.

In 1942, the official slogan was `Hemp for Victory'. And in 1946 it became a

`menace to society'.

Until 1937, the American government was exhorting farmers to grow it.

In 1937 the same government was sending growers and users to jail. In 1942, a propaganda film was going the rounds, urgin increased production and offering growers special subsidies and exemption from military service.

But in 1946, the government turned the heavy artillery of the police and the law against them and by 1976, started spraying their land with Paraquat.

How was it possible that a plant, which, from 1000 BC to the mid-nineteenth century, had been one of the biggest crops farmed on the planet and an important factor for satisfying many of the daily needs of people all over the world, should suddenly be transformed from a benediction into a curse?

http://www.drugtext.org/library/books/grivas/introduction.htm (1 of 2)3/7/2005 11:41:08 PM

Introduction Cannabis: From Benediction to Condemnation

Such a crucial question cries out for an answer, which cannot be eternally blocked by the combined political

and financial interests that lie behind the prohibition of cannabis and the persecution of those who use it.

The authoritarian perversity of suddenly transforming cannabis from a benediction of nature into a curse

to be exorcised by police and judicial `operations' became possible in the age of the dead-end industrial

civilisation, when so-called technological `progress' made developmental folly so powerful that it could

place the combined interests of the petrochemical, pharmaceutical, tobacco, and alcohol industries over

and above the interests of humankind.

This is precisely the key to interpreting the cancer of selective prohibition which is tearing human

society apart in our time, and helping to weaken the natural defences of its members, to blunt their moral

resistance, and to undermine the ties that bind them.

In the past, the professional suppression maniacs offered no proof whatsoever of the perils of cannabis to

justify prohibiting it and prosecuting users. Their rabid campaign was a matter of inarticulate shouting

and intimidating slogans. And their success only goes to show that in this complacently dubbed `age of

reason' the Middle Ages are still very much with us. Today the same people demand scientific proof that

cannabis is safe whenever any demand is made to reduce or lift the penal sanctions attendant on its

cultivation, possession, use, or distribution.

I intend to provide that scientific proof, not as a concession to the paranoia of the fanatical

suppressionists, but as further evidence of the overwhelming folly of a society that allows itself to be

treated like an irresponsible baby and prefers the dubious security of servitude to the risks and hazards of

freedom.

1 G. Nahas, Keep off the Grass (1990), p.24.

http://www.drugtext.org/library/books/grivas/introduction.htm (2 of 2)3/7/2005 11:41:08 PM

Chapter One The Identity of Cannabis

Chapter One

The Identity of Cannabis

Until the end of the 19th century, 90% of all ships' sails... 80% of all mankind's textiles and fabrics... 75-

90% of all paper in the world... 70-90% of all rope, twine, and cordage... art canvas, paints, varnishes,

and lighting oil... the most commonly used medicines in the world... the most complete and available-tothe-

body proteins... a lot of building materials and housing... and a number of relaxational substances...

were made from hemp.

Jack Herer (2)

1. The plant

Cannabis belongs to the genus Cannabaa. It comprises only one species, Cannabis sativa, of which there

are over a hundred natural varieties. In the past, the many varieties of the plant, which Linnaeus

classified as Cannabis sativa in 1753, have caused botanists to argue fiercely about its precise

classification. Today it is accepted that there is one original species, Cannabis sativa, from which have

come many varieties (Cannabis indica, Cannabis ruderalis, etc.), which are distinguished mainly by the

active substances they contain.

Cannabis belongs to one of the most highly developed plant families. It uses sunlight more efficiently

than any other plant and is a splendid wealth-producing resource that renews itself, thus helping to

maintain an ecological balance. It is a self-sown plant, cultivable, fibrous, annual, dioecious (having the

male and female flowers on separate plants), capable of being spun, and it produces oil. It looks like a

rather erect bush, grows in moist ground under any climatic conditions, and reaches a height of between

1 and 7 metres, depending on the variety grown and on the environmental conditions.(3) The trunk is

straight and strong and thickly branched. The leaves are hairy, firm, long-stalked, and palmatisect, with

between five and eleven lanceolate, dentate lobes. The male flowers are yellowish green in colour; the

female flowers are arranged in characteristic spicate bunches. The seeds are oval, some 4-5 mm long,

and contain a thick oil.

2. The uses of cannabis

Throughout history, into the early decades of the twentieth century, cannabis was widely and

systematically cultivated because of its extremely useful nutritional, therapeutic, and euphoriant

properties.(4) A quick look at its many uses will help us to appreciate the real reasons why cannabis was

outlawed and to realise which economically powerful groups had a vital interest in seeing the ban

imposed and enforced.(5)

NUTRITIONAL VALUE Until the twentieth century, hemp seeds, either ground or whole, were, and in

some cases still are, a staple part of many people's diet, for they are a source of high-quality vegetable

http://www.drugtext.org/library/books/grivas/chapterone.htm (1 of 13)3/7/2005 11:41:36 PM

Chapter One The Identity of Cannabis

protein.(6)

No other single plant source can compare with the nutritional value of hemp seeds. Both the complete

protein and the essential oils contained in hemp seeds are in ideal ratios for human nutrition. Only

soybeans contain a higher percentage of protein; however, the composition of the protein in hemp seed

is unique in the vegetable kingdom. Sixty-five percent of the proteit content in hemp seed is in the form

of globulin edestin.(7) The exceptionally high edestin content of hemp seed combined with albumin,

another globular protein contained in all seeds, means the readily available protein in hemp seed contain

all the essential amino acids in ideal proportions to assure your body with the necessary building blocks

to create proteins like disease-fighting immunoglobulins-antibodies whose job is to ward off infections

before the symptoms of sickness set in.(8)

These properties of cannabis led many researchers to conclude that its essential oils provide the immune

system with defences against the viruses and various other agents that attack it.

These essential oils support the immune system and guard against viral and other insults to the immune

system. Studies are in progress using the essential oils to support the immune system of victims of HIV.

So far they have been extremely promising... The insane prohibitions against the most valuable plant on

Earth, cannabis hemp, must yield to public demand... The promise of super health and the possibility of

feeding the world is at our fingertips.(9)

THERAPEUTIC VALUE Throughout human history cannabis and its derivatives have occupied a

paramount position in day-to-day therapeutic practice. Lavishly supplied by nature, non-toxic, safe, and

with a wide range of applications, cannabis was recommended for `neuralgia, gout, tetanus,

hydrophobia, epidemic cholera, convulsions, chorea hysteria, mental depression, insanity, and uterine

haemorrhage'.(10)

In the nineteenth century, the various products of marihuana and hashish in the form of distillations,

tinctures, and elixirs were the third most favoured type of medicine of all doctors and patients in the

USA. This is why they were included in the American Pharmacopoeia until 1942. Since then, despite the

ban, cannabis and its derivatives have remained a major therapeutic agent in the arsenal of natural

medicine. (11)

EUPHORIANT PROPERTIES The euphoriant effects of the derivatives of cannabis are superior in

every way to those of tobacco and alcohol, making marihuana and hashish formidable rivals to these.

Alcohol is extremely toxic. It triggers aggressive behaviour: 50% of all fatal road accidents, 65% of all

crimes, 80% of rapes of children and women, and 80% of all cases of domestic violence every year in

the US take place under the influence of alcohol. It is addictive and is responsible for many of the

mental and physical pathological states (with cirrhosis of the liver leading the field) that kill 150,000

people in the United States every year. An effective dose is very close to a fatal dose (from 1:4 to 1:10).

http://www.drugtext.org/library/books/grivas/chapterone.htm (2 of 13)3/7/2005 11:41:36 PM

Chapter One The Identity of Cannabis

Tobacco too is toxic and addictive. It seriously affects all the functions of the user's body, particularly

the cardiovascular system. It is a powerful carcinogen and 450,000 people die in the US every year of

lung cancer due to smoking .(12)

Cannabis is the least toxic of all the mind-affecting substances on this planet. It has a sedative effect, is

non-addictive, is responsible for no mental or physical pathological state, and it is virtually impossible

for it to cause death. In short, one may say that cannabis has all the positive and none of the negative

features of alcohol (with the exception of possible dizziness or disorientation in inexperienced users

consuming large amounts, or panic attacks, again in cases of over consumption).

ENERGY The biomass produced by cannabis can be converted into methane, methanol, or liquid fuel.

In view of the environmental destruction attendant on the production, processing, and use of oil, coal,

and nuclear power, it would obviously be much cheaper to produce energy from cannabis, and the

effects on the environment would be far less damaging.

Methanol, one of the products of pyrolysis of the biomass of cannabis, was extensively used between

1920 and 1945 to power agricultural and military vehicles, and is still used today in most racing cars.

Methanol can also be converted into high-octane liquid fuel by means of a catalytic process the patent

for which is owned by Mobil Oil.

PAPER Until 1883, some 75-90% of the world's paper (books, newspapers, maps, banknotes) was made

from cannabis. Paper made from cannabis is of higher quality and more durable than any other paper

ever made. `Hemp paper lasted 50 to 100 times longer than most preparations of papyrus, and was a

hundred times easier and cheaper to make.' (13)

Many historians believe that the long-lasting superiority of Chinese over Islamic and Western science

and art was due to the fact that the Chinese knew how to make paper from cannabis at least as early as

the first century BC (i.e. 800 years before the Islamic civilisation and 1,200 years before Western

civilisation adopted it). The possession of paper which was of better quality and longer lasting than that

produced by other means enabled the Chinese to pass on knowledge from generation to generation,

constantly enriching it along the way.

All the major works that have made their mark on modem Western culture were printed on cannabis

paper, from the Gutenberg Bible in the fifteenth century to Lewis Carroll's Alice in Wonderland in the

nineteenth; and the first (28 June 1776) and second (2 July 1776) drafts of the American Declaration of

Independence were written and signed on cannabis paper, just before independence was gloriously

proclaimed on 4 July 1776 and the United States of America came into being.(14)

SHIPS' EQUIPMENT From the fifth century BC to the nineteenth century AD, when the steamship was

invented, 90% of all ships' equipment was made from cannabis: all the sails, the rigging, the maps, the

logs, the books, and the flags were products of 'grass'.(15)

http://www.drugtext.org/library/books/grivas/chapterone.htm (3 of 13)3/7/2005 11:41:36 PM

Chapter One The Identity of Cannabis

FABRICS AND TEXTILES Eighty percent of the fabrics and textiles people used to make clothes,

tents, linen, bedcovers, towels, rugs, babies' napkins, and many, many other things were made from

cannabis. Until the eighteenth century, the renowned Irish and Italian linens were made from cannabis;

after the eighteenth century, Levi jeans were made from cannabis, though it was later superseded by

cotton denim; and right up until the interwar years, the parachutes, tents, rucksacks, and flags used by

armies and air forces were also made of cannabis.

ROPE, THREAD, CORD Seventy to 90% of the world's rope, thread, and cord was made from cannabis

and was 100% recyclable. After the ban on cannabis in 1937, they were all replaced by non-recyclable

petrochemical products, on which DuPont had the monopoly, having reached an agreement with I. G.

Farben, the German company that owned the relevant patents.

PAINTING CANVAS All the works of the great painters who have changed the way we view the world,

from Caravaggio to Van Gogh, were painted on canvas made from cannabis, which has the advantage of

not deteriorating and of remaining in perfect condition for centuries on end.

PAINTS AND DYES For thousands of years, almost all the paints and varnishes that people used either

were produced from cannabis or contained hempseed oil. In 1935 alone `58,000 tons of hemp seed were

used in America just for paint and varnish. '(16) Since 1937 these natural dyes have been replaced by

petrochemical products.

BUILDING MATERIAL The cellulose pulp obtained from cannabis can be made into an excellent

building and construction material that is practical, cheap, and fire-resistant, and has splendid heat- and

sound-insulating properties. We would do well to replace building material produced by felling timber

and destroying forests with that produced from cannabis in order to preserve our forests, which are being

eroded at a dangerous rate. Unlike forest trees, cannabis renews itself annually and produces 4.1 times

more cellulose pulp per acre than other trees.

LAMP OIL Until 1800, hempseed oil fulfilled most of the world's demand for lamp oil. From 1800 to

1870 it lost its place to whale oil, and after that both began to be superseded by petroleum products.

As we shall see, it was precisely this plethora of advantages that led to cannabis' being prohibited,

relentlessly persecuted, and harshly suppressed from 1937 onwards.(17) But despite the legal risks, the

`forbidden plant' and its derivatives continue to be used for their euphoriant and therapeutic properties

and as raw materials to satisfy many people's day-to-day needs.

NB. From Benediction to Condemnation, shall be continued in a day or two. Come back for a looksee and read all of this factual book about Cannabis, it just might change the way you view Cannabis/Hemp. irra

2011-11-22T15:26:00.000-08:00

Cancer Metastasis Rev. 2011 Oct 27. [Epub ahead of print]

Cannabinoids, endocannabinoids, and cancer.

Hermanson DJ, Marnett LJ.

Source

A.B. Hancock Jr. Memorial Laboratory for Cancer Research, Departments of Biochemistry, Chemistry, and Pharmacology, Vanderbilt Institute of Chemical Biology, Center in Molecular Toxicology, Vanderbilt Ingram Comprehensive Cancer Center, Vanderbilt University School of Medicine, Nashville, TN, 37232-0146, USA.

Abstract

The endocannabinoid system consists of an array of endogenously produced bioactive lipids that activate cannabinoid receptors. Although the primary focus of endocannabinoid biology has been on neurological and psychiatric effects, recent work has revealed several important interactions between the endocannabinoid system and cancer. Several different types of cancer have abnormal regulation of the endocannabinoid system that contributes to cancer progression and correlates to clinical outcomes. Modulation of the endocannabinoid system by pharmacological agents in various cancer types reveals that it can mediate antiproliferative and apoptotic effects by both cannabinoid receptor-dependent and -independent pathways. Selective agonists and antagonists of the cannabinoid receptors, inhibitors of endocannabinoid hydrolysis, and cannabinoid analogs have been utilized to probe the pathways involved in the effects of the endocannabinoid system on cancer cell apoptosis, proliferation, migration, adhesion, and invasion. The antiproliferative and apoptotic effects produced by some of these pharmacological probes reveal that the endocannabinoid system is a promising new target for the development of novel chemotherapeutics to treat cancer.

PMID: 22038019 [PubMed - as supplied by publisher]

Why is US shoring up presence in Asia Pacific? - CCTV 111122

2011-11-22T09:44:00.000-08:00

COPENHAGEN VOTES TO LEGALISE MARIJUANA

2011-11-21T08:27:00.000-08:00

COPENHAGEN VOTES TO LEGALISE MARIJUANA

Published on Sunday 20 November 2011 21:15, by encod . Modified on Sunday 20 November 2011 21:15

All the versions of this article: [English] [Español] [Nederlands]

Source: The Telegraph

18 November 2011

The scheme, if approved by the Danish parliament at the start of next year, could make the city the first to fully legalise, rather than simply tolerate, marijuana consumption.

The drug is already sold openly on the streets of Christiania, a self-proclaimed ’free town’ in the city centre, despite the closure of the neighbourhood’s Amsterdam-style coffee shops in 2004.

But marijuana has never been officially decriminalised and those caught in possession of even small amounts face fines of up to £450.

"We are thinking of perhaps 30 to 40 public sales houses, where the people aren’t interested in selling you more, they’re interested in you," said Mikkel Warming, the Mayor in charge of Social Affairs at Copenhagen City Council. "Who is it better for youngsters to buy marijuana from? A drug pusher, who wants them to use more, who wants them to buy hard drugs, or a civil servant?"

The City Council voted on Thursday night, by a margin of 39 votes to nine, to empower Mr Warming’s Social Affairs committee to draw up a detailed outline of how the plan would work. Related Articles

The proposal will then be sent to to the Danish Parliament for approval early next year.

"We want to make it a little bit more concrete what kind of decriminalisation we want: should it be a public buying system, should there be an age limit?" Mr Warming explained.

He said he was opposed to instituting cannabis cafés, where marijuana use is tolerated, despite it remaining illegal to grow and import the drug.

This, he argued, would leave the revenues, which are estimated at £200m, in the control of the city’s notorious biker gangs.

"We don’t want an Amsterdam model. We want a way to make it legal to import or grow marijuana." he said.

Cannabis possession and production in the Netherlands are still technically punishable by fines. Its notorious coffee shops are also illegally but are tolerated.

The Danish parliament voted down a previous proposal submitted by Copenhagen City Council three years ago.

Dr. Jahan Marcu Explains the Endocannabinoid System with Dr. Michelle Se...

2011-11-21T07:46:00.000-08:00

2011-11-21T07:41:00.000-08:00

Share http://www.youtube.com/watch?feature=player_embedded&v=h2SKGtT7XRE#t=26s

Martin Barriuso arrested by Municipal police of Bilbao Spain.

2011-11-21T05:38:00.000-08:00

Home page > English (en) > PRESS RELEASES > PRESS RELEASE OF THE EXTRAORDINARY GENERAL ASSEMBLY OF PANNAGH

BECOME AN ENCOD MEMBER

EUROPEAN COCA LEAF SOCIAL CLUB

PRESS RELEASE OF THE EXTRAORDINARY GENERAL ASSEMBLY OF PANNAGH

Published on Monday 21 November 2011 10:21, by encod . Modified on Monday 21 November 2011 10:34

All the versions of this article: [English] [Español] [français]

2

Bilbao 19 november 2011

The Extraordinary General Assembly of Cannabis Users Association Pannagh, in an urgent meeting today, has unanimously agreed the following:

We energically denounce the disproportionate intervention of the Municipal Police of Bilbao against our association, stressing the fact that our premises were entered using lies, abuse of power and without a rogatory commission.

We publically declare that all the material that was confiscated in the office and its surroundings that were rent on behalf of the association, including the derivates of cannabis, are the collective property of all members of the association. The money that was deposited on the accounts of Pannagh proceeds integrally from our contributions and legal activities that are carried out by the association.

We declare that our president Martin Barriuso Alonso, as well as the other members of the Executive Committee, have always acted in representation of the mandate given to them by the successive general assemblies in order to organise the collective cultivation of cannabis to provide for the personal consumption of its members. This follows from the statutes that have been legally registered in the register of Associations. Likewise, we declare that two other members who have been detained were carrying out their tasks under a labour contract. These tasks refer to activities that have been commanded by the rest of the association. These members have the same influence in the decision making process than the rest of the general assembly.

We declare that the destination of the cannabis derivates that have been confiscated in the police operation is a collective fond that would be distributed through a closed circuit, composed of only members, adults, who use these products for personal consumption only, and that we have never given, or intended to give a part of this cannabis to third persons.

We urge the immediate withdrawal of the file in charge that has been opened against the three members who were arrested last Monday, in recognition of the fact that they have not committed any crime, taking into account that our association carries out its activities according to the jurisprudence regarding the ’shared consumption’ such as has been approved by the Provincial Tribunal of Bizkaia in its decision to withdraw the prosecution that was opened by the municipal police in 2005. Thus we urge the immediate return of the confiscated cannabis and the rest of the material and the documents that were confiscated, as well as the return of our premises and the release of our bank accounts.

We particularly denounce the fact that the police intervention means a halt in the provision of cannabis to the 157 members of Pannagh have been diagnotised as holders of pathologies, certain of them severe, in which cannabis has a proven therapeuthical efficacity. In this sense we consider those who have ordered this traumatising and absurd intervtnion as responsible for the consequences on the health of these people.

We protest against the deliberate intentions to present us as drug traffickers, since we have created a closed circuit for legal provision of cannabis as an alternative to the black market, which has precisely contyributed to reduce drug trafficking. The intervention of the municipal police goes in the opposite sense, facilitating the promotion of the drug trafficking that they say they wish to prosecute, sending the 327 members of Pannagh again to the illegal market.

We demand an end to this absurd harassment that has been imposed on our association as well as on our président. We demand respect for our work and our rights, especially our right to health, freedom of movement, the free development of the personality and not to be stigmatized for personal choices that do no harm to anyone.

We want to clarify that the figure of 78 kilograms of marijuana seized by the municipal city police is false because this includes, in addition to products that are suitable for consumption, crop residues, plants that were infected with fungi, and shamefully, two boxes of marijuana that were harvested in 2005, the same that were confiscated before and that were returned to us by the courts.

We demand a clear legal regulation for the cultivation, possession, consumption and distribution of cannabis in order to end the current situation of legal insecurity. If not we will we suffer again and again police and judicial interventions despite that fact that we have already won the case on the legality of our operations. In this sense, the members of Pannagh support the proposal for legal regulation approved today by the Federation of Cannabis Associations (FAC).

We will open a bank account whose number shall be released as soon as possible, for the collection of funds to pay the bond of 15,000 euros imposed on our President. The account is open to all the gifts of our members and others, communities or entities that wish to collaborate. In case the funds raised would exceed 15,000 euros, the surplus will be redistributed to a resistance fund, that will be administered by the FAC. This fund will be used for any other bonds that will be imposed on members of the FAC for activities of collective cultivation. In the case of a refund of this bond, that amount will be deposited in the resistance fund.

We will continue our work of sharing the collective cultivation of cannabis, with priority given to members with a therapeutic indication but without excluding anyone as far as possible. This activity will be managed collectively, forbidding the three members who were charged with offenses against public health and safety, to participate actively in this task.

We will convene a new extraordinary general assembly next Tuesday, November 22 at 19:30, to decide on concrete collective actions that we will implement for the proper conduct of this activity.

We communicate these agreements to the public opinion.

Extraordinary General Assembly of Pannagh

Contact: Joseba del Valle, Press officer + 34 676681363.

Email: ✉pannagh@pannagh.org

— ✉Asociación PANNAGH Elkartea

http://pannagh.org

http://pannagh.blogspot.com

http://www.facebook.com/Pannagh

English (en) > NEWS > POTENT POT IS SAFER

2011-11-19T08:05:00.000-08:00

Home page > English (en) > NEWS > POTENT POT IS SAFER

BECOME AN ENCOD MEMBER

EUROPEAN COCA LEAF SOCIAL CLUB

POTENT POT IS SAFER

Published on Thursday 17 November 2011 23:58, by encod . Modified on Thursday 17 November 2011 23:58

All the versions of this article: [English]

Source: Ottawa Citizen

By Russell Barth

17 November 2011

Dan Gardner’s column didn’t mention that "more potent" pot is actually much safer because THC is a therapeutic agent, not a toxin.

I use nine grams a day, and my prescription was recently increased to 16. The pot I use is among the finest, cleanest, and most potent in the world.

I got out of a wheelchair, cured my restless leg, my sleep apnea, and my erectile dysfunction. I sleep better than I have in decades and I am stronger than I have been in years, so the idea that pot is dangerous because it is more potent is, to me, utter nonsense.

Imagine a cop going on TV talking about how people should avoid oranges because "they have way more vitamin C than in the 1970s!" and you get the idea.

American neuroscientist Ethan Russo has an article coming up in the British Journal of Pharmacology called "Taming THC - Potential Cannabis Synergy and Phytocannabinoid-Terpenoid Entourage Effects," which explains how it is not just THC that brings about pot’s many medical benefits, it is the combination of THC, phytocannabinoids, terpenoids and other active ingredients found in pot.

And those medical benefits include the shrinking of cancerous tumours.

Russell Barth, Educators For Sensible Drug Policy, Federally Licensed Medical Marijuana User

Share

Reply to this article

Sections

Czech (cz, sk)

Dansk (dk)

Deutsch (de)

English (en)ACTION APPEALS

AGENDA

BULLETIN

CAMPAIGNS

CANNABIS SOCIAL CLUBS

DOWNLOADS

EU LOBBY CAMPAIGN

MEMBERSHIP

NEWS2007

2008

2009

2010

2011

PRESS RELEASES

REGIONAL ACTIVITIES

SHOP

STATEMENTS

STUDIES

WORKING GROUPS

Español (es)

Français (fr)

Italiano (it)

Magyar (hu)

Nederlands (nl)

Norsk (no)

Polski (pl)

Portugues (pt)

Română

Suomi (fi)

Svenska (sv)

Türkçe

Syndicate the whole site

In the same section

DRUGS AND DEVELOPMENT - CAUGHT IN A VICIOUS CYCLE

2ND INTERNATIONAL HEMP BUILDING SYMPOSIUM

A WAR WE SHOULD FIGHT NO LONGER

AIDE-MEMOIRE ON THE BOLIVIAN PROPOSAL TO AMEND THE SINGLE CONVENTION ON NARCOTIC DRUGS OF 1961

ALL ABOARD THE LATIN-AMERICAN DRUG WAR GRAVY TRAIN

AMERICAN BANKS HIGH ON DRUG MONEY

AWARD FOR “WHAT IF CANNABIS CURED CANCER”

BAN ON MIAOW MIAOW HAS DONE MORE HARM THEN GOOD

BANKERS, DRUG WARS AND GENOCIDES

BELGIAN VICE-MINISTER: TREKT UW PLANT MUST BE PERSECUTED

BOLIVIA COULD DENOUNCE THE 1961 CONVENTION

BOLIVIA WILL MAKE EFFORTS IN EUROPE TO LEGALISE THE COCA LEAF

CANADIAN EXPERTS: LEGALISATION WOULD CUT VIOLENCE

CANNABIS AS A MEDICINE

CANNABIS COULD EASE POST-TRAUMATIC STRESS DISORDER

CARRYING CANNABIS MEDICINE TO BE LEGAL IN IRELAND

CHAKIB IS FREE

CHILDREN OF THE DRUG WAR

COCA IS NOT ONLY COCAINE

COCA LEAVES AS A TOBACCO HABIT CURE

0
20
40
60
80

Agenda

From 25 November 10:00 to 27 November 17:00 : CANNAFEST, PRAGUE, PRAGUE, CZECH REPUBLIC [English]

From 1 December 19:00 to 2 December 22:30 : UN BUEN DEAL, ANTWERPEN, BRUSSEL [English] [Español] [Nederlands]

Latest comments

Most recent forum messages

18 November – WHY IS IT ONLY FORMERS WHO WANT TO LEGALISE DRUGS?

16 November – your comments on de regularisation

15 November – US National Cancer Institute Updates Confirm Successful Cancer Treatments with Medical Cannabis

9 November – your comments on de regularisation

6 November – ENCOD BULLETIN 81

2 November – ENCOD BULLETIN 81

24 October – COLOMBIAN PRESIDENT CALLS FOR LEGALISATION

23 September – US National Cancer Institute Updates Confirm Successful Cancer Treatments with Medical Cannabis

Encod Web Site

Encod.org

Encod Österreich

Encod Deutschland

Facebook

Youtube

Twitter

Cedars-Sinai Denying Transplant to Medical Marijuana Patient with Inoperable Liver Cancer.

2011-11-19T07:50:00.000-08:00

Cedars-Sinai Denying Transplant to Medical Marijuana Patient with Inoperable Liver Cancer

Patient advocacy group calls on preeminent health center to change harmful transplant policy

For Immediate Release: November 17th, 2011

Los Angeles, CA -- Sixty-three year-old medical marijuana patient Norman B. Smith was diagnosed with inoperable liver cancer in 2009 and sought treatment from the internationally lauded Cedars-Sinai Medical Center in Los Angeles. Smith's oncologist at Cedars-Sinai, Dr. Steven Miles, approved of his medical marijuana use as a means to deal with the effects of chemotherapy and pain from an unrelated back surgery. In September 2010, Smith became eligible for a liver transplant, but after testing positive for marijuana in February he was removed from the transplant list. Smith's cancer was in remission until just recently, but now he is scheduled to undergo radiation treatments in the next few days.

Medical marijuana advocacy group Americans for Safe Access (ASA) issued a letter today urging the Cedars-Sinai Transplant Department to promptly re-list Smith for a liver transplant. The letter also urges Cedars-Sinai to change its transplant eligibility policy. "Denying necessary transplants to medical marijuana patients is the worst kind of discrimination," said ASA Chief Counsel Joe Elford, who also authored the letter to Cedars-Sinai. "Cedars-Sinai would not be breaking any laws, federal or otherwise, by granting Norman Smith a liver transplant, and it's certainly the ethical thing to do."

Smith is not the only medical marijuana patient in the U.S. being denied a transplant. At least one other Cedars-Sinai patient reported to ASA in 2008 that they had been kicked off the transplant list because of their legal medical marijuana use. Over the past four years, ASA has received numerous reports of patients being purged from transplant lists across California, as well as in other medical marijuana states like Hawaii, Oregon, and Washington. In 2008, Seattle resident and medical marijuana patient Timothy Garon died after being denied a liver transplant by the University of Washington Medical Center. A year later, in 2009, Big Island resident and medical marijuana patient Kimberly Reyes died at Hilo Hospital after being denied a liver transplant.

Cedars-Sinai is demanding that Smith not only abstain from marijuana use for at least six months, forcing him to undergo random toxicology tests, but he is also required to participate in weekly substance abuse counseling over the same period. Although Smith was within two months of receiving a transplant before he was de-listed, he will be put at the bottom of the list even after satisfying the policy requirements. "ASA seeks to change this harmful and uncompassionate policy not only for Smith's benefit, but also for the benefit of numerous other medical marijuana patients who are being made to suffer unnecessarily as a result of political ideology," said Elford.

Between January 2010 and October 2011, Smith took part in a rare clinical trial to combat his liver cancer. The trial, which included only 60 people worldwide, involved weekly infusions and daily pills. Smith also smoked medical marijuana during this time, but stopped in August 2011 to try to adhere to the transplant eligibility requirements. Smith was the only patient in the entire 93-week trial who had a successful remission, earning him the moniker of "Miracle Man." Because of the cancer's return, Smith may not have six months to live. However, instead of re-listing him for a transplant, Cedars-Sinai is scheduling him for radiation treatment. "Norman Smith's life hangs in the balance between his desperate need for a liver and an anti-marijuana sentiment that informs a misguided and life-threatening transplant policy," continued Elford.

Smith not only has the support of his oncologist and other Cedars-Sinai staff, but also his psychologist, who wrote a strong letter of recommendation that Smith be approved for a liver transplant. Nonetheless, Dr. Steven D. Colquhoun, the director of Cedars-Sinai's Liver Transplant Program compared Smith's legal medical marijuana use to "substance abuse." In a letter sent to Smith in May, Dr. Colquhoun indicated that the liver transplant center "must consider issues of substance abuse seriously since it does often play a role in the evolution of diseases that may require transplantation, and may adversely impact a new organ after a transplant." Despite Dr. Colquhoun's assertions and Cedars-Sinai's restrictive policy, an independent study has shown that marijuana use has no adverse impact on the survival rate of transplant recipients.

Further information:

Video of Norman Smith: http://www.youtube.com/watch?v=i_kYTwQ6jdY&feature=youtu.be

ASA letter to Cedars-Sinai: http://AmericansForSafeAccess.org/downloads/Cedars_Letter_ASA.pdf

Cedars-Sinai transplant denial letter to Norman Smith: http://AmericansForSafeAccess.org/downloads/Smith_Transplant_Denial.pdf

Liver transplant study: http://deepblue.lib.umich.edu/bitstream/2027.42/73843/1/j.1600-6143.2008.02468.x.pdf

Take ActionMedicalLegalCommunityJoin ASA

As Feds Crack Down on Medical Pot, Groundbreaking Lawsuit Fights Back

2011-11-13T07:18:00.000-08:00

NORML / ByRuss Belville

44 COMMENTS

As Feds Crack Down on Medical Pot, Groundbreaking Lawsuit Fights Back

Claiming states' rights, entrapment, and constitutional violations, NORML attorneys file suit in four CA districts to challenge the federal assault on legal weed.

November 8, 2011

LIKE THIS ARTICLE ?

Join our mailing list:

Sign up to stay up to date on the latest headlines via email.

TAKE ACTION

Change.org
Get Widget
Start an Online Petition �

NORML Attorneys Matt Kumin, David Michael, and Alan Silber, have filed suit (read here) in the four federal districts in California to challenge the Obama Administration’s recent crackdown on medical marijuana operations in the Golden State. Aided by expert testimony from NORML Deputy Director Paul Armentano and research from California NORML Director Dale Gieringer, the suits seek an injunction against the recent federal intrusion into state medical marijuana laws at least and at most a declaration of the unconstitutionality of the Controlled Substances Act with respect to state regulation of medical marijuana

The NORML attorneys allege the federal government has engaged in entrapment of California patients and their caregivers. They point to the courts’ dismissal of County of Santa Cruz, WAMM et al. v. Eric Holder et al.where the Department of Justice (DOJ) “promised a federal judge that it had changed its policy toward the enforcement of its federal drug laws relative to California medical cannabis patients.” So after 2009, California providers had reason to believe that the federal government had changed its policy. The legal argument is called ‘judicial estoppel’, which basically means that courts can’t hold true to a fact in one case and then disregard it in another.

Kumin, Michael, and Silber also argue the government has engaged in ‘equitable estoppel’, which most people commonly think of as ‘entrapment’. That is to say, you can’t bust a person for committing a crime when the authorities told him it wasn’t a crime to do it!

Under established principles of estoppel and particularly in the context of the defense of estoppel by entrapment, defendants to a criminal action are protected and should not be prosecuted if they have reasonably relied on statements from the government indicating that their conduct is not unlawful. That principle should be applied to potential defendants as well, the plaintiffs in this action. Such parties, courts have noted, are “person[s] sincerely desirous of obeying the law”. They “accepted the information as true and [were]…not on notice to make further inquiries.” U.S. v. Weitzenhoff, 1 F. 3d 1523, 1534 (9th Cir. 1993).

The US Constitution figures prominently in the legal challenge as well. The 9th Amendment says that “The enumeration in the Constitution, of certain rights, shall not be construed to deny or disparage others retained by the people.” The NORML attorneys argue that threatening seizure of property and criminal sanctions violates the rights of the people to “consult with their doctors about their bodies and health.”

The 10th Amendment provides that “The powers not delegated to the United States by the Constitution, nor prohibited by it to the States, are reserved to the States respectively, or to the people.” The NORML attorneys argue that the States have the “primary plenary power to protect the health of its citizens” and since the government has recognized and not attempted to stop Colorado’s state-run medical marijuana dispensary program, it cannot suggest Colorado has a state’s right that California does not.

The 14th Amendment says that all citizens have equal protection under the law. The NORML attorneys argue that the federal government:

1. Actively provides cannabis for medical purposes to individuals through its own IND program.

2. Actively allows patients in Colorado to access medical cannabis through a state-licensing system that allows individuals to make profit from the sales of medical cannabis.

3. Actively restricts scientific research into the medical value and use of cannabis to alleviate human suffering and pain.

Thus, according to Kumin, Michael, and Silber, the government can’t be allowing Colorado medical marijuana commerce, engaging it its own IND program that mails 300 joints a month to four federal medical marijuana patients yet squelching all attempts to study medical value of marijuana, then have a rational basis for shutting down medical marijuana dispensaries in California. Under the 14th Amendment, the feds can’t treat Californians differently than Coloradoans and differently than four US citizens who get legal federal medical marijuana.

Finally, while acknowledging that Raich v. Gonzales 545 US 1 (2005) set the precedent that the Constitution’s Interstate Commerce Clause does allow the feds to prosecute California’s medical marijuana, the NORML attorneys argue:

…it is still difficult to imagine that marijuana grown only in California, pursuant to California State law, and distributed only within California, only to California residents holding state-issued cards, and only for medical purposes, can be subject to federal regulation pursuant to the Commerce Clause. For that reason, Plaintiffs preserve the issue for further Supreme Court review, if necessary and deemed appropriate.

We will keep you posted on all updates related to this groundbreaking lawsuit. Archive of our interview with the lead attorneys in this case is available in our “Audio/Video” section on The NORML Network.

Russ Belville is the NORML Outreach Coordinator.

2digg

63Share

44 COMMENTS

A

A

A

LIKED THIS ARTICLE? JOIN OUR EMAIL LIST

Stay up to date with the latest AlterNet headlines via email

You might like:

Compassionate Conservatism? 4 Popular Safety-Net Programs Tea Party Republicans Have Turned Against In the Age of Obama (AlterNet)

The Telecom Scam: 5 Behemoths That Strangle Innovation and Ensure You Pay Too Much for Bad Service (AlterNet)

Paid Distribution

Banned: Video labeled “too controversial” by some. See economists prophetic warning. (Moneynews)

Paid Distribution

Appeals Court Ruling Puts An End to 'Red Flag' Controversy (MedPageToday.com)

‘Occupy’ protesters dig in against police
The Raw Story (The Raw Story)

[?]

See more stories tagged with: constitution, obama, california, lawsuit, medical marijuana, entrapment, crackdown, feds, federal, dispensaries, norml

2011-11-06T10:12:00.000-08:00

Cannabinoids As Cancer Hope

by Paul Armentano

Senior Policy Analyst

NORML
NORML Foundation

“Cannabinoids possess ... anticancer activity [and may] possibly represent a new class of anti-cancer drugs that retard cancer growth, inhibit angiogenesis (the formation of new blood vessels) and the metastatic spreading of cancer cells." So concludes a comprehensive review published in the October 2005 issue of the scientific journal Mini-Reviews in Medicinal Chemistry.

Not familiar with the emerging body of research touting cannabis' ability to stave the spread of certain types of cancers? You're not alone.

For over 30 years, US politicians and bureaucrats have systematically turned a blind eye to scientific research indicating that marijuana may play a role in cancer prevention -- a finding that was first documented in 1974. That year, a research team at the Medical College of Virginia (acting at the behest of the federal government) discovered that cannabis inhibited malignant tumor cell growth in culture and in mice. According to the study's results, reported nationally in an Aug. 18, 1974, Washington Post newspaper feature, administration of marijuana's primary cannabinoid THC, "slowed the growth of lung cancers, breast cancers and a virus-induced leukemia in laboratory mice, and prolonged their lives by as much as 36 percent."

Despite these favorable preclinical findings, US government officials dismissed the study (which was eventually published in the Journal of the National Cancer Institute in 1975), and refused to fund any follow-up research until conducting a similar -- though secret -- clinical trial in the mid-1990s. That study, conducted by the US National Toxicology Program to the tune of $2 million concluded that mice and rats administered high doses of THC over long periods experienced greater protection against malignant tumors than untreated controls.

Rather than publicize their findings, government researchers once again shelved the results, which only came to light after a draft copy of its findings were leaked in 1997 to a medical journal, which in turn forwarded the story to the national media.

Nevertheless, in the decade since the completion of the National Toxicology trial, the U.S. government has yet to encourage or fund additional, follow up studies examining the cannabinoids' potential to protect against the spread cancerous tumors.

Fortunately, scientists overseas have generously picked up where US researchers so abruptly left off. In 1998, a research team at Madrid's Complutense University discovered that THC can selectively induce apoptosis (program cell death) in brain tumor cells without negatively impacting the surrounding healthy cells. Then in 2000, they reported in the journal Nature Medicine that injections of synthetic THC eradicated malignant gliomas (brain tumors) in one-third of treated rats, and prolonged life in another third by six weeks.

In 2003, researchers at the University of Milan in Naples, Italy, reported that non-psychoactive compounds in marijuana inhibited the growth of glioma cells in a dose dependent manner and selectively targeted and killed malignant cancer cells.

The following year, researchers reported in the journal of the American Association for Cancer Research that marijuana's constituents inhibited the spread of brain cancer in human tumor biopsies. In a related development, a research team from the University of South Florida further noted that THC can also selectively inhibit the activation and replication of gamma herpes viruses. The viruses, which can lie dormant for years within white blood cells before becoming active and spreading to other cells, are thought to increase one's chances of developing cancers such as Karposis Sarcoma, Burkitts lymphoma, and Hodgkins disease.

More recently, investigators published pre-clinical findings demonstrating that cannabinoids may play a role in inhibiting cell growth of colectoral cancer, skin carcinoma, breast cancer, and prostate cancer, among other conditions. When investigators compared the efficacy of natural cannabinoids to that of a synthetic agonist, THC proved far more beneficial – selectively decreasing the proliferation of malignant cells and inducing apoptosis more rapidly than its synthetic alternative while simultaneously leaving healthy cells unscathed.

Nevertheless, US politicians have been little swayed by these results, and remain steadfastly opposed to the notion of sponsoring – or even acknowledging – this growing body clinical research, preferring instead to promote the unfounded notion that cannabis use causes cancer. Until this bias changes, expect the bulk of research investigating the use of cannabinoids as anticancer agents to remain overseas and, regrettably, overlooked in the public discourse.

David Icke - Essential Knowledge For A Wall Street Protestor

2011-11-06T07:18:00.000-08:00

It all starts as a Debt!

2011-11-06T07:17:00.000-08:00

http://www.youtube.com/watch?feature=player_embedded&v=gV9A2IGShuk#t=711s

2011-11-05T12:13:00.000-07:00

Occupy Wall Street is heading for its third week of protests. The movement was hesitant in its first steps, but it's now picking up momentum and spreading across the U.S. From its birth in New York, the 'Occupy' premise now has a foothold; the U.K is planning Occupy London Stock Exchange.

The movement has been born out of pure frustration and the attrition of an unjust financial system; an arguably feral system of fiscal authority. Those who endorse the 'Occupy' ethos seek change - and fairness - in a financial crisis that was created through neoliberal economics.

There are, however, aspects that are simply not being addressed, and this is further symbiotic of the modern world. The conventional media has only just caught up with the Occupy movement, but it's taken far too long. Why has it taken three weeks for the mainstream media to address such a significant movement, especially when so many spectators were/are following the story? Are the mainstream not supposed to break news? Why are so many people still left in the dark? Are the mainstream deciding what actually constitutes as news as opposed to reporting on it? For example, the Icelandic revolution has received no attention from the mainstream, and when it has become such a poignant happening, why do so few know of Iceland's momentum?

Speaking on the UK, mainstream sources only began to report on the Occupy Wall Street protests when the news broke that 700 arrests had been made owing to an "unauthorised protest". The Occupy movement has, by enlarge, been conducted in peace, and is arguably exemplary in its conduct. Maybe this in itself is a worrying trend, that peaceful demonstrations don't receive attention until violence or misconduct intervenes. Only when something juicy is afoot do the mainstream turn a speculative eye. If society is serious about abating the riots that have been incessant in 2011, then a voice has to be given back to those with something to say before engorged emotion spills.

Mainstream media is failing the very people that it's supposed to keep informed, and it doesn't just stop at Occupy. It's becoming increasingly apparent that those who subscribe solely to mainstream media have a fatally narrow view on the world. The myopic reporting has long become the stuff of urban legend, but in the digital age, the once joke of mainstream media has lost its punchline. No longer reliant on the big money making news companies to inform of their stance on world affairs, the internet and alternative sources often provide a platform for the words that dare not cross the lines of corporate mainstream.

The RT news network - specifically the Alyona Show - will surely receive a fair share of negative connotations from the right; but left/right arguments should be negated for just a moment. The Alyona Show presents a section on what the mainstream miss with some truly astounding stories of media negligence.

Anyone who accumulates a broad range of news feeds will also attest to the lack of brevity between the mainstream and the actuality of issues. The Alyona Show has covered the Occupy movement since its inception, and once more, it says a lot when you have to turn to foreign broadcast channels such as RT and Al Jazeera to get a fuller picture. The Huffington Post also provides a welcome stage to the voices and opinions that would perhaps be overwhelmed by big business media.

It can certainly be agreed that we are in a global crisis, but to place full onus on an economic crisis is fairly crass; we are facing turbulent times far beyond finance. The West has lived under a benign democracy for many years, and society is now feeling the strain from the severely disenfranchised. Sure, the UK and U.S certainly enjoy many freedoms and basic human rights that are not granted to other countries, but that's not to rest on laurels. Freedoms are not concessions, they should be a given and not treated as a state privilege; a fundamental necessity. There's a politicians' rhetoric that exclaims "be grateful you have the freedoms of speech and expression" and indeed, this is right, but it's also correct to evoke other traits. The democratic right to protest peacefully and speak your mind is the case in point, but it is being threatened at every turn. The summer UK riots saw the British government jeopardise freedoms with the erosion of the civil liberties surrounding social media. The riots were deplorable, but this is not an excuse to restrict any media, let alone a source that belongs society.

The differences between the UK riots and Occupy Wall Street are leagues apart. There has been little to no violence in New York from protestors, but as previously stated, it took the arrest of 700 people on the Brooklyn Bridge in an "unauthorised protest" to receive any attention. What actually is an unauthorised protest? Is this not an oxymoron to the highest degree? The UK also faces parallel concessions on civil liberties: Parliament Square was considered a no go area for protests; the UK comedian/activist Mark Thomas documented this dark hour of British history in his show Seriously Organised Criminal. To be told when and where it's ok to evoke a democratic right of free speech and protest is contradictory to say the least.

So, as the Occupy movement spreads, and the UK's version of Occupy London Stock Exchange is set to run from the 15th October to the 12th December, it will be an interesting time indeed. Both the media and protestors should be watched and evaluated to see how they conduct themselves. Politicians desperately need to listen and put down the dusty rhetoric.

Lawyer makes a comment on Drug-Policy. Has Government/s been mis-interpretating the Mis-Use of Dugs Act 1971?

2011-11-05T07:03:00.000-07:00

Darryl Bickler April 14, 2011 at 10:27 am

I support this initiative wholeheartedly but am dismayed to still see various errors of law and language. I have made these points for some years as indeed has the creator of this critique, Casey Hardison.

Perhaps the most important thing is to remember that the primary law hands powers to government to administer it rationally. Indeed the Misuse of Drugs Act is so flexible and indeed rational that it does not need to be changed at all in order to realise all the necessary regulatory instruments to achieve the purpose of maximal harm reduction to society caused by drug misuse.

This is not a question of government following the law, but of misunderstanding it and failing in their [legal]responsibilities.

It is absolutely vital to recognise that the law regulates persons, not drugs!

There is no war on drugs, it is a war on people, there are no illegal or illicit drugs, only persons criminalised for their activities irrespective of whether those are harmful or not, there are no legal drugs, only persons ignored by a policy that has not basis in law.

Further, drug use as you claim to be illegal, is not. Parliament drafted the law so that problematic use that leads to a social problem could be regulated through the control of drug property interests, the significant point is that the Act is revealed to be a regulatory instrument.

The sections on the ACMD also reveal this when one reads what suggestions they may make re: making arrangements for the supervision of the supply of controlled drugs.

On the evening of August 4th, 2010 Fabio Santacrocealso known as Wify theStrain Hunter, was arrested .

2011-11-05T06:51:00.000-07:00

On the evening of August 4th, 2010 Fabio Santacrocealso known as Wify theStrain Hunter, was arrested with

the accusation ofcultivation and possession of cannabis for the purpose of trafficking.

He stayed four days in jail, with the help of his lawyer was placed under house arrest

At his mothers house.

The desperate situation of his family with many disorders and diseases,

Sparked in him a desperate search for alternative healing methods through

which he found that the diseases responded positively to cannabinoids.

It is unacceptable, that a person disappointed by the results

of traditional medicine who devotes his life

looking for an effective solution for his family,

And for every person with health problems that could be helped

or solved through the use of cannabinoids.

Fabio is charged with drug dealing, cultivation, & trafficking.

We demand that his officially recognized

Merit in commitment to the cause and we ask for the

Immediate release from unjust accusation that now has him

trapped in a situation of terror and helplessness,

Fabio is now also very sick and is now being deprived

of life saving medicine to continue his care and research for

Himself and all who would benefit from his study's.

Pablo GreenWeed

FREE FABIO SANTACROCE aka WIFY STRAIN HUNTER

La sera dello scorso 4 agosto 2010 Fabio Santacroce, meglio conosciuto da tutti noi con il nome di WIFY STRAIN HUNTER, è stato arrestato con l' accusa di coltivazione e detenzione di canapa a fini di spaccio.

Dopo 4 giorni di carcere, grazie all' intervento dell' avvocato Zariani gli vengono concessi gli arresti domiciliari.

va sottolineato che la gravitá della situazione di salute dei suoi familiari ha scatenato in lui una disperata ricerca di metodi curativi alternativi grazie alla quale ha constatato che le malattie di cui soffrono rispondono in modo positivo ai cannabinoidi.

E' inammissibile che una persona delusa dai risultati della medicina tradizionale che dedica la propria vita alla ricerca di una soluzione efficace dei suoi, ma soprattutto dei vostri problemi di salute, venga incriminato con l' accusa di spaccio di stupefacenti.

Noi chiediamo che gli venga riconosciuto ufficialmente il suo merito nell' impegno profuso alla causa e la sua conseguente liberazione da un accusa ingiusta, che lo imprigiona in una situazione di terrore e impotenza, senza possibilità di poter continuare le proprie cure e le proprie ricerche nel campo.

Pablo GreenWeed

FREE FABIO SANTACROCE aka WIFY STRAIN HUNTER

Fabio Santacroce aka Wify Strain Hunter - Crush Cancer Seminary -

How can you help save human lives?

Donate as little as €1.00 to Fabio Santacroce aka Wify Strain Hunter

Spread the good word about the tour to family, friends and co-workers.

mail donations to:

Fabio Santacroce

Via Giovanni XXIII, 76

28845 Domodossola VB

ITALY

bank donations to:

Account number BancoPosta: 000087242848

IBAN: IT57 Q076 0110 1000 0008 7242 848

owned by:

Fabio Santacroce

Phone Fabio Santacroce

+44 750.921.6826 (international caller)

0324 241659 (Italian caller)

Fabio Santacroce aka Wify Strain Hunter - Seminario per la lotta della distruzione del cancro

Come si può contribuire a salvare vite umane?

Donare un minimo di 1,00 euro a Fabio Santacroce aka Wify Strain Hunter

Diffondere la buona parola per il tour della vs. famiglia, gli amici

e colleghi di lavoro.

donazioni postali a:

Fabio Santacroce

Via Giovanni XXIII, 76

28845 Domodossola VB

ITALY

donazione bancaria a:

Numero di conto BancoPosta: 000087242848

IBAN: IT57 Q076 0110 1000 0008 7242 848

intestato a:

Fabio Santacroce

Telefono Fabio Santacroce

+44 750.921.6826 (chiamate internazionali)

0324 241659 (chiamata nazionale italiana)

The Beckley Foundation’s Global Initiative for Drug Policy Reform is driving forward alternative approaches to control.

2011-11-04T16:24:00.000-07:00

in Policy,Policy Featured

The Beckley Foundation’s Global Initiative for Drug Policy Reform is driving forward alternative approaches to drug control in order to create more humane, evidence-based, policies.

The Global Initiative for Drug Policy Reform is a joint initiative with the All Party Parliamentary Group on Drug Policy Reform. The Meeting at the House of Lords on 17/18 November will launch the first ever Cost/Benefit Analyses of a Regulated and Taxed Cannabis Market, the new Draft UN Convention and other evidence to support the need for change. The Meeting will also enable the Global Commission on Drug Policy, to present their recent findings.

For this major new Initiative the Beckley Foundation commissioned a new draft UN convention on all drugs that would allow signatory countries more freedom in deciding their own drug policy. Together with the All-Party Parliamentary Group the Foundation has commissioned the Cost/Benefit Analyses of both a regulated cannabis market and government regulated heroin supply to addicts.

Whilst many people agree that the War on Drugs has failed, the Beckley Foundation’s Global Initiative is unique in providing a concrete opportunity to examine ways forward.

It will achieve this through:

1. Commissioning new reports to widen the evidence base

2. Influencing current political leaders and influential figures by disseminating the new evidence and debating possible ways forward, at a Meeting to be held at the House of Lords, jointly hosted by the Beckley Foundation (BF) and the All-Party Parliamentary Group on Drug Policy Reform (APPG DPR);

3. Giving a platform to the Global Commission with whom the BF will collaborate on a publicity campaign

4. Educating the public about the failure of the War on Drugs and creating public support to trigger a call for action;

5. Using the House of Lords Meeting as a launch pad for the Global Initiative and it’s new reports, and the Global Commission’s recent findings and it’s report

6. Spreading knowledge of the Global Initiative through social media networks and via a new dedicated website (www.reformdrugpolicy.org)

7. Partnering NGOs around the world who recognise the need for new policies and who work in both drug policy reform and associated areas, such as: human rights; environmental causes; woman’s rights; international security etc.

8. Continued advocacy of the need to reform drug control into 2012, using the evidence-base created for the Meeting

The Beckley Foundation has worked over the last 18 months to strategise, plan and implement the launch of the Global Initiative at the House of Lords Meeting. The Meeting will bring together current political leaders from countries interested in reform, together with the Global Commission, providing new evidence and the opportunity to consider alternatives to the current criminalising approach to drug control. The surrounding media coverage will act to arouse public interest and provide an excellent opportunity to educate the public about the failure of the War on Drugs and provide constructive alternatives.

The Meeting at the House of Lords will act as a launch pad for the call for a new approach to drug policy based on the evidence supplied by the BF and the Global Commission. We will use various media channels to educate the public and policy makers and galvanise support for change. Partnering with APPGDPR, Release, IDPC and the Global Commission we will work to optimise media coverage and provide information to the public.

Global Initiative Documents:

.

{ 14 comments… read them below or add one }

Nicole Abrams April 4, 2011 at 11:50 am

I would like to stay informed about this initiative. I plan to also do my part and spread awareness.

Reply

. Edward Bowland April 4, 2011 at 1:02 pm

Not sure how I can help, but you have my support.

Reply

. Nathan Gomez April 4, 2011 at 2:14 pm

I would like to get to know what I could do to help reforming our nations drug policy

Reply

. Doug April 4, 2011 at 2:45 pm

Its about time that someone tried to change drug policies. The punishments for many drugs are completely inappropriate to the use/amount of harm possible done by the drug. Finally a wide spread movement that may change the way the world thinks about drugs.

Reply

. Alexis Sellers April 4, 2011 at 3:16 pm

I’m interested in promoting this….what can i do to help?

Reply

. Darryl Bickler April 14, 2011 at 10:27 am

I support this initiative wholeheartedly but am dismayed to still see various errors of law and language. I have made these points for some years as indeed has the creator of this critique, Casey Hardison. Perhaps the most important thing is to remember that the primary law hands powers to government to administer it rationally. Indeed the Misuse of Drugs Act is so flexible and indeed rational that it does not need to be changed at all in order to realise all the necessary regulatory instruments to achieve the purpose of maximal harm reduction to society caused by drug misuse. This is not a question of government following the law, but of misunderstanding it and failing in their [legal]responsibilities.

It is absolutely vital to recognise that the law regulates persons, not drugs! There is no war on drugs, it is a war on people, there are no illegal or illicit drugs, only persons criminalised for their activities irrespective of whether those are harmful or not, there are no legal drugs, only persons ignored by a policy that has not basis in law. Further, drug use as you claim to be illegal, is not. Parliament drafted the law so that problematic use that leads to a social problem could be regulated through the control of drug property interests, the significant point is that the Act is revealed to be a regulatory instrument. The sections on the ACMD also reveal this when one reads what suggestions they may make re making arrangements for the supervision of the supply of controlled drugs.

Reply

. Yumita Yumara April 30, 2011 at 2:12 am

“Not sure how I can help, but you have my support.”

+1

Reply

. james freathy June 16, 2011 at 9:09 pm

As a 37 year old with an adequate inteligence is it not within my decision to which way i chose to relax on my free time. i tried drinking alcahol and didnt agree with the way it made me feel, then i found cannabis which gave me the same type of release a lot of non law -breakers get from alcohol. anyone who has tried both will agree you feel more in control with cannabis rather that alcohol. why because i use cannabis respectfully am i treated with the same contempt as criminals for other crimes.

Reply

. admin June 28, 2011 at 11:39 am

Calum, sorry for the late reply, if you want to get involved send us an email beckley@beckleyfoundation.org) with your CV and what you can see yourself doing for us. Your marketing experience could come in use for our Global Initiative promotion campaign.

James

Reply

. yang July 1, 2011 at 11:27 am

Have you considered including more business perspective into your reform group? You’re talking about reforming a big commodity market after all, any succesful attempt of reforming the market would need a lot of market research about the motivations and needs of the drug consumers.

The health and human rights approach is good but there also needs to be understanding of the capital involved in the market and to capture the market from the criminals you’ll need to provide a more desirable product with adequate consumer protection.

The reasonable thing would be to integrate all psychoactives such as alcohol and tobacco too into a single market since they all share the demand pool for mind alteration, even though they are legally separated. This could offset the health/crime costs occurring from alcohol, tobacco etc. use by providing competing products. But that is the problem, because legal psychoactive substance businesses will have every incentive to prevent competition and to keep their monopoly status so where do you think you’ll get the economic/political capital to match theirs?

If you want to get things done in the world you need to concentrate on how much capital there is to be gained. You can’t treat drugs just as an issue of the health sector, drug users can’t be just patients to cure but more importantly as consumers whose needs have to be adressed.

So I suggest a lot of market/marketing research. Of course the drugs market should be a state controlled one where the responsibility is to taxpayers instead of stockholders but business is still business and any plan for reforming the drugs market will have to be able to compete with the stakeholders in the current market.

Reply

.

. Atilade August 19, 2011 at 3:50 pm

Please share the various steps taking to achieve the feat in Greece. The learning will be used in some developing countries.

Reply

. Peter Reynolds September 8, 2011 at 5:09 pm

Cannabis Law Reform (CLEAR) is announcing a detailed analysis of a regulated cannabis market in Britain on 14th September 2011. We have commissioned a study of the financial implications from the Independent Drug Monitoring Unit (IDMU) and spent many months developing our proposals.

I hope that we can work together to advance a common sense approach that will minimise all health and social harms as well as enabling the people of Britain to enjoy the tremendous benefits that cannabis offers.

Reply

. Ian Harris November 4, 2011 at 11:48 pm

Your comment is awaiting moderation.

I add my support for this intiative.

I’m minded to make a point of noting Darryl Bicklers comment. I would like to ask Darryl, “has our governments been mis-interpretating the Mis-Use of Drugs act 1971 over the past centuries?”

As for the present system the offence & punishment certainly outweighs and are more harmful than the drugs themselves. I.H

Reply

.

Leave a Comment

Name *

E-mail *

Website

CAPTCHA Code *

Previous post: Fifty Years of the 1961 Single Convention on Narcotic Drugs: A Reinterpretation

Next post: Why Drugs Should Be Legalised

.

Search

Latest News

Home Office rejects decriminalising possession of drugs for personal use

Official advisory body says better to educate and apply civil...

Cannabis as Medicine, a New Beckley Study

A Survey Investigating the Effectiveness of Medical Marijuana A...

Drug war: What prohibition costs us

Stephen Downing, a retired deputy chief of the Los Angeles Police...

Police Commissioner Calls on NYPD to Stop Improper Marijuana Arrests

Police Commissioner Ray Kelly has issued an internal order to...

Horizons Conference

Horizons is a conference about psychedelics that is held annually...

Gary Johnson Pledges to Legalise Cannabis if elected

Gary Johnson has told the Drug Policy Alliance conference that,...

CDC report that Prescription Painkiller overdoses have reached “epidemic levels” in the US

The Centers for Disease Control and Prevention (CDC) have reported...

Amanda Feilding to speak at the Drug Policy Alliance’s 2011 International Drug Policy Reform Conference

http://www.reformconference.org Wednesday, November 2nd –...

Ecuador to Debate Decriminalisation

Written by Jeanna Cullinan – Monday 24 October 2011 Proposed...

Former Mexican president: ‘US must legalise drugs to stop violence’

19 October 2011 The former President of Mexico has told the...

Home Office rejects decriminalising possession of drugs for personal use

Official advisory body says better to educate and apply civil...

Library Updates

The Science of Addiction – Drugs, Brains and Behaviours

Throughout much of the last century, scientists studying drug abuse [...]

Drug and Chemical Control

Bureau for International Narcotics and Law Enforcement Affairs. Chemicals play [...]

Effect of drug law enforcement on drug market violence: A systematic review

Violence is amongst the primary concerns of communities around the [...]

Ecstasy Does Not Wreck the Mind

The drug known as ecstasy has been used by 12 [...]

Innocent Bystanders: Developing Countries and the War on Drugs

Drug use/abuse is one of the most difficult challenges facing [...]

International Drug Survey

Take Part in our International Drug Survey, which aims to find out what people think are the harms and benefits associated with recreational drugs, including alcohol and tobacco. We hope its findings will feed into the growing movement that is calling for a major overhaul of existing drugs laws. Taking part is a way of making your opinion count.

Featured Videos

Brazilian Police Clash with Drug Cartel Gangs in Rio

Prohibition Vogue

New Film ‘Raw Opium’ Explores the Mixed Results of Global Efforts to Stem Trafficking

Losing the ‘War on Drugs’

Howard Marks Interviews Prof. David Nutt On The Dangers of Drug Policy Reform

A 50 Year Old Convention: What’s Wrong With an Update?

We Allow Alcohol to Kill and Harm so Many People

New Strain of Cannabis with ‘High’ CBD Content

History of Psychedelic Research in the United Kingdom

Beckley Psilocybin Study in BBC Documentary

Dr Michael Mosley: Taking The Magic Mushroom Drug Psilocybin For a Trial

Psilocybin in Smoking Cessation: A Pilot Study

Brazilian Police Clash with Drug Cartel Gangs in Rio

Prohibition Vogue

Podcast

Amanda Feilding talks to Drug Truth Network

Amanda Feilding talks about the Global Imitative for Drug Policy Reform on the radio show Cultural Baggage hosted by Dean Becker. The Drug Truth Network has more than 90 broadcast affiliates dedicated to exposing the fraud, misdirection, and wastefulness of the war on drugs. It is the only nationally distributed radio program focused on discussing [...]

Standard Podcast [29:00m]: Play Now
Play in Popup

Donate

Newsletter - Sign Up

Email Address *

First Name

Last Name

* = required field

.

Links

► Other (7)

► Policy (18)

▼Research (16)Cluster Busters

Council on Spiritual Practices

Erowid

Harborside Health Centre

Heffter Research Institute

Horizons

I.M.Sechenov Institute of Evolutionary Physiology and Biochemistry

Imperial College Neuropsychopharmacology Unit

Independent Scientific Committee on Drugs

Institute of Psychiatry, Kings College London

International Drug Survey

IONS Institute of Noetic Sciences

Lomonosov Moscow State University

MAPS

PaIN Group FMRIB Centre, Oxford University

UCL Institute of Cognitive Neuroscience

Social Networks

...

© The Beckley Foundation 2010

info@beckleyfoundation.org

Pot Shrinks Tumors, Government Knew in ’74

2011-11-03T17:15:00.000-07:00

Patients for Medical Cannabis

Articles Legalize it Links Marijuana info Medical marijuana Movies, documentaries Sharing information about medicinal use & legalization of Cannabis (Marijuana) & Hemp Marijuana cures cancer – US government has known since 1974

by 99%

17diggsdiggRecent findings

January 2010 Marijuana Components Fight Brain Cancer

From Compultense University, Madrid

April 2009 Cannabinoid action induces autophagy-mediated cell death

“…These findings describe a mechanism by which THC can promote the autophagic death of human and mouse cancer cells and provide evidence that cannabinoid administration may be an effective therapeutic strategy for targeting human cancers”

The most censored news story of the decade! This is a holiday message

from Rob Robinson and Jen Rog of Damn Sam Productions

Visit Rick Simpson’s website for

more on cannabis as a cancer cure

See also: Project Censored – U.S. Government Repressed Marijuana-Tumor Research

Pot Shrinks Tumors, Government Knew in ’74

Raymond Cushing, AlterNet

Originally posted May 31, 2000

The term medical marijuana took on dramatic new meaning in February 2000 when researchers in Madrid announced they had destroyed incurable brain cancer tumors in rats by injecting them with THC, the active ingredient in cannabis.

The Madrid study marks only the second time that THC has been administered to tumor-bearing animals; the first was a Virginia investigation 26 years ago. In both studies, the THC shrank or destroyed tumors in a majority of the test subjects.

Most Americans don’t know anything about the Madrid discovery. Virtually no U.S. newspapers carried the story, which ran only once on the AP and UPI news wires, on Feb. 29.

The ominous part is that this isn’t the first time scientists have discovered that THC shrinks tumors. In 1974 researchers at the Medical College of Virginia, who had been funded by the National Institute of Health to find evidence that marijuana damages the immune system, found instead that THC slowed the growth of three kinds of cancer in mice — lung and breast cancer, and a virus-induced leukemia.

The DEA quickly shut down the Virginia study and all further cannabis/tumor research, according to Jack Herer, who reports on the events in his book, “The Emperor Wears No Clothes“. In 1976 President Gerald Ford put an end to all public cannabis research and granted exclusive research rights to major pharmaceutical companies, who set out — unsuccessfully — to develop synthetic forms of THC that would deliver all the medical benefits without the “high.”

The Madrid researchers reported in the March issue of “Nature Medicine” that they injected the brains of 45 rats with cancer cells, producing tumors whose presence they confirmed through magnetic resonance imaging (MRI). On the 12th day they injected 15 of the rats with THC and 15 with Win-55,212-2 a synthetic compound similar to THC.

“All the rats left untreated uniformly died 12-18 days after glioma (brain cancer) cell inoculation … Cannabinoid (THC)-treated rats survived significantly longer than control rats. THC administration was ineffective in three rats, which died by days 16-18. Nine of the THC-treated rats surpassed the time of death of untreated rats, and survived up to 19-35 days. Moreover, the tumor was completely eradicated in three of the treated rats.” The rats treated with Win-55,212-2 showed similar results.

The Spanish researchers, led by Dr. Manuel Guzman of Complutense University, also irrigated healthy rats’ brains with large doses of THC for seven days, to test for harmful biochemical or neurological effects. They found none.

“Careful MRI analysis of all those tumor-free rats showed no sign of damage related to necrosis, edema, infection or trauma … We also examined other potential side effects of cannabinoid administration. In both tumor-free and tumor-bearing rats, cannabinoid administration induced no substantial change in behavioral parameters such as motor coordination or physical activity. Food and water intake as well as body weight gain were unaffected during and after cannabinoid delivery. Likewise, the general hematological profiles of cannabinoid-treated rats were normal. Thus, neither biochemical parameters nor markers of tissue damage changed substantially during the 7-day delivery period or for at least 2 months after cannabinoid treatment ended.”

Guzman’s investigation is the only time since the 1974 Virginia study that THC has been administered to live tumor-bearing animals. (The Spanish researchers cite a 1998 study in which cannabinoids inhibited breast cancer cell proliferation, but that was a “petri dish” experiment that didn’t involve live subjects.)

In an email interview for this story, the Madrid researcher said he had heard of the Virginia study, but had never been able to locate literature on it. Hence, the Nature Medicine article characterizes the new study as the first on tumor-laden animals and doesn’t cite the 1974 Virginia investigation.

“I am aware of the existence of that research. In fact I have attempted many times to obtain the journal article on the original investigation by these people, but it has proven impossible.” Guzman said.

In 1983 the Reagan/Bush Administration tried to persuade American universities and researchers to destroy all 1966-76 cannabis research work, including compendiums in libraries, reports Jack Herer, who states, “We know that large amounts of information have since disappeared.”

Guzman provided the title of the work — “Antineoplastic activity of cannabinoids,” an article in a 1975 Journal of the National Cancer Institute — and this writer obtained a copy at the UC medical school library in Davis and faxed it to Madrid.

The summary of the Virginia study begins, “Lewis lung adenocarcinoma growth was retarded by the oral administration of tetrahydrocannabinol (THC) and cannabinol (CBN)” — two types of cannabinoids, a family of active components in marijuana. “Mice treated for 20 consecutive days with THC and CBN had reduced primary tumor size.”

The 1975 journal article doesn’t mention breast cancer tumors, which featured in the only newspaper story ever to appear about the 1974 study — in the Local section of the Washington Post on August 18, 1974. Under the headline, “Cancer Curb Is Studied,” it read in part:

“The active chemical agent in marijuana curbs the growth of three kinds of cancer in mice and may also suppress the immunity reaction that causes rejection of organ transplants, a Medical College of Virginia team has discovered.” The researchers “found that THC slowed the growth of lung cancers, breast cancers and a virus-induced leukemia in laboratory mice, and prolonged their lives by as much as 36 percent.”

Guzman, writing from Madrid, was eloquent in his response after this writer faxed him the clipping from the Washington Post of a quarter century ago. In translation, he wrote:

“It is extremely interesting to me, the hope that the project seemed to awaken at that moment, and the sad evolution (lastimosa evolucion) of events during the years following the discovery, until now we once again draw back the veil over the anti-tumoral power of THC, twenty-five years later. Unfortunately, the world bumps along between such moments of hope and long periods of intellectual castration.”

News coverage of the Madrid discovery has been virtually nonexistent in this country. The news broke quietly on Feb. 29, [2000] with a story that ran once on the UPI wire about the Nature Medicine article. This writer stumbled on it through a link that appeared briefly on the Drudge Report web page.

The New York Times, Washington Post and Los Angeles Times all ignored the story, even though its newsworthiness is indisputable:

a benign substance occurring in nature destroys deadly brain tumors.

THC treated cells – unhealthy cells commit suicide (autophagy)

Of all interest groups, the Pharmaceutical Industry

has the highest number of lobbyists in DC;

Two for every Congressperson.

Cannabis has in total… one.

Here is a reprint of this story as told by Paul Armentano,

senior policy analyst for the NORML Foundation in Washington, DC. Source

Unlocking a Cure for Cancer – With Pot

by Paul Armentano August 17, 2004

Who could imagine that cannabis might one day offer hope as a cure for cancer? The United States government, that’s who.

For the past 30 years, U.S. officials have willfully ignored clinical research indicating that marijuana can inhibit the growth of certain type of malignant tumors. However, the recent publication of a trio of clinical studies and a pair of scientific reviews have effectively blown the lid off “Cancergate,” and revealed that pot’s medical value may be far greater than ever presumed.

THE EMERGING EVIDENCE

Last year, five scientific journals published prominent articles trumpeting cannabinoids (compounds in marijuana) as potential anti-cancer agents.

These include:

Clinical trial data published in January 2003 issue of the Journal of the American Society of Clinical Investigation that found cannabinoids significantly inhibit skin tumor growth in mice. Investigators of the study concluded, “The present data indicate that local cannabinoids administration may constitute an alternative therapeutic approach for the treatment of non-melanoma skin cancer.”

Clinical trial data published in the March 2003 issue of The FASEB Journal that found that the “local administration of a non-psychoactive cannabinoid inhibits angiogenesis (tissue growth) of malignant gliomas (brain tumors).”

A clinical review in the October 2003 issue of the prestigious journal Nature Reviews Cancer that concluded that cannabinoids’ “favorable drug safety profile” and proven ability to inhibit tumor growth make them desirable agents in the treatment of cancer. According to the review’s author, tumors inhibited by cannabinoids include: lung carcinoma, glioma, thyroid epithelioma, lymphoma/leukemia, skin carcinoma, uterus carcinoma, breast carcinoma, prostate carcinoma, and neuroblastoma (a malignant tumor originating in the autonomic nervous system or the adrenal medulla and occurring chiefly in infants and young children).

Clinical trial data published in the November 2003 issue of the Journal of Pharmacology and Experimental Therapeutics that found the administration of the cannabinoid cannabidiol (CBD) inhibits the growth of human glioma cells both in vitro (e.g., a petri dish) and in animals in a dose-dependent manner. Investigators concluded, “Non-psychoactive CBD produce[s] a significant antitumor activity both in vitro and in vivo, thus suggesting a possible application of CBD as an antineoplastic agent (something which prevents the growth of malignant cells.)”

And finally, a clinical review in the December 2003 issue of the journal Expert Opinion on Therapeutic Targets that summarized “the demonstrated antitumor actions of cannabinoids,” and elaborated on “possible avenues for the future development of cannabinoids as antitumor agents.”

AND SUBSEQUENT MEDIA BLACKOUT

Despite these stunning findings, media coverage of them in North America has been virtually non-existent. As noted by Richard Cowan, editor of the website MarijuanaNews.com, “The New York Times, The Washington Post and Los Angeles Times all ignored this story, even though its newsworthiness is indisputable: a benign substance occurring in nature destroys deadly brain tumors.”

Why the media blackout? For starters, all of these studies were conducted overseas. And secondly, not one of them has been acknowledged by the U.S. government.

U.S. KNEW IN ’74… AND AGAIN IN ’96!

This wasn’t always the case. In fact, the first ever experiment documenting pot’s anti-tumor effects took place in 1974 at the Medical College of Virginia at the behest of the U.S. government. The results of that study, immortalized in an August 18, 1974 Washington Post newspaper feature, were that “THC slowed the growth of lung cancers, breast cancers and a virus-induced leukemia in laboratory mice, and prolonged their lives by as much as 36 percent.”

Despite these favorable preliminary findings, U.S. government officials banished the study, and refused to fund any follow up research until conducting a similar – though secret – study in the mid-1990s. That study, conducted by the U.S. National Toxicology Program to the tune of $2 million concluded that mice and rats administered high doses of THC over long periods had greater protection against malignant tumors than untreated controls. However, rather than publicize their findings, government researchers shelved the results – which only became public one year later after a draft copy of its findings were leaked in 1997 to the journal AIDS Treatment News, which in turn forwarded the story to the national media.

Nevertheless, in the nearly eight years since the completion of the National Toxicology trial, the U.S. government has yet to fund a single additional study examining pot’s potential as an anti-cancer agent.

SCIENCE IGNORED NO MORE

Fortunately, researchers at Madrid, Spain’s Complutense University, School of Biology have generously picked up where U.S. researchers so abruptly left off. In 1998, the research team – led by investigator Manuel Guzman – discovered that THC can selectively induce program cell death in brain tumor cells without negatively impacting the surrounding healthy cells. Then in 2000, Guzman’s team reported in the journal Nature Medicine that injections of synthetic THC eradicated malignant gliomas (brain tumors) in one-third of treated rats, and prolonged life in another third by six weeks. A commentary to the study noted that the results were the first to convincingly demonstrate that cannabis-based treatments may successfully combat cancer.

Today, Guzman believes that enough favorable clinical evidence exists supporting pot’s anti-cancer properties to warrant clinical trials in humans. “The scientific community has gained substantial knowledge of the palliative and anti-tumor actions of cannabinoids during the past few years,” Guzman wrote in the October 2003 issue of Nature Reviews Cancer. “Anti-tumor compounds should selectively affect tumor cells [and] it seems that cannabinoids can do this, as they kill [malignant] tumor cells but do not affect their non-transformed counterparts and might even protect them from cell death. … As cannabinoids are relatively safe compounds, it would be desirable that clinical trials using cannabinoids … could accompany [ongoing] laboratory studies to allow us to use these compounds in the treatment of cancer.” Guzman concludes the article by noting that the Spanish Ministry of Health recently approved a human clinical trial – the first ever – aimed at investigating the effects of intracranially administered THC on the life expectancy of volunteers suffering from malignant brain tumors.

“Cannabinoid research continues to show tremendous potential in the treatment of cancer,” summarizes University of Southern California professor Mitch Earleywine, author of the book Understanding Marijuana: A New Look at the Scientific Evidence. However, he laments that the “vast majority of this work originates outside the United States, often in countries that lack our economic and scientific advantages. Let’s hope that our drug policy won’t stymie the battle against the second leading cause of death in America.”

Indeed. Let’s not add a potential treatment for cancer to the ever-growing list of victims of pot prohibition.

You might also enjoy:

I smoke pot and I like it by Will Wilkinson of the CATO Institute

Run From the Cure – The Rick Simpson Story Hemp Oil to cure cancer

Illegal Drugs and How They Got That Way – Marijuana History Channel

Advertisement

Eco World Content From Across The Internet.

Featured on EcoPressed

Solar incentives to fall amid uncertain global economy

FacebookTwitterMoreDiggEmailRedditStumbleUponPrintLike this:Like3 bloggers like this post.

Published: January 4, 2010

Filed Under: cancer, glaucoma, gliomas, Jack Herer, panic attacks, Rick Simpson

41 Responses to “Marijuana cures cancer – US government has known since 1974”s.c.deschamps says:

April 16, 2010 at 8:32 pm I have been on the cure for 2 years i take the size of a pea in the morning

my diabetes numbers have dropped from 16 to 7

my glacoma eye pressures have dropped to 18 from 28

i have lost 80 lbs

i also ingest hemp hearts daily

this is the most amazing product using a natural product the seed inside the male hemp seed cases

the list of vitamin ,omega 3 6 9 ,20 % protein, most of b vitamins

that you sprinkle on salad, yogurt , eat in oat mea,l in mashed potatoes with 5 tsp hemp hearts is 20 % of your protein for the day

Reply

Medical Patients of California says:

August 1, 2010 at 1:40 pm President Barack Obama

The White House

1600 Pennsylvania Avenue NW

Washington, D.C. 20500

An Open Letter to President Obama

A Travesty of Justice Occurs:

When cannabis is intentionally miss-scheduled by the Federal government, as having no medical use and not safe under a physician’s supervision, despite mountains of scientific evidence proving multiple medical uses and safety, unsurpassed by any man-made medication.

When scientific medical study of cannabis is prevented by the government to perpetuate intentional miss-scheduling of cannabis.

When intentional miss-scheduling of cannabis is used by local government to profit from seized property and incarceration of citizens, and deny them the right of Life, Liberty, and the Pursuit of Happiness.

When police seize legally purchased property prior to court appearance or a chance to defend your self in court (establishes guilt prior to proving innocence).

When police act as the judicial branch of the law and become Judge and Jury.

When police and local government profit from property seizure, giving motive to hunt the public and find you guilty. By human nature, this profit motive will turn a “good man bad”.

I am a retired cardiovascular surgeon, who has been targeted and victimized. I have lost my Freedom and Constitutional Right to Bail, which limits my ability to defend myself. I have lost my family, my career, my property, my family photos and heirlooms, and everything I worked for my entire life. Police have made public statements, indicating I am guilty, prior to court, and placed false photos in local media, showing marijuana plants, when none were found! This, and the profit motive, will prevent me from receiving a fair trial. I have been subjected to cruel treatment, which amounts to physical and mental torture.

Jimmy Carter stated, “The punishment should not be more than the harm to society by the drug (medicine)”. If no laws are broken by the personal use of marijuana, then property seizure and taking freedom from citizens, is itself a crime. I am a P.O.W. in the war on drugs; the war against our own citizens. Stop the War!…Reschedule Cannabis as a medicine. If I could give my life so this would not happen to others, I would. President Obama, I say this to you, “Give me Liberty or Give me Death!”

David B. Allen, M.D.

July 21, 2010

If you agree with this, please print & sign your name, and include your address – and send a copy to President Obama (see address above)…please send original signature to President Obama.

If you would, please send me copies of your signed letter to President Obama to both addresses listed below – one to me directly, and one to my office.

Together we can change our nation’s view on natural medicine.

“Don’t tell me Cannabis isn’t medicine” motto of David B. Allen, M.D.

Print Name: _________________________________

Sign Name& Date : _________________________________

Address: ____________________________________

City, State & Zip ____________________________________

S.C.R.C. F.

David B. Allen, M.D. (2009120099)

M Zone, Rack 10

1420 Industrial Park Dr.

Wiggins, MS. 39577

David B. Allen, M.D.

c/o: 3830 Auburn Blvd., Suite C

Sacramento, Ca. 95821

*Concerned Californians for Medical Cannabis (C.C.M.C.)*

Reply

Olli says:

October 19, 2011 at 9:20 am I really don’t care if it cures cancer or not. It should not be illegal. nor should any drug. There should be appropriate legislation to control its use by minors and to provide quality controls for consumers and even government sponsors advertising to warn of it’s dangers. But making it illegal is an infringement of our human rights to do what we want with our lives. This applies to ALL drugs, and indeed all potentially self-harmful activities

Reply

The Entropy Report › Thursday, September 2, 2010 says:

September 2, 2010 at 5:51 am [...] Marijuana cures cancer – US government has known since 1974 [...]

Reply

Izzy says:

September 6, 2010 at 5:33 pm This is great news – I’m way ahead of the game!

I’ll be dancing on all their graves!

Reply

Tim says:

October 2, 2010 at 1:38 am Weed could save the planet and end a chemical holocaust.

Reply

Marijuana cures cancer – US government has known since 1974 (via Patients for Medical Cannabis) « MediCann's Blog (Medical Cannabis Specialists) says:

December 7, 2010 at 6:38 pm [...] Here are the most recent findings January 2010 Marijuana Components Fight Brain Cancer From Compultense University, Madrid April 2009 Cannabinoid action induces autophagy-mediated cell death "…These findings describe a mechanism by which THC can promote the autophagic death of human and mouse cancer cells and provide evidence that cannabinoid administration m … Read More [...]

Reply

Jeremy Britton says:

February 5, 2011 at 11:00 pm OK, I can be open-minded enough to believe that a naturally-occurring substance can create health or fight cancer. However, I find it hard to believe that none of the rats “got the munchies” or gained weight!

“Food and water intake as well as body weight gain were unaffected during and after cannabinoid delivery.”

Reply

Malikah says:

February 7, 2011 at 2:44 pm Im so happy that there is people that speaks out!

Reply

Anonymous says:

March 11, 2011 at 8:01 am governments arent interested in cures or anything that might make the world peacefull thats why they hate cannabis

Reply

Cannabis, Effective Therapeutic Strategy For Targeting Human Cancers
Il Giraresole says:

March 19, 2011 at 8:02 am [...] Marijuana cures cancer – US government has known since 1974 [...]

Reply

Damion says:

March 19, 2011 at 11:30 pm I demand that the United States Government stand trial for war crimes against

America.

Crimes that led to the deaths of hundreds of thousands of American citizens,

and if proven that the Govt. had infact willfully and decietfully hidden life

saving information for any reasons, throughout what they chose to label

“the drug war”,that the officials in current posistions of keeping the laws intact

be charged for contributing to these deaths.

The elected officials proclaimed “war” with lies to the american citizens, when

infact had knowledge since 1974 to the contrary, yet chose to let the citizens die.

If the average citizen willfully took away a medicine (such as insulin) knowing that

the results could mean death, then that citizen would be tried to the fullest extent of

the law for murder.

I ask that given the role of the accused, they be held for treason.

This is not a joke, nor a drummed up exaggeration.

I, as a citizen of the United States Of America, want the accused to stand trial

for such a gross display of power and expect the harshest of punishments for

crimes of war and treason.

Mr. Obama, I ask that you hold yourself accountable and assist in bringing others

to justice as well.

Reply

Anonymous says:

March 30, 2011 at 10:40 am It’s all about the almighty $ .

Reply

llort1000 says:

April 1, 2011 at 9:10 pm FUCK THE GOVERNMENT. LOVE THE PEOPLE AND PLANET!

Reply

Anonymous says:

April 2, 2011 at 11:21 am im leo im 30yrsold im a bradicardic my heart rate is less than 60 wich abnormal and when i smoke canabis my haert rate is geting normal so im glad and im proud that canabis cure haert deseas.

Reply

Ossie says:

May 4, 2011 at 9:58 am If Cannabis cures cancer, why did Bob Marley die of Cancer

Reply

editors says:

May 4, 2011 at 5:03 pm There are several form of cancer Cannabis has been shown to heal – lungs, brain and breast. Marley had cancer on his foot.

Reply

GSWAGFLY says:

October 26, 2011 at 12:55 am bob marley did not die off cancer, where did you get that from, he died cuz someone killed him buddy

Reply

Anonymous says:

May 6, 2011 at 7:51 pm maybe when u smoke it it cures the lungs, if his toe had smoked it, hed prolly be fine. Forreal tho i know what ur saying, however i believe it all about how it is administered.

Reply

Ryan says:

June 3, 2011 at 4:45 pm The reason he died from cancer could be 1. the THC was not gave in the correct way to kill the cancer he had. You see his cancer started in his foot smoking marijuana does not have as reliably effect as actually putting extract THC on the infected part or injecting it. So the cancer spread slowly because the small amount of THC in his body was actually fighting the cancer cells off. Another reason is that his was caused by an infection he got from hurting his toe in soccer, which is much different from most cases of cancer. Try this out for yourself if you don’t believe it has cancer fighting benefits. If you have a cancerous Mole or even a none cancerous mole get THC extract put it on a band-aid put the band-aid on the area where the mole is keep re applying it for about a week once a day and your mole will be gone cancerous or not.

Reply

Anonymous says:

October 28, 2011 at 7:09 pm Bob Marley died from a fatal case of gangrene, after he suffered a severe laceration on his toe, but refused to have it treated because the rastafarian religion condemned medical treatment. Not Cancer.. Get your facts straight

Reply

so canada found the cure for cancer.. but we dont want it. says:

May 16, 2011 at 8:12 am [...] it is. lol It's actually been proven to help fight some brain cancers and many more. ~~~> http://patients4medicalmarijuana.wor…wn-since-1974/ ~~~> http://www.sciencedaily.com/releases…0401181217.htm [...]

Reply

gigi says:

May 21, 2011 at 12:45 pm Well I think that marijuana has a really bad rap just like Pitbulls. I had a Pitbul and it was the best experience I ever had in my life besides having my four children. Why is it that when something is good, somebody always has to make it seem so bad and horrible. I have known and met people that do use it and they are more human then the so called human. No need to over do to feel the effect. Its all about control, those with addictive tendencies should not try this method. I think that those that do smoke pot will be the

ones that will survive at any tragic event in this world…Just think/

Reply

editors says:

May 22, 2011 at 3:30 pm The only problem with that analogy, is that Cannabis has never been the cause of any death, ever…

Reply

marinapet07@yahoo.com says:

May 31, 2011 at 6:52 am Yet more evidence documenting the medical benefits of THC, the active chemical, in cannabis. As usual, big business in USA and, in particular, the pharmaceutical, companies, don’t want this news to be widely publicised. When will America wake up and legalise but control cannabis in much the same way that it does with tobacco?

Reply

Anonymous says:

June 17, 2011 at 5:10 am Very interesting I must say. I watched ‘the union’ yesterday. I highly recommend it, it really shows to what extent the government has and will go in order to protect its core beliefs. As with the Vietnam, hippies were targeted for marijuana possession and growers and even people who spoke in favour of cannabis were excruciated in the media for undermining the US government. It’s a load of bullshit that the Western world is said to have complete freedom of anything, whether press, speech or thought. We are all succumbed to government influence and pressured by media ideology. Millions of taxpayer money is used on rehabilitating involuntary people caught with marijuana, imprisoning marijuana users and on prosecuting anyone who has any sort of relation or connection to it. The black market of drugs is booming, especially for marijuana, and it is illegal! Imagine if it could be decriminalized or legal

It is a dangerous game because so much effort, time and money is spent on prosecuting people with a drug that shouldn’t even be illegal yet the media makes it seem that marijuana smoking is worse than murder or rape. Also, even sex offenders can be put off criminal records yet marijuana users have to abide that using some herb for personal use can have a detrimental effect on not only their future but also their families and friends when the truth says, they are not bad people at all. Of course you have bad marijuana people but have you ever heard of domestic violence or violent behaviour caused by marijuana users? No. The irony of it all is, so much shit is said about alcohol and so much rage is caused by it but it remains legal despite all the obvious indications that it is worse than marijuana, both short term and long term. A glass of wine a day doesn’t kill anyone, I’m not saying that but weed has never killed anyone. Whether in large or small quantities.

The war on drugs is as hopeless as the Vietnam war. It’s game over. What we need is a new way of running things. CCTV, espionage on consumer behaviour, human rights abuse are constantly happening in our daily lives yet we don’t even realize. Sooner or later things will get out of control and the new generation, which I am part of, will have to pay for all the mistakes the old generation made.

This isn’t only about marijuana and legalizing or decriminalizing it, it’s about reaching out to people about why they are stuck in a bubble between reality and fiction. We are in a recession, which has hit the world worse than ever before yet so much is spent on pursuing hopeless paths.

Want change?

It takes everyone of us.

Reply

Steven Santos says:

July 27, 2011 at 8:53 am check it yourself. If you are on a jury in a trial about someone in possesion of marijauna, a federal offense, regardless if there is overwhelming evidence against this person, if you feel that the law is unjust in which they are being tried, regardless of the crime, you have the right to vote not guilty.

Reply

NoVa DC says:

August 29, 2011 at 8:11 pm Turmeric, Ginger, cannabis,

I was a dead man walking..

Gastro-intestinal & lung metastisis. stage IV..

complete clinical response

Same with my buddy that had pancreatic & liver

Good docs, great facilities and an enlightened oncologist

The canabis also helped with nausea as did the ginger & tomato juice

/don’t kid yourself..

marinol whatever

Reply

al says:

September 12, 2011 at 1:43 pm seems to me mj has the same terpines as found in pacific hew / taxol .

Reply

Can cannabis cure cancer - Page 2 - MNS Forums says:

September 13, 2011 at 12:30 am [...] [...]

Reply

Jeruel Hernando says:

September 19, 2011 at 10:11 pm I have a friend who is currently in and out of the hospital because of breast cancer. Can smoking marijuana also help her? Can hemp oil or lotion help her? where can I get them?

Reply

editors says:

September 20, 2011 at 1:07 am Look into Rick Simpson’s ‘hemp oil’ and be sure to read the testimonials. You can get it at your local dispensary. From what i understand, the very high levels of cannabiniods one needs to heal cancer cannot be obtained by smoking. Hemp oil is very concentrated – a pea-sized amount every day is recommended by Simpson and others who have healed their cancer with cannabis.

Reply

Why Obama Reneged, On Medical Marijuana
OHRELA.COM says:

October 11, 2011 at 4:02 am [...] In 1974 a study funded by the National Institute of Health, conducted by the Medical Colledge of Virginia was trying to show that marijunna surrpessed the immune system. It seemed a good way to do this was to infect mice with brain cancer, and then expose them to high levels of Tetrahydrocannabinol (THC), and watch as they died faster than the other mice. What they found however, was the tumors in the mice exposed to THC were shrinking, and in some cases had disappeared altogether while the control group died. Subsequently the DEA shut down the study, and in 1976 president Gerald Ford banned public studies and granted exclusive rights for further studies to be conducted by the pharmaceutical industry. [...]

Reply

jill bachert (@JillBilly2) says:

October 18, 2011 at 5:13 pm legalize!

Reply

Jill Bachert says:

October 18, 2011 at 5:14 pm good read!

Reply

Yithpistol says:

October 18, 2011 at 7:10 pm This is overstated. WAY overstated. I agree we should legalize it for any use, and regulate it the way we regulate alcohol (a much more dangerous, addictive, and impairing drug).

This article, however, betrays a major misunderstanding of the studies it quotes. These are not cures for cancer. At best they are just another potential pharmaceutical tool to use in cancer treatment. It is doing our cause a great disservice to keep screaming that cannabis is a panacea, when it is most definitely not. Like many plants it is just a tool. It makes some interesting chemicals and we can find uses for them. Just because the plant makes you feel good when you inhale it while it burns doesn’t mean the plant cures cancer or diabetes or anything. You have to follow the science, and the science does NOT say this cures cancer. The fact that this study was done shows that research isn’t banned, for one. That at least is good news. So enough with the over-hype of this drug.

Reply

John Kindred says:

October 19, 2011 at 7:22 am Two packs a day for 40 plus years, family full of current and former potheads with tobacco addictions, and never as much as a melanoma in the bunch. Won’t protect you from COPD, however.

Reply

Anonymous says:

October 19, 2011 at 9:13 pm The federal government (in addition to Big Pharma and Prison Unions) makes too much money keeping marijuana illegal. How could they justify the massive expenditures fighting the war on drugs if marijuana was legal. There simply isn’t enough of a problem with all other drugs combined to justify the budgets set yearly for the DEA and local law enforcement without marijuana on their list. DEA, Police, DA’s,Judges, Jails, Parole Officers, drug tests, fines, seizure of property…they would all be out of jobs or the need for them lessened to such an extent that they will never vote to legalize it. Doing so would put them out of a job, so simply in the interest of self preservation they will never back its legalization. Obama caved to his own personal and public beliefs about marijuana once he got in office. The lobbyists from pharma, prison unions, law enforcement, the religious right, were such a financial power to his getting elected and staying for a possible 2nd term that he could not ignore them, and therefore flipped on his position prior to election.

The united states is the biggest drug dealer of them all. And the biggest killer of people world wide with what we already export. The fact is that we market and sell something that kills more people annually in this country and world wide than Cocaine, Heroin, Methamphetamine and all prescription drugs combined. So its apparently not about the safety of substances, or their addictive potential that causes us to determine policies of what we market and sell world wide. Product X is something that is smoked, is legal, regulated, marketed and distributed around the world and kills 430,000 Americans and 5 million worldwide (not total ever… but EACH YEAR!). Product Y is another substance that is smoked and has never once been reported to be the cause of death in 10,000 years of known use, yet is illegal basically world wide and thousands of people around the world are prosecuted and millions persecuted for its use. Can anyone guess what product X and product Y are? If you can your prize is that you have now been freed from the nonsense and are able to with an open mind seek out more information about why our government does these seemingly illogical things?

If marijuana has not been tested to the governments satisfaction, why don’t they test it. Many tests have already been conducted that show its success and benefits. Why do they ignore the tests that have already been conducted? The fact is that enough research already exists to support marijuana’s positive benefits in all aspects of life. Funding more studies that would show similar results to what all the other studies have already shown would be counterproductive to their agenda stated above.

The only way to get past this nonsense is to get out this November and vote for what you believe in, get involved in speaking out to everyone you know. We can no longer afford to be “Closet Tokers”. We have all been fed a line of BS for generations about this amazing plant. Be proud that you have taken the step to knowledge and no longer believe everything you are spoon fed by the government and media. Think critically about what you are told, educate yourself, educate others and vote to elect open minded individuals that will support the logical conclusions you find the answers to.

Your Friendly Neighborhood Budman Bill.

Reply

Bill says:

October 19, 2011 at 9:15 pm The federal government (in addition to Big Pharma and Prison Unions) makes too much money keeping marijuana illegal. How could they justify the massive expenditures fighting the war on drugs if marijuana was legal. There simply isn’t enough of a problem with all other drugs combined to justify the budgets set yearly for the DEA and local law enforcement without marijuana on their list. DEA, Police, DA’s,Judges, Jails, Parole Officers, drug tests, fines, seizure of property…they would all be out of jobs or the need for them lessened to such an extent that they will never vote to legalize it. Doing so would put them out of a job, so simply in the interest of self preservation they will never back its legalization. Obama caved to his own personal and public beliefs about marijuana once he got in office. The lobbyists from pharma, prison unions, law enforcement, the religious right, were such a financial power to his getting elected and staying for a possible 2nd term that he could not ignore them, and therefore flipped on his position prior to election.

The united states is the biggest drug dealer of them all. And the biggest killer of people world wide with what we already export. The fact is that we market and sell something that kills more people annually in this country and world wide than Cocaine, Heroin, Methamphetamine and all prescription drugs combined. So its apparently not about the safety of substances, or their addictive potential that causes us to determine policies of what we market and sell world wide. Product X is something that is smoked, is legal, regulated, marketed and distributed around the world and kills 430,000 Americans and 5 million worldwide (not total ever… but EACH YEAR!). Product Y is another substance that is smoked and has never once been reported to be the cause of death in 10,000 years of known use, yet is illegal basically world wide and thousands of people around the world are prosecuted and millions persecuted for its use. Can anyone guess what product X and product Y are? If you can your prize is that you have now been freed from the nonsense and are able to with an open mind seek out more information about why our government does these seemingly illogical things?

If marijuana has not been tested to the governments satisfaction, why don’t they test it. Many tests have already been conducted that show its success and benefits. Why do they ignore the tests that have already been conducted? The fact is that enough research already exists to support marijuana’s positive benefits in all aspects of life. Funding more studies that would show similar results to what all the other studies have already shown would be counterproductive to their agenda stated above.

The only way to get past this nonsense is to get out this November and vote for what you believe in, get involved in speaking out to everyone you know. We can no longer afford to be “Closet Tokers”. We have all been fed a line of BS for generations about this amazing plant. Be proud that you have taken the step to knowledge and no longer believe everything you are spoon fed by the government and media. Think critically about what you are told, educate yourself, educate others and vote to elect open minded individuals that will support the logical conclusions you find the answers to.

Your Friendly Neighborhood Budman Bill.

Reply

Ellen Chick says:

October 20, 2011 at 1:00 pm If we called it “the war on the cure for cancer”, maybe we could make a mature choice about this.

Reply

Lisa Rouleau Isaac says:

November 2, 2011 at 5:37 pm This is eye opening !!!!

Reply

Leave a Reply Cancel reply

Enter your comment here...

Guest Log In Log In Log In Email (Not published)

Name

Website Please log in to WordPress.com to post a comment to your blog.

You are commenting using your Twitter account. ( Log Out )

You are commenting using your Facebook account. ( Log Out )

Cancel

Connecting to %s

Notify me of follow-up comments via email.

Notify me of new posts via email.

« Previous PostNext Post »

Ken Block's Gymkhana THREE, Part 2; Ultimate Playground; l'Autodrome, Fr...

2011-11-03T06:49:00.000-07:00

2011-11-03T06:48:00.000-07:00

http://www.youtube.com/watch?v=4TshFWSsrn8&feature=player_detailpage#t=305s

Sheffield Police And Judge Engaged In ‘Brutal Terrorism’ Against The Public

2011-11-02T11:18:00.000-07:00

Clear > News > Politics > Sheffield Police And Judge Engaged In ‘Brutal Terrorism’ Against The Public

Monday, October 31, 2011 - Peter Reynolds

Sheffield Police And Judge Engaged In ‘Brutal Terrorism’ Against The Public

10

Press Release

For immediate release 31st October 2011

Sheffield Police And Judge Engaged In ‘Brutal Terrorism’ Against The Public

The Sheffield police and Judge Alan Goldsack QC, recorder of Sheffield, are promoting false science, misinformation, prejudice and discrimination against people who use cannabis.

According to independent research, based on national averages and official population statistics, 138,000 people in Sheffield will use cannabis in their lifetime and more than 33,000 use it regularly (at least once per month).

Judge Alan Goldsack QC has said that “cannabis is a dangerous drug” but there is no basis in science or medicine for this claim. According to Professor Les Iversen, the government’s chief drugs advisor, cannabis is “one of the safer recreational drugs”. Based on a recent analysis of mortality, hospital admissions, toxicity and propensity to psychosis, cannabis is nearly 3000 times safer than alcohol, safer than virtually all other recreational drugs, OTC and POM medicines and less toxic than many common foodstuffs.

Acting Detective Chief Inspector Bob Chapman has said that “The strength of some of the skunk cannabis on sale is, in my opinion, of a strength comparable to Class A rather than Class B drugs.”. This is a reckless, misleading and false statement which has no basis in science or medicine.

Cannabis Law Reform (CLEAR) has lodged a formal complaint to the Office of Judicial Complaints about Judge Goldsack and to the Independent Police Complaints Commission about Acting DCI Chapman.

Peter Reynolds, leader of CLEAR, said:

“It is astonishing that people like Judge Goldsack and Acting DCI Chapman should be making such irresponsible statements. These are not matters of opinion but matters that are determined by scientific evidence. These statements demonstrate ignorance and prejudice in people who should know better.”

DCI Chapman was responsible for a “Cannabis Action Week” in the last week of October which resulted in 15 arrests and the seizure of an alleged £50,000 worth of cannabis. In response, CLEAR has announced a “Cannabis Truth Week” which will offer information on the scientific and medical facts about cannabis. This will start with the appearance of Howard Marks, “Mr Nice”, at the Foundry, Sheffield University on Saturday 12th November. CLEAR will be bringing the Cannabis Truth roadshow to Sheffield throughout the week. There will also be a public debate held in a central location. Sheffield MPs Nick Clegg and David Blunkett, both of whom advocate a safer, more responsible policy of legal regulation of cannabis have been invited. Scientific and medical experts will be present as will a number of people who use cannabis as medicine to treat conditions such as MS and Crohn’s. Sheffield police have also been invited to attend.

Peter Reynolds said:

“CLEAR is standing up for tens of thousands of reasonable, responsible and respectable Sheffield citizens who are under attack with lies and misinformation in a campaign that seeks to terrorise them in the most brutal and threatening way.

The laws that prohibit cannabis are in direct contradiction to science, medicine and all available evidence on public health, harm reduction and effective drugs policy. We accept that Judge Goldsack and the police have a duty to uphold the present law but not by the promotion of untruths, false science and terror tactics

Is there not a dangerous drug problem in Sheffield with alcohol, heroin and crack cocaine? Why is so much public money being wasted on cannabis with paedophilia and violent assault being treated more leniently in the courts?”

ENDS

For more information or to arrange an interview please contact:

Peter Reynolds – peterreynolds@clear-uk.org +44(0)788 0872022

www.clear-uk.org

P.O.Box 674, Salfords, REDHILL, Surrey, RH1 1BN

CANNABIS SCIENCE - The Endocannabinoid System

2011-10-30T14:47:00.000-07:00

Jury Nullification

2011-10-30T14:14:00.000-07:00

Nullification.

2011-10-30T14:13:00.001-07:00

http://www.youtube.com/watch?v=pVGPPD8xPbU&feature=player_embedded#t=132s

The War on Drugs: Count the Costs Statement

2011-10-27T10:01:00.000-07:00

The War on Drugs: Count the Costs and Explore the Alternatives

The global 'war on drugs' has been fought for 50 years, without preventing the long-term trend of increasing drug supply and use. Beyond this failure, the UN Office on Drugs and Crime has also identified the many serious 'unintended negative consequences' of the drug war. These costs result not from drug use itself, but from choosing a punitive enforcement-led approach that, by its nature, places control of the trade in the hands of organised crime, and criminalises many users. In the process this:

•undermines international development and security, and fuels conflict

•threatens public health, spreads disease and causes death

•undermines human rights

•promotes stigma and discrimination

•creates crime and enriches criminals

•causes deforestation and pollution

•wastes billions on ineffective law enforcement

The 'war on drugs' is a policy choice. There are other options that, at the very least, should be debated and explored using the best possible evidence and analysis.

We all share the same goals – a safer, healthier and more just world.

Therefore, we the undersigned, call upon world leaders and UN agencies to quantify the unintended negative consequences of the current approach to drugs, and assess the potential costs and benefits of alternative approaches.

* We welcome individual endorsements of this statement – please enter you name and email below. Names may be publicly displayed, but your email will not be displayed or shared with any third parties.

* We also welcome organisational, corporate or collegiate endorsements of the statement. If your organisation is interested in endorsing this statement, please contact the Count the Costs project coordinator, Martin Powell.

. .
Follow us on twitter

Find us on Facebook

Subscribe to our RSS feed

Secondary menu

Contact Us

About Count the Costs

Supporters

.
© Counting the Costs 2011

http://www.countthecosts.org/take-action/sign-our-statement

.

BlunTV - Cannabis Social Clubs mit Martin Barrioso von ENCOD

2011-10-26T05:01:00.000-07:00

A Video by BlunTV - Showing how Cannabis Social Clubs (CSC) were started in
the Basque provence of Spain by Martin Burrioso (Martin is also a member of ENCOD).

Martin attended the CND in Vienna, Austria, in 2008 and explained to the conference held by ENCOD
in Vienna at that time how he started with this project and his trials & tribulations. Since then ENCOD has worked on a document that should be exceptable
to all countries that are member states of the E.U, and should be a document that will take much worry over the Single Conventions of 1961, 1971 & 1986, away from National & Local government/s if and when such a proposal is made in this country even this town.
[NB. it is the 1971 convention that is responsible for the large amount of cannabis possesion which is responsible for non-violent & in all other respects are law-abiding citizens being imprisoned for cannabis possesion.]

There are many lonely people who would love to be able to get out of the home & go to an adult club & meet other residents of their locale. Within such CSC's the atmosphere would be welcoming and a much needed resbite from the daily drudge of 'austerity'.
It is a fact that cannabis smoking adults do not become violent as is the way with alcohol. For mature adults, only good can come from such projects, giving people involved some purpose in life by being involved of the planting of a seed into a flower pot, waqtering and looking after that plant until it is smoked.
Within ENCOD's document to governments shows how to open a CSC without conflicting with the single conventions mentioned above. Strict Guidelines must be adhered to and involvement from Local government would be encouraged. If one looks into the matter of CSC's and the practical running of such a Club, it will be seen that it is within the public interest. A CSC, will be a non-profit club, will not have advertisement, will be situated out of the way and will be situated away from young people's routes.
One member, one plant.
Spain is not the only member state to have CSC's Antwerp, Belgium started a similiar project using the concept that Martin used in Spain. Many of the member states have already surpassed us here in the U.K, places such as Croatia, & surrounding states, also Denmark, Germany and many more have this facility. However, the U.K seems to have problem in that we the public are perceived to 'not know what is best for them', the government takes the stance that it they that know what is best for all individuals.
If any person actually wants/needs to know more about CSC's you can contact Joep Oomen, Secretary of ENCOD

www.encod.org

ciao irra

2011-10-19T08:59:00.001-07:00